Clinical Deep Dives

Medlock Holmes enters an immense Neo-Victorian medical complex called The House of Bodily Signals.

Every corridor is crowded.

One patient reports abdominal pain. Another dizziness. Another weakness. Another chest discomfort. Another is convinced that a subtle bodily sensation means serious disease. One patient has undergone scan after scan without reassurance. Another has genuine physical illness but has become consumed by fear and monitoring. In a neighbouring neurological ward, someone presents with limb weakness that does not conform to recognised neurological anatomy.

Holmes notices immediately that the central mystery is not:

“Are the symptoms real?”

The symptoms are real experiences.

The more useful question is:

“How does the person interpret, respond to, and organise life around those symptoms?”

This is the conceptual shift at the heart of modern somatic symptom and related disorders.

Earlier diagnostic systems relied heavily on whether symptoms were medically unexplained. DSM-5 moved away from that distinction because medicine cannot always establish whether a symptom is medically explained, partially explained or idiopathic, and because patients with genuine medical disease can still become disproportionately preoccupied with bodily symptoms.

Somatic symptom disorder therefore focuses upon the combination of:

distressing somatic symptoms

plus

excessive thoughts, feelings or behaviours related to those symptoms.

The diagnostic table on page 11 makes this explicit. One or more somatic symptoms must cause distress or disruption, while the patient also shows disproportionate concern about seriousness, persistently high health anxiety, or excessive time and energy devoted to the symptoms. The overall symptomatic state is persistent, usually for more than six months.

Holmes sees why this distinction matters.

A patient can have chronic pain caused by osteoarthritis and still develop somatic symptom disorder if the response to that pain becomes excessive, consuming and disabling.

Conversely, a person can have many medically unexplained symptoms without meeting criteria if they are not excessively preoccupied or impaired.

The disorder is therefore not diagnosed by proving that nothing is physically wrong.

It is diagnosed by understanding the relationship between bodily symptoms and the patient’s cognitive, emotional and behavioural response.

The chapter then separates several neighbouring conditions.

In illness anxiety disorder, somatic symptoms are absent or relatively mild, but the fear of serious illness dominates the person’s life.

In functional neurological symptom disorder, symptoms such as weakness, tremor, seizures, gait disturbance or sensory loss are incompatible with recognised neurological disease.

In psychological factors affecting another medical condition, psychological or behavioural factors demonstrably worsen an established medical illness.

In factitious disorder, symptoms are intentionally falsified or induced without an obvious external reward.

And in malingering, which is not itself a psychiatric disorder, symptoms are intentionally produced for an external incentive such as money, avoiding work or obtaining drugs.

Holmes realises that these categories sit at one of medicine’s most difficult boundaries.

The distinction between physical and psychological is not a clean line.

Pain, autonomic symptoms, fatigue, dizziness, gastrointestinal disturbance, weakness and bodily vigilance are all influenced by:

* biology

* attention

* expectation

* emotion

* learning

* culture

* previous experience

* social context.

The figure on page 4 demonstrates another important principle: whether physical symptoms are medically explained or not, a high burden of somatic symptoms predicts greater rates of depression and anxiety. The number of symptoms often matters more clinically than the certainty of their medical explanation.

Holmes enters the Amplification Chamber.

A harmless bodily sensation passes through an attention lens.

It becomes larger.

The person notices it more frequently.

Catastrophic interpretation increases anxiety.

Anxiety increases physiological arousal.

The amplified sensation then seems to confirm the original fear.

The loop becomes:

Sensation → Attention → Catastrophic Interpretation → Anxiety → More Sensation → More Attention.

Healthcare use can then become part of the cycle.

A new test provides temporary reassurance.

The reassurance fades.

Another symptom appears.

Another specialist is consulted.

Another scan is performed.

Occasionally, unnecessary procedures themselves produce complications.

The chapter therefore emphasises iatrogenic harm.

The clinician can inadvertently reinforce the disorder through repeated investigations, invasive procedures and fragmented specialist care.

Holmes sees that treatment requires a very different medical style.

Not abandonment.

Not confrontation.

Not:

“It is all in your head.”

Instead:

* take symptoms seriously

* perform an appropriate medical assessment

* explain what is known

* avoid endless re-investigation without new indication

* arrange regular planned appointments

* treat genuine comorbid illness

* gradually explore stress, beliefs and behaviour

* focus on function rather than endlessly pursuing symptom elimination.

The severe case described in the chapter illustrates the danger of the opposite approach: years of investigations and operations can progressively deepen disability while leaving the underlying pattern unchanged.

CBT becomes particularly useful because it addresses the maintenance cycle.

The patient learns to identify:

* catastrophic interpretations

* excessive symptom monitoring

* avoidance

* inactivity

* reassurance seeking

* unhelpful health behaviours.

Behavioural activation, graded activity, relaxation and cognitive restructuring can help restore functioning.

The goal is not to persuade the patient that the body is irrelevant.

It is to teach the patient that bodily sensations can be understood without allowing them to dominate life.

Holmes then enters the neurological wing.

Here lies functional neurological symptom disorder.

The essential modern diagnostic principle is crucial:

The diagnosis should rest upon positive evidence of incompatibility with recognised neurological disease, rather than simply the absence of an abnormal scan or an assumption that stress must have caused the symptom.

A psychological stressor may be present.

It may not.

The symptom is not presumed to be consciously produced.

And the patient should not be accused of malingering.

This represents an important departure from older psychodynamic formulations of “conversion.”

Treatment may include:

* explanation

* reassurance

* physiotherapy

* behavioural approaches

* treatment of comorbid anxiety or depression

* careful exploration of predisposing, precipitating and perpetuating factors.

The final chamber is labelled:

THE THERAPEUTIC ALLIANCE.

Holmes understands that this may be the most important room.

Patients with chronic somatic symptoms often arrive after years of feeling dismissed, doubted, investigated or frightened.

The clinician who immediately insists upon a psychological explanation may lose the patient.

The clinician who endlessly investigates may reinforce the problem.

The useful position lies between them:

Validate the suffering without validating every catastrophic interpretation.

Investigate appropriately without investigating indefinitely.

Care without colluding.

Reassure without dismissing.

Shift the goal from finding the perfect explanation to restoring function.

That is the central therapeutic skill in somatic symptom and related disorders.

Key Takeaways

1. Somatic symptoms are common

Everyone experiences bodily symptoms.

Most resolve or are managed without major disruption.

A smaller group develops persistent symptoms accompanied by excessive:

* concern

* monitoring

* anxiety

* healthcare seeking

* functional impairment.

The clinical problem is therefore not the existence of symptoms alone.

2. DSM-5 Changed the Core Concept

Older classifications asked:

“Is the symptom medically unexplained?”

DSM-5 instead asks:

“Is the person’s response to the symptom excessive, persistent and impairing?”

This was a major conceptual change.

3. Symptoms Do Not Need to Be Medically Unexplained

A patient may have:

* genuine medical illness

* partially explained symptoms

* idiopathic symptoms

and still meet criteria for somatic symptom disorder.

Conversely, unexplained symptoms alone do not establish the diagnosis.

4. DSM-5 Somatic Symptom Disorder

The diagnostic framework shown on page 11 requires:

A. One or more somatic symptoms

that are:

* distressing

* or significantly disruptive.

B. At least one excessive response

such as:

* disproportionate thoughts about seriousness

* persistently high health anxiety

* excessive time and energy devoted to symptoms.

C. Persistence

The state of being symptomatic is typically:

more than 6 months.

5. Severity

DSM-5 allows:

Mild

One excessive cognition/behaviour feature.

Moderate

Two or more.

Severe

Two or more plus multiple symptoms or one very severe symptom.

A persistent specifier reflects severe, impairing and long-lasting illness.

6. Pain Is Now a Specifier

The old separate psychiatric diagnosis of:

pain disorder

was removed.

Pain can now be described as:

Somatic Symptom Disorder - With Predominant Pain

The diagnosis does not imply that the pain is fabricated or purely psychogenic.

7. DSM-5 Somatic Symptom and Related Disorders

The broad group includes:

* somatic symptom disorder

* illness anxiety disorder

* functional neurological symptom disorder

* psychological factors affecting another medical condition

* factitious disorder

* other specified disorders

* unspecified disorders.

8. Body Dysmorphic Disorder Moved Elsewhere

BDD is now classified with:

obsessive-compulsive and related disorders

rather than the somatic symptom group.

9. Hypochondriasis Was Replaced

The older diagnosis of:

hypochondriasis

was removed from DSM-5.

Most patients now fall into either:

Somatic Symptom Disorder

when substantial somatic symptoms are present.

or

Illness Anxiety Disorder

when bodily symptoms are absent or relatively minor.

10. The DSM-IV → DSM-5 Shift

The diagram on page 5 shows the conceptual reorganisation:

Previous:

* somatisation disorder

* undifferentiated somatoform disorder

* pain disorder

largely merged into:

SOMATIC SYMPTOM DISORDER

while hypochondriasis splits according to symptom burden into:

SSD

or

ILLNESS ANXIETY DISORDER.

11. ICD-11 Uses a Different Structure

ICD-11 includes:

Bodily Distress Disorder

within:

Disorders of Bodily Distress and Bodily Experience.

Like DSM-5 SSD, it focuses on excessive attention and distress rather than requiring symptoms to be medically unexplained.

12. Body Integrity Dysphoria

ICD-11 also describes body integrity dysphoria.

This rare condition involves a persistent sense that a healthy limb or body part does not belong to one’s desired body configuration.

It is distinct from body dysmorphic disorder.

13. Functional Somatic Syndromes

The chapter lists many syndromes encountered across medical specialties, including:

* irritable bowel syndrome

* noncardiac chest pain

* tinnitus

* dizziness

* chronic pelvic pain

* fibromyalgia

* chronic low back pain

* hyperventilation

* interstitial cystitis

* functional gastrointestinal syndromes.

The chapter stresses their substantial overlap in:

* symptom patterns

* psychiatric comorbidity

* functional impairment

* treatment response.

14. “Functional” Does Not Mean “Imaginary”

An increasingly preferred conceptualisation is:

FUNCTIONAL SOMATIC DISORDER

because it avoids claiming that symptoms are either:

purely physical

or

purely psychological.

15. Somatic Symptoms Predict Psychopathology

The figure on page 4 illustrates that increasing numbers of physical symptoms are associated with increasing rates of:

* depressive disorders

* anxiety disorders

* substance-use disorders.

This relationship exists whether symptoms are medically explained or unexplained.

16. Somatic Presentations Are Extremely Common

In primary care, physical symptoms are among the most common ways psychiatric distress presents.

Many patients with depression or anxiety initially report:

* pain

* fatigue

* dizziness

* palpitations

* gastrointestinal symptoms

* sleep disturbance

rather than describing psychological distress directly.

17. Culture Shapes Presentation

Somatic expression varies across cultures.

Cultural context influences:

* interpretation of bodily sensation

* what counts as illness

* willingness to discuss emotional distress

* stigma

* help-seeking

* explanatory models.

Somatic expression can function as an idiom of distress.

18. Avoid Cultural Overinterpretation

Somatic expression should not automatically be interpreted as psychological avoidance.

Some cultures communicate distress more naturally through bodily language.

The clinician should explore:

What does the symptom mean to this person in this cultural context?

19. A Biopsychosocial Model Is Essential

Relevant contributors include:

Biological

* pain sensitivity

* sensory processing

* autonomic reactivity

* neuroendocrine function

* possible familial vulnerability.

Psychological

* attention

* catastrophic interpretation

* alexithymia

* anxiety

* depression

* illness beliefs.

Behavioural

* checking

* avoidance

* inactivity

* reassurance seeking

* healthcare use.

Social

* family responses

* cultural expectations

* socioeconomic adversity

* compensation systems

* healthcare structure.

20. Symptom Amplification

A useful maintenance model is:

BODY SENSATION

↓

ATTENTION

↓

INTERPRETATION AS THREAT

↓

ANXIETY

↓

PHYSIOLOGICAL AROUSAL

↓

MORE BODY SENSATION

↓

MORE ATTENTION

The sensation becomes increasingly salient.

21. Somatosensory Amplification

Some patients appear especially attentive to bodily sensations.

Minor sensations may be perceived as:

* intense

* unusual

* dangerous

* medically significant.

Research discussed in the chapter suggests altered functional connectivity may relate to symptom amplification.

22. Alexithymia

Alexithymia refers broadly to difficulty:

* identifying

* processing

* expressing

emotional states.

It has been associated with a greater tendency to communicate distress somatically.

23. Secondary Gain Is Not the Same as Fabrication

A patient may gain:

* attention

* relief from obligations

* financial compensation

* support

through illness.

This does not automatically mean that symptoms are consciously produced.

Secondary gain can maintain genuine symptoms without implying malingering.

24. Comorbidity Is Extremely Common

High somatic symptom burden commonly coexists with:

* depression

* anxiety

* personality disorders

* substance misuse.

The chapter reports very high rates of depression or anxiety among heavily somatising primary-care patients.

25. High Symptom Burden Predicts Disability

The number of physical symptoms may remain high even as the specific symptoms change over time.

High symptom burden predicts:

* poorer functioning

* increased healthcare use

* more severe psychiatric illness

* greater disability.

26. Somatic Symptoms May Change but the Pattern Persists

A patient may initially present with:

abdominal pain

then later:

headaches

then:

palpitations

then:

dizziness.

The individual symptoms change.

The broader pattern of bodily preoccupation may remain.

27. The Differential Diagnosis Must Remain Medical

Never assume that multiple symptoms automatically mean a psychiatric disorder.

Appropriate assessment must still consider:

* neurological disease

* endocrine disease

* autoimmune disease

* infection

* medication effects

* substance effects

* malignancy

* other medical causes.

28. Occult Medical Disease Can Coexist

Patients with SSD can still develop genuine medical illness.

Once a psychiatric formulation exists, clinicians must avoid the opposite cognitive error:

DIAGNOSTIC OVERSHADOWING

New symptoms still require appropriate clinical assessment.

29. Establishing the Alliance Comes First

Many patients arrive expecting:

* disbelief

* dismissal

* another negative test

* another clinician saying “nothing is wrong.”

A useful therapeutic stance begins with:

“I believe that you are experiencing these symptoms.”

That is different from agreeing with every interpretation of their cause.

30. Avoid “It’s All in Your Head”

This phrase:

* invalidates suffering

* polarises physical versus psychological explanations

* damages trust

* increases doctor shopping.

The chapter explicitly advocates avoiding dismissive or confrontational explanations.

31. Premature Reassurance Often Fails

Simply saying:

“Your tests are normal.”

may not reduce anxiety.

The patient may conclude:

“They have missed something.”

Effective reassurance depends upon:

* adequate assessment

* trust

* consistency

* explanation.

32. Regular Scheduled Appointments

A key management strategy is:

PLANNED FOLLOW-UP

rather than symptom-driven emergency visits.

Regular, relatively infrequent appointments can:

* provide containment

* maintain continuity

* reduce crisis-driven healthcare use

* limit doctor shopping.

33. One Coordinating Clinician Helps

Where possible, treatment should be coordinated through:

one primary clinician

with selective specialist consultation.

Fragmented care increases the risk of:

* repeated investigations

* contradictory explanations

* unnecessary procedures

* iatrogenic harm.

34. Brief Physical Examination Can Be Therapeutic

The chapter supports brief, appropriate physical assessment during scheduled visits.

This communicates:

“Your bodily symptoms are still being taken seriously.”

without repeating extensive diagnostic investigations.

35. Iatrogenic Harm Is a Major Risk

Repeated:

* scans

* endoscopies

* operations

* invasive tests

* medications

can cause actual harm.

The severe case in the chapter demonstrates how relentless investigation may culminate in irreversible surgical consequences without solving the underlying problem.

36. Functional Improvement Is Often a Better Goal Than Symptom Elimination

Early treatment goals may include:

* fewer medical visits

* improved daily function

* return to activity

* reduced checking

* better sleep

* reduced healthcare utilisation.

The clinician may not eliminate every symptom.

That does not mean treatment has failed.

37. “Caring” Rather Than Only “Curing”

The chapter emphasises a useful clinical shift:

CARING

rather than relentlessly attempting:

CURING

when symptoms are chronic and refractory.

This is not therapeutic pessimism.

It means prioritising:

* function

* safety

* continuity

* reduced harm

* quality of life.

38. The Consultation Letter

A classic intervention directed primary-care clinicians to:

* schedule regular appointments

* perform brief examinations

* avoid unnecessary investigations

* avoid hospitalisation unless indicated

* avoid dismissive explanations

* briefly explore stressors.

The intervention reduced healthcare utilisation and improved function even when symptoms themselves changed little.

39. CBT Has the Strongest Psychotherapy Evidence

CBT targets:

* catastrophic thinking

* symptom monitoring

* avoidance

* inactivity

* illness beliefs

* maladaptive behaviours.

It may include:

* relaxation

* graded activity

* cognitive restructuring

* behavioural experiments

* symptom diaries.

40. Catastrophic Thinking Maintains Disability

For example:

“Pain means damage.”

↓

Avoid activity

↓

Deconditioning

↓

More pain

↓

More evidence of damage

CBT attempts to break this loop.

41. Evidence for CBT

A pivotal study discussed in the chapter found substantially greater improvement with a structured CBT programme compared with augmented standard care.

The benefits included:

* reduced symptom severity

* improved functioning

* lower healthcare use.

42. Medication Has a Limited Direct Role in SSD

Medication is usually most useful for clearly defined comorbid:

* depression

* anxiety

* psychosis.

There is less evidence for medication aimed solely at somatic symptom disorder itself.

43. Illness Anxiety Disorder

The core problem is:

FEAR OF SERIOUS ILLNESS

rather than a high burden of somatic symptoms.

Somatic symptoms are:

* absent

* or mild.

44. Illness Anxiety Disorder: Core Pattern

Typical elements include:

BODY SENSATION

↓

SERIOUS DISEASE INTERPRETATION

↓

HEALTH ANXIETY

↓

CHECK / SEEK REASSURANCE / AVOID

↓

TEMPORARY RELIEF

↓

ANXIETY RETURNS

45. Disease Conviction, Disease Fear, Bodily Preoccupation

The chapter describes three useful components:

* disease conviction

* disease fear

* bodily preoccupation.

Different patients may emphasise different parts of this triad.

46. Illness Anxiety Can Become Severe

At the extreme, health beliefs may approach:

delusional intensity.

This requires careful differential diagnosis with:

* OCD

* depression

* psychosis

* GAD

* somatic symptom disorder.

47. Illness Anxiety Is Often Chronic

The chapter describes persistence over several years in a substantial proportion of patients.

It can therefore become highly disabling despite the relative absence of major physical symptoms.

48. CBT Is First-Line for Illness Anxiety

CBT can target:

* catastrophic health beliefs

* body checking

* repeated reassurance seeking

* internet searching

* medical consultation cycles.

Evidence supports sustained improvement.

49. Fluoxetine Has Evidence

A controlled trial discussed in the chapter found greater improvement with fluoxetine than placebo beginning around week eight.

Medication may be particularly useful when health anxiety coexists with depression or anxiety.

50. Functional Neurological Symptom Disorder

Functional neurological symptom disorder includes neurological symptoms such as:

* weakness

* paralysis

* tremor

* abnormal gait

* sensory loss

* aphonia

* blindness

* seizure-like episodes.

51. The Diagnosis Should Be Positive

A crucial DSM-5 principle is:

INCOMPATIBILITY WITH RECOGNISED NEUROLOGICAL DISEASE

The diagnosis should not simply mean:

“tests were negative.”

Positive clinical signs should support the diagnosis.

52. A Psychological Stressor Is Not Required

Older conversion models assumed psychological conflict was transformed into neurological symptoms.

DSM-5 no longer requires that a psychological stressor be identified.

This is clinically important because stress is:

* common

* nonspecific

* sometimes absent.

53. Symptoms Are Not Assumed to Be Intentional

Functional neurological symptoms are not the same as:

* malingering

* factitious disorder.

The patient is not presumed to consciously produce the symptom.

54. “La Belle Indifférence” Is Not Diagnostic

Apparent emotional calm despite dramatic symptoms was historically emphasised.

It is neither sufficiently specific nor reliable to diagnose FND.

55. Functional Neurological Disorder Requires Neurological Expertise

Assessment must consider disorders such as:

* epilepsy

* multiple sclerosis

* movement disorders

* peripheral neurological disease.

Appropriate examination and targeted investigations remain essential.

56. Psychogenic Nonepileptic Seizures

Seizure-like episodes without epileptic physiology are one presentation of FND.

EEG or video-EEG may be necessary to differentiate them from epilepsy.

57. Physiotherapy Can Be Important

For motor FND:

* weakness

* gait disturbance

* balance problems

physiotherapy can help restore normal movement patterns and function.

It is not simply “supportive care.”

It may be a central therapeutic intervention.

58. Psychological Explanation Should Be Timed Carefully

Prematurely saying:

“This is caused by stress.”

may alienate the patient.

A more useful explanation is:

“The nervous system is not functioning normally even though we do not see structural damage.”

The distinction between:

function

and

structure

can be clinically powerful.

59. Explore Predisposing, Precipitating and Perpetuating Factors

A useful formulation considers:

Predisposing

* previous illness

* trauma

* vulnerability

* learned illness behaviour.

Precipitating

* injury

* illness

* stress

* physiological events.

Perpetuating

* fear

* avoidance

* deconditioning

* maladaptive beliefs

* healthcare interactions.

60. Pain and SSD

Pain should be understood through a:

BIOPSYCHOSOCIAL MODEL

rather than divided rigidly into:

physical pain

versus

psychological pain.

Pain experience is influenced by:

* nociception

* mood

* attention

* sleep

* expectation

* previous experience

* behaviour.

61. Antidepressants and Functional Pain

The chapter describes evidence particularly for older antidepressants such as:

tricyclic antidepressants

in several functional pain syndromes.

The analgesic effect can occur at doses lower than those typically used for major depression.

62. CBT for Chronic Pain

CBT has demonstrated benefit across several chronic pain syndromes.

Targets include:

* catastrophising

* fear of movement

* inactivity

* attention

* coping behaviour.

63. Psychological Factors Affecting Another Medical Condition

This diagnosis differs from SSD.

A genuine medical disorder is present.

Psychological or behavioural factors then clearly worsen it.

Examples include:

* anxiety worsening asthma

* behavioural manipulation of insulin

* medication non-adherence

* denial of serious illness.

64. The Causal Link Must Be Clear

The diagnosis should only be made when the psychological or behavioural factor has a demonstrable adverse impact upon:

* course

* severity

* treatment

* risk

* outcome.

65. Factitious Disorder

Factitious disorder involves:

INTENTIONAL FALSIFICATION OR INDUCTION OF ILLNESS

without an obvious external reward.

Examples include:

* contaminating specimens

* inducing bleeding

* causing skin lesions

* manipulating laboratory results

* producing fever.

66. Factitious Disorder Imposed on Another

The patient induces or falsifies illness in another person.

This was historically termed:

factitious disorder by proxy.

It raises major safeguarding concerns.

67. Factitious Disorder versus Malingering

The distinction is essential.

Factitious Disorder

Intentional symptom production

but no obvious external reward.

The psychological motivation centres around adopting the sick role.

Malingering

Intentional symptom production

for external incentives such as:

* money

* compensation

* drugs

* avoiding work

* avoiding prosecution.

68. Intentionality Separates Factitious Disorder From FND

FND

Symptoms are not presumed consciously produced.

Factitious Disorder

Symptoms are intentionally produced.

Malingering

Symptoms are intentionally produced for external gain.

This distinction is central to differential diagnosis.

69. Other Specified Disorders

Examples include:

* brief somatic symptom disorder

* brief illness anxiety disorder

* illness anxiety without excessive health-related behaviour

* pseudocyesis.

70. Primary Care Is the Main Treatment Arena

Many patients with somatic presentations never reach psychiatric services.

Primary care therefore functions as a major mental-health setting for these disorders.

71. A Stepped-Care Approach

The chapter outlines a practical progression.

Step 1

Identify persistent idiopathic physical symptoms and psychiatric need.

Step 2

Provide:

* psychoeducation

* stress reduction

* biofeedback

* brief symptom-focused interventions.

Step 3

Introduce onsite mental-health expertise and time-limited CBT.

Step 4

Escalate to:

* psychotherapy

* medication

* coordinated specialist care

for persistent or severe presentations.

72. Personalised Care Matters

There is no single treatment protocol that fits every patient.

Some patients need:

* reassurance

* continuity

* CBT.

Others require:

* pain treatment

* physiotherapy

* psychiatric medication

* neurological intervention

* multidisciplinary rehabilitation.

Severity and mechanism matter.

73. The Central Therapeutic Principle

The clinician should avoid two extremes.

Extreme One

“There is definitely a hidden physical disease and we must keep investigating.”

This can produce:

iatrogenic harm.

Extreme Two

“Nothing is wrong; this is psychological.”

This produces:

invalidating dismissal.

The useful position is:

“The symptom is real. We have appropriately assessed dangerous causes. Now we need to understand what is keeping the symptom and disability going.”

74. The Core Clinical Model

Somatic symptom disorder can be conceptualised as:

BODY SENSATION

↓

ATTENTION

↓

THREAT INTERPRETATION

↓

HEALTH ANXIETY

↓

CHECKING / AVOIDANCE / MEDICAL SEEKING

↓

TEMPORARY REASSURANCE

↓

RENEWED ATTENTION

↓

MORE SYMPTOMS

Treatment attempts to introduce:

VALIDATION

↓

COHERENT EXPLANATION

↓

REGULAR CARE

↓

REDUCED INVESTIGATION

↓

CBT / GRADED ACTIVITY

↓

FUNCTIONAL RECOVERY

Medlock Holmes enters an immense Neo-Victorian institution called The Citadel of the Unfinished Alarm.

At the centre is a vast clock frozen at the moment of trauma.

Outside the citadel, the danger has passed.

Inside, however, bells continue to ring.

A veteran ducks at the sound of a car backfiring. A survivor avoids a street that resembles the place of an assault. Another wakes from the same nightmare night after night. A fourth scans every room for exits.

Holmes immediately recognises the defining paradox of post-traumatic stress disorder:

The event belongs to the past, but the nervous system continues to respond as though danger remains present.

PTSD is classified as a trauma- and stressor-related disorder. Diagnosis requires exposure to actual or threatened death, serious injury or sexual violence, followed by characteristic symptoms lasting longer than one month and causing meaningful distress or impairment.

Those symptoms fall into four major clusters:

Intrusion. Avoidance. Negative alterations in cognition and mood. Alterations in arousal and reactivity.

Intrusive memories are not ordinary recollections. They possess a disturbing “here and now” quality. Flashbacks, nightmares and physiological reactions to reminders can make the past feel emotionally immediate.

Avoidance then emerges as an understandable attempt to control this intrusion. The person avoids places, people, conversations, memories, feelings and bodily sensations associated with trauma.

But avoidance comes at a cost.

It prevents the nervous system from learning:

“This reminder is not the original danger.”

Fear spreads. One battlefield cue becomes avoidance of uniforms, crowds, loud noises and unfamiliar places. Life becomes increasingly organised around preventing surprises.

The third cluster alters the person’s world beyond the trauma itself.

I cannot trust anyone.

The world is completely dangerous.

I should have prevented it.

Something in me is permanently damaged.

Interests fade. Positive emotion becomes difficult. Relationships become distant. Guilt, shame and emotional numbing can replace the person’s previous assumptions about self and world.

Meanwhile, the alarm system remains sensitised.

Hypervigilance.

Exaggerated startle.

Poor sleep.

Irritability.

Concentration difficulty.

Reckless behaviour.

The syndrome therefore becomes more than fear of a memory. It is a disturbance of threat detection, contextual processing, emotion regulation, attention, learning and recovery.

The brain-circuit diagram on page 25 captures this particularly well. Four interacting systems are highlighted: emotion regulation and executive function, threat and salience detection, contextual processing, and fear learning. Rather than one damaged “trauma centre”, PTSD involves altered communication among the prefrontal cortex, anterior cingulate, insula, amygdala, hippocampus, thalamus and related structures.

Holmes reaches the amygdala first.

It rapidly tags potential threat.

The insula monitors salient internal and external signals.

The dorsal anterior cingulate helps orient attention towards danger.

But prefrontal regulatory systems that should inhibit unnecessary alarm may function less efficiently.

The hippocampus supplies another critical function:

context.

A loud noise in combat meant one thing.

A loud noise at home years later means another.

PTSD can impair the ability to use context to update the meaning of the signal.

This is why the chapter presents PTSD as, in part, a disorder of recovery.

Many people show substantial symptoms immediately after trauma.

Most improve.

Those who develop PTSD fail to follow the expected trajectory of extinction, contextual updating and restoration of safety.

Fear conditioning provides one model.

During trauma, previously neutral stimuli become associated with extreme threat.

Later, those stimuli can trigger defensive responses even when the original threat is absent.

Normally, repeated safe encounters produce extinction learning.

But PTSD is associated with impaired extinction and impaired retention of extinction.

The person may learn safety briefly and then lose access to that learning when reminded of danger.

Holmes also discovers that biology before the trauma matters.

PTSD does not occur in everyone who experiences trauma.

Risk reflects interactions among:

* previous trauma

* childhood adversity

* genetic vulnerability

* social support

* severity of exposure

* peri-traumatic responses

* continuing stress

* post-trauma environment.

The traumatic event is therefore necessary but not sufficient.

Genetics contribute, but there is no single PTSD gene. The disorder has a polygenic architecture, with environmental experiences and epigenetic regulation shaping biological vulnerability.

The neuroendocrine system also becomes involved.

Noradrenergic hyper-reactivity may strengthen traumatic memory and contribute to hypervigilance and nightmares.

Cortisol regulation is altered in some patients.

Neuropeptide Y appears associated with resilience.

GABA-modulating neurosteroids may be reduced.

Dopamine contributes to stress responses and disrupted reward.

Sleep becomes another crucial clue.

Up to 90% of people with PTSD report sleep disturbance.

Nightmares and fragmented sleep do not merely accompany the disorder; disrupted sleep may interfere with emotional memory processing and fear extinction, potentially helping maintain PTSD.

Holmes then turns from mechanism to treatment.

Trauma-focused psychotherapies have the strongest evidence.

Prolonged Exposure asks the patient to approach rather than avoid trauma memories and safe reminders.

Cognitive Processing Therapy examines distorted beliefs involving danger, blame, guilt and permanent damage.

EMDR combines trauma recall with structured sensory stimulation.

Other therapies can also help, including present-centred and interpersonal approaches in selected patients.

Medication provides another route.

SSRIs have the strongest evidence, particularly sertraline and paroxetine, while venlafaxine is also supported.

Prazosin has been used particularly for trauma-related nightmares.

Benzodiazepines, despite their intuitive appeal for acute distress, are poorly supported and may interfere with trauma recovery mechanisms.

The chapter also explores emerging approaches including rTMS, neurofeedback, cannabinoids, glutamatergic interventions and MDMA-assisted psychotherapy, while emphasising the limits of current evidence.

Holmes finally enters the room marked:

PREVENTION.

Here he discovers one of the most important lessons in trauma care.

Immediate emotional debriefing was once widely believed to prevent PTSD.

It does not.

Routine single-session psychological debriefing can be ineffective and may even interfere with natural recovery.

Most trauma survivors do not require immediate trauma processing.

What they often need first is:

safety, practical assistance, human contact, sleep, shelter, information and monitoring.

Early targeted CBT can help people who have already developed significant acute traumatic stress symptoms.

But blanket intervention for everyone exposed to trauma is neither necessary nor supported.

Holmes leaves the citadel with a final insight.

PTSD is not simply the presence of a terrible memory.

It is the failure of that memory to acquire an appropriate timestamp.

The nervous system knows what happened.

What it struggles to learn is:

“It happened then. I am here now.”

Recovery therefore requires more than forgetting.

It requires rebuilding the capacity to distinguish:

memory from current danger,

reminder from recurrence,

and

the world that contained the trauma from the world that exists today.

Key Takeaways

1. PTSD Is a Trauma- and Stressor-Related Disorder

PTSD requires a clear relationship between current symptoms and exposure to a qualifying traumatic event.

Unlike most psychiatric diagnoses, the triggering event is part of the diagnostic definition.

2. What Qualifies as Trauma?

Criterion A includes exposure to actual or threatened:

DEATH

SERIOUS INJURY

or

SEXUAL VIOLENCE

through:

* directly experiencing it

* witnessing it

* learning that it happened violently or accidentally to a close person

* repeated or extreme occupational exposure to aversive details.

Routine exposure through television or social media does not qualify unless it occurs as part of professional duties.

3. The Four Core Symptom Clusters

PTSD requires symptoms across four domains:

B - Intrusion

C - Avoidance

D - Negative Cognitions and Mood

E - Altered Arousal and Reactivity

The pattern must persist for:

MORE THAN 1 MONTH

and cause clinically significant distress or impairment.

4. Intrusion

Intrusion symptoms include:

* involuntary memories

* nightmares

* flashbacks

* psychological distress to reminders

* physiological reactions to reminders.

The defining quality is that the memory feels emotionally:

HERE AND NOW

rather than simply:

THERE AND THEN.

5. Flashbacks Are More Than Remembering

At the severe end of intrusion, the person may temporarily experience the traumatic event as though it is recurring.

Awareness of the present can become partially or completely overshadowed.

This makes dissociative re-experiencing qualitatively different from ordinary autobiographical memory.

6. Avoidance

Avoidance can target:

Internal reminders

* memories

* thoughts

* feelings.

External reminders

* places

* people

* conversations

* activities

* objects

* situations.

Avoidance initially reduces distress but may prevent corrective learning.

7. Avoidance Can Generalise

Fear often spreads beyond the original danger.

For example:

battlefield danger

may generalise to:

uniforms → loud noises → crowds → mail → public places

The patient’s world progressively contracts.

This represents inappropriate generalisation of threat.

8. Negative Cognitions and Mood

This cluster includes:

* inability to remember part of the trauma

* persistent negative beliefs

* distorted blame

* persistent fear, horror, anger, guilt or shame

* reduced interest

* detachment

* inability to experience positive emotions.

9. Trauma Can Alter Worldview

Common beliefs include:

“The world is completely dangerous.”

“Nobody can be trusted.”

“I am permanently damaged.”

“It was my fault.”

These are not merely passing thoughts.

They can become enduring cognitive frameworks through which future experience is interpreted.

10. Hyperarousal and Reactivity

Symptoms include:

* irritability

* angry outbursts

* reckless behaviour

* hypervigilance

* exaggerated startle

* concentration problems

* sleep disturbance.

The nervous system remains prepared for threat even when current circumstances are safe.

11. PTSD Is Heterogeneous

Different patients can meet diagnostic criteria with substantially different symptom combinations.

One patient may primarily show:

fear and hyperarousal

another:

dysphoria and anhedonia

another:

anger

another:

dissociation

another:

social withdrawal and emotional numbing.

PTSD is therefore a syndrome rather than one uniform phenotype.

12. Dissociative Subtype

Some patients show prominent:

* depersonalisation

* derealisation.

Rather than extreme hyperarousal, they may show an overmodulated response to threat.

The chapter cites an estimated prevalence of approximately 14.4% of individuals with PTSD for this subtype.

13. Depersonalisation

The person feels detached from:

* body

* thoughts

* emotions

* sense of self.

They may describe:

“I feel as if I am watching myself from outside.”

14. Derealisation

The surroundings feel:

* unreal

* distant

* dreamlike

* distorted.

These symptoms should not be better explained by intoxication or another medical condition.

15. Delayed Expression

DSM-5 allows a delayed expression specifier when full diagnostic criteria are not met until at least six months after the trauma.

Importantly, the chapter emphasises that truly delayed onset from a completely asymptomatic state appears uncommon.

More often there are earlier subthreshold symptoms that later intensify.

16. Complex PTSD

ICD-11 distinguishes complex PTSD.

This includes core PTSD symptoms together with broader disturbances involving:

* emotion regulation

* self-concept

* interpersonal relationships.

It is particularly associated with prolonged or repeated trauma.

17. PTSD Is Not a Normal Reaction to Trauma

Distress immediately after trauma is common and often normal.

Most people exposed to trauma do not develop PTSD.

PTSD represents a persistent pathological outcome in which recovery mechanisms fail.

18. Trauma Is Necessary but Not Sufficient

A useful formulation is:

TRAUMA TRIGGERS PTSD - IT DOES NOT FULLY EXPLAIN IT

Risk reflects interaction among:

Pre-trauma vulnerability

Trauma characteristics

Post-trauma environment

Recovery processes

19. Trauma Exposure Is Very Common

Lifetime exposure to traumatic events is common.

The chapter cites estimates of:

50–89%

in the United States.

A worldwide survey found around:

70%

reported at least one traumatic event.

Around:

30.5%

reported four or more.

20. PTSD Is Much Less Common Than Trauma Exposure

US lifetime prevalence in a major national survey was approximately:

6.8%

Past-year prevalence:

3.5%

This disparity reinforces the importance of studying resilience as well as vulnerability.

21. Sex Differences

The cited US lifetime rates were approximately:

Men - 3.6%

Women - 9.7%

But risk varies considerably with the type and severity of trauma.

22. Trauma Type Matters

Conditional PTSD risk is not equal across traumatic events.

Interpersonal violence, particularly sexual assault, tends to carry substantially higher risk than many accidents or disasters.

23. Repeated Trauma Matters

Experiencing multiple traumatic events increases risk.

Particularly relevant exposures include:

* childhood abuse

* interpersonal violence

* repeated combat

* repeated occupational trauma.

24. Social Support Is Protective

One of the most consistent modifiable factors is:

POST-TRAUMA SOCIAL SUPPORT

Poor support increases risk.

Stable, soothing interpersonal relationships may facilitate recovery and fear extinction.

25. Continuing Stress Can Prevent Recovery

The traumatic event may have ended, but the person may continue experiencing:

* homelessness

* interpersonal conflict

* financial problems

* litigation

* danger

* discrimination

* repeated exposure.

Persistent stress can interfere with extinction and contextual updating.

26. Early Symptom Severity Predicts Later PTSD

Early PTSD symptom severity is one of the strongest indicators of later chronic symptoms.

But early symptoms do not inevitably lead to chronic PTSD.

Many initially symptomatic survivors recover naturally.

27. PTSD Has a Genetic Component

Twin studies suggest that approximately:

30%

of variability in PTSD vulnerability may be genetically influenced.

But there is no single PTSD gene.

28. PTSD Is Polygenic

Many genetic variants each contribute small effects.

Relevant research has examined genes related to:

* serotonin

* dopamine

* GABA

* glucocorticoid signalling

* FKBP5

* stress peptides

* neuroplasticity.

The eventual phenotype arises through:

GENES × ENVIRONMENT × DEVELOPMENT

29. Gene–Environment Interaction

Genetic vulnerability may become clinically relevant only in particular environmental contexts.

Examples described include interactions between:

* childhood adversity

* adult trauma

* stress-response genes.

Thus:

genetic susceptibility is conditional, not deterministic.

30. Epigenetics

Trauma may alter regulation of gene expression without changing the underlying DNA sequence.

Research has identified differences in DNA methylation associated with PTSD.

Some epigenetic patterns may change following successful treatment or recovery.

31. PTSD as a Disorder of Recovery

One of the chapter’s most powerful concepts is:

PTSD MAY BE A DISORDER OF RECOVERY

Immediately after severe trauma:

symptoms are common.

Over time:

most recover.

In PTSD:

the alarm persists.

The scientific question therefore becomes not simply:

“Why did someone react?”

but:

“Why did the reaction fail to resolve?”

32. Fear Conditioning

During trauma:

Neutral cue + Extreme threat

↓

Conditioned association

Later:

Neutral cue alone

↓

Defensive response

For example:

explosion + smell of diesel

may later become:

diesel smell → panic

even in safety.

33. Amygdala

The amygdala is central to:

* threat learning

* salience

* conditioned fear

* defensive responses.

The central amygdala coordinates:

* autonomic activity

* fight

* flight

* freezing

* endocrine responses.

34. Basolateral Amygdala

The basolateral amygdala participates particularly in forming associations between:

stimulus

and

threat.

Once established, previously neutral cues can trigger defensive responses.

35. Prefrontal Cortex

Prefrontal systems help regulate the amygdala.

They contribute to:

* inhibitory control

* extinction

* emotion regulation

* cognitive flexibility.

Reduced prefrontal regulation may allow threat responses to persist.

36. Hippocampus

The hippocampus helps answer:

“WHERE AND WHEN IS THIS DANGER RELEVANT?”

It provides contextual information.

Impaired contextual processing can cause a reminder in the present to evoke the same reaction as the original trauma.

37. The Four Major Neural Systems

The diagram on page 25 highlights four interacting circuits:

Emotion Regulation and Executive Function

Prefrontal systems.

Threat and Salience Detection

Amygdala, insula, ACC and related circuitry.

Contextual Processing

Hippocampus, vmPFC, thalamus and associated pathways.

Fear Learning

Amygdala-centred associative circuitry.

38. Salience Network

The salience network includes important contributions from:

* insula

* ACC

* amygdala.

In PTSD it may become excessively oriented towards potentially threatening information.

39. Default Mode Network

The default mode network contributes to:

* internal mentation

* autobiographical processing

* self-related processing.

PTSD has been associated with abnormal DMN connectivity.

40. Network Dysregulation

Research suggests:

salience network engagement ↑

while:

regulatory/default-mode integration ↓

This may help explain persistent attention to threat and difficulty disengaging from trauma-related internal experience.

41. Failure of Extinction

Normally:

CS without danger → fear gradually decreases

In PTSD:

* extinction may be impaired

* extinction memory may be poorly retained.

The person therefore continues responding defensively to safe reminders.

42. Safety Learning Is Central

Recovery is not simply forgetting trauma.

It involves learning:

“This cue no longer predicts danger.”

“This environment is different.”

“I survived.”

“I can respond differently now.”

43. Cortisol

Cortisol regulation in PTSD is complex.

Some studies have described:

* lower cortisol output

* increased glucocorticoid receptor sensitivity

* enhanced negative feedback.

Findings are not universal.

The chapter explicitly cautions against assuming one HPA-axis abnormality in every patient.

44. Noradrenaline

Exaggerated noradrenergic activity contributes to:

* hyperarousal

* hypervigilance

* sleep fragmentation

* nightmares

* strong emotional-memory consolidation.

The α2 antagonist yohimbine can provoke intense PTSD symptoms in susceptible patients.

45. Prazosin

Prazosin blocks:

α1 adrenergic receptors.

It has been used particularly for:

PTSD-related nightmares

with some evidence of benefit.

46. Neurosteroids

Allopregnanolone and pregnanolone enhance GABAergic inhibition.

Lower levels have been reported in PTSD and may relate to symptom severity.

They also have potential roles in:

* neuroprotection

* neurogenesis

* myelination.

47. Neuropeptide Y

NPY has been associated with:

STRESS RESILIENCE

Potential effects include:

* reduced anxiety

* improved homeostasis

* better sleep

* reduced autonomic reactivity

* enhanced hippocampal neurogenesis.

48. Dopamine

Dopamine contributes to:

* conditioned stress responses

* amygdala activation

* PFC inhibition

* reward signalling.

Reward processing may be reduced in PTSD, potentially contributing to:

anhedonia

and reduced motivation.

49. Serotonin

Serotonergic systems contribute to PTSD vulnerability and symptoms.

Provoking serotonergic systems experimentally can reproduce anxiety and flashback-like symptoms in susceptible patients.

SSRIs remain among the main established pharmacological treatments.

50. Structural Imaging

One of the best-known structural findings is:

reduced hippocampal volume

in groups with PTSD.

However, this is not specific to PTSD.

51. Smaller Hippocampus: Cause or Consequence?

A particularly important twin study suggested that smaller hippocampal volume may sometimes be a:

PRE-EXISTING VULNERABILITY FACTOR

rather than simply damage caused by PTSD.

This illustrates a general warning:

an abnormality associated with a disorder is not automatically caused by that disorder.

52. Other Structural Findings

Reported abnormalities include changes in:

* corpus callosum

* ACC

* cingulum

* amygdala

* insula.

Findings vary substantially between studies.

53. Sleep Is Central

Up to:

90%

of patients with PTSD report sleep disturbance.

Important problems include:

* insomnia

* nightmares

* fragmented sleep.

54. REM Sleep and Trauma Memory

REM sleep contributes to emotional-memory processing.

Disrupted REM may impair adaptive processing and maintenance of extinction memories.

Poor sleep may therefore be both:

a symptom

and

a maintaining factor.

55. Sleep Before Trauma May Predict Vulnerability

Some studies suggest sleep disturbance before trauma exposure may predict subsequent PTSD.

Sleep problems are therefore not always simply consequences of trauma.

56. Differential Diagnosis Begins With Trauma

PTSD cannot be diagnosed without a qualifying traumatic event.

Then ask:

Are the symptoms linked to that trauma in timing or content?

This linkage is essential.

57. Acute Stress Disorder

The key temporal distinction is:

Acute Stress Disorder

Symptoms occur in the first month.

PTSD

Symptoms persist beyond one month.

58. Adjustment Disorder

Adjustment disorder follows a significant psychosocial stressor that does not necessarily meet the traumatic threshold.

PTSD requires Criterion A trauma.

59. GAD

GAD primarily concerns:

future possibilities.

PTSD intrusion concerns:

a past event that continues to feel present.

60. OCD

OCD intrusive thoughts commonly concern:

* contamination

* harm

* uncertainty

* unacceptable thoughts.

PTSD intrusions reproduce or symbolically relate to a specific traumatic event.

61. Depression

PTSD and depression overlap substantially in:

* anhedonia

* sleep disturbance

* guilt

* withdrawal

* concentration problems.

The trauma-linked intrusion and avoidance symptoms help distinguish PTSD.

62. PTSD and Depression Commonly Coexist

Around half of adults with PTSD may concurrently meet criteria for major depression in some samples.

Lifetime overlap is even higher.

Both diagnoses may therefore be appropriate.

63. Substance Use Disorders

Alcohol and other substances may be used to:

* suppress arousal

* aid sleep

* block memories

* reduce emotional pain.

Substance use can worsen PTSD and interfere with treatment.

Both conditions may require simultaneous treatment.

64. Suicide Risk

Patients with PTSD should be assessed for:

* depression

* hopelessness

* impulsivity

* substance misuse

* suicidal thoughts

* suicidal behaviour.

Safety-threatening conditions take priority over trauma processing.

65. Natural Recovery Is Common

Immediately after trauma, symptoms are common.

Most people improve.

This is why early distress should not automatically be pathologised.

66. Chronic PTSD

Approximately one-third of people who develop PTSD may experience a chronic course in some studies.

Symptoms can persist for decades.

This makes long-term follow-up important.

67. Delayed-Onset PTSD Is Usually Not Truly Symptom-Free

Many apparently delayed cases involve:

earlier subthreshold symptoms

followed by:

later worsening.

New stressors, illness, ageing or reminders may reactivate previously contained symptoms.

68. Trauma-Focused CBT

Trauma-focused CBT has one of the strongest evidence bases.

It may include:

* exposure

* cognitive restructuring

* behavioural work

* processing of trauma meanings.

69. Prolonged Exposure

PE deliberately addresses:

avoidance

through:

Imaginal exposure

Repeated engagement with trauma memory.

In vivo exposure

Approaching objectively safe trauma reminders.

The therapeutic principle is:

APPROACH → PROCESS → UPDATE

rather than:

REMEMBER → ESCAPE.

70. Cognitive Processing Therapy

CPT focuses particularly on maladaptive beliefs involving:

* blame

* guilt

* safety

* trust

* power

* control

* esteem

* intimacy.

The person learns to revise overgeneralised trauma-derived beliefs.

71. EMDR

EMDR involves recalling distressing traumatic material while receiving structured bilateral sensory stimulation.

It has demonstrated efficacy for PTSD.

Its exact mechanism remains debated.

72. Present-Centred Therapy

PCT focuses more on:

* current relationships

* work

* daily problems

rather than direct trauma processing.

It can provide meaningful benefit, particularly when patients struggle to tolerate trauma-focused approaches.

73. Interpersonal Therapy

Interpersonal approaches focus upon:

* relationships

* role changes

* interpersonal consequences of trauma.

Some evidence suggests outcomes can be comparable with exposure-based treatment among completers, with potentially lower dropout in some patients with depression.

74. Military PTSD Can Be Difficult to Treat

Trauma-focused treatments improve symptoms in many veterans.

However:

* dropout can be high

* residual symptoms are common

* many retain diagnostic-level PTSD.

Non-trauma-focused treatment can therefore be reasonable when it improves continued engagement.

75. Treatment in Children and Adolescents

Psychological treatment is beneficial.

The strongest evidence discussed is for:

CBT

with improvements lasting up to a year in some studies.

76. Pharmacotherapy

The strongest medication evidence is for:

Sertraline

Paroxetine

Both have regulatory approval for adult PTSD.

Venlafaxine also has supportive evidence.

77. Benzodiazepines

Evidence for benzodiazepines in PTSD is poor.

They may interfere with:

* learning

* memory

* extinction.

They are therefore generally not recommended as routine PTSD treatment.

78. Nightmares

Prazosin has some evidence for trauma-related nightmares.

Sleep should be actively assessed and treated because of its central role in illness maintenance.

79. Combined Treatment

Evidence has not clearly established that:

medication + psychotherapy

is always superior to either intervention alone.

Treatment should therefore be individualised rather than assuming combination is automatically best.

80. MDMA-Assisted Psychotherapy

The chapter discusses evidence that MDMA used as an adjunct to psychotherapy can reduce PTSD symptoms more effectively than psychotherapy alone in some studies.

The crucial distinction is:

MDMA-ASSISTED PSYCHOTHERAPY

not:

MDMA alone.

The source emphasises that MDMA alone has no established therapeutic role and has abuse potential.

81. Emerging Treatments

Investigational approaches include:

* rTMS

* neurofeedback

* cannabinoids

* glutamatergic interventions

* endocannabinoid modulation

* oxytocin-related treatments.

Evidence remains developing.

82. Neurofeedback

Neurofeedback attempts to teach patients to modify activity in specific brain systems.

Amygdala-targeted approaches have shown preliminary promise.

This represents a move towards:

process-based neuromodulation.

83. Prevention Is Possible in Principle

PTSD is unusual because the triggering event often has a clear time point.

That creates an opportunity to identify high-risk survivors before chronic illness develops.

84. Three Early Trajectories

Trauma survivors commonly follow trajectories such as:

Resilience

Little persistent symptom burden.

Recovery

Initial symptoms gradually decrease.

Non-remission

Symptoms emerge and persist.

A less common trajectory involves later symptom worsening.

85. Routine Psychological Debriefing Is Not Recommended

Single-session debriefing after trauma was historically popular.

Controlled studies found:

no reliable preventive benefit

and possible:

negative effects on natural recovery.

Routine debriefing should therefore not be offered indiscriminately.

86. Early Care Should Prioritise Immediate Needs

Immediately after trauma, important interventions often include:

* safety

* shelter

* food

* sleep

* medical treatment

* information

* practical support

* social connection.

Not everyone needs immediate trauma-focused psychotherapy.

87. Early CBT Is Best Targeted

Early CBT is most useful for people who already show significant traumatic stress symptoms.

Delivering intensive trauma treatment to asymptomatic survivors does not appear justified.

88. Timing of CBT May Be Flexible

Some studies found that delaying CBT for several months did not worsen eventual outcomes compared with beginning very early.

This supports careful targeting rather than reflexively treating everyone immediately.

89. Hydrocortisone Prevention

Hydrocortisone has shown some preventive signal in selected studies.

Possible mechanisms include:

* reducing excessive adrenergic activation

* facilitating extinction

* enhancing plasticity.

Evidence remains limited and this is not routine universal prevention.

90. Propranolol Prevention

Although theoretically attractive because it can reduce adrenergic enhancement of emotional memory:

controlled studies have not demonstrated reliable prevention of PTSD.

It may reduce physiological responses to reminders without preventing the full disorder.

91. Benzodiazepines After Trauma

The chapter describes concerning evidence that benzodiazepines immediately after trauma may worsen later outcome.

Possible mechanisms include interference with:

extinction learning.

They are therefore not recommended as routine early preventive treatment.

92. Morphine

Observational studies suggest adequate analgesia with morphine after severe physical trauma may be associated with lower later PTSD risk.

However, causal interpretation remains uncertain.

Pain itself is a risk factor, making the relationship complex.

93. Precision Prevention

No intervention works for every trauma survivor.

Future prevention should increasingly answer:

WHO is at risk?

WHICH mechanism is operating?

WHEN should intervention occur?

WHAT treatment fits that pathway?

94. The Central Clinical Model

PTSD can be conceptualised as:

TRAUMA

↓

STRONG AVERSIVE LEARNING

↓

THREAT GENERALISATION

↓

INTRUSION

↓

AVOIDANCE

↓

FAILURE TO UPDATE SAFETY

↓

HYPERVIGILANCE

↓

PERSISTENT PTSD

Recovery attempts to reverse this process through:

SAFETY + APPROACH + CONTEXT + REAPPRAISAL + EXTINCTION + CONNECTION

Medlock Holmes enters an immense Neo-Victorian casino called The House of the Endless Chase.

At first, the place appears glamorous.

Roulette wheels turn beneath chandeliers. Cards slide across green felt. Slot machines sing. Sports odds flicker across brass boards. Online betting screens glow in distant alcoves.

But Holmes notices something that ordinary gamblers do not.

Almost every corridor leads back to the tables.

A sign above the entrance reads:

“The first wager is about winning. The disorder is about continuing.”

Gambling has existed across human history - dice, cards, lotteries, races, casinos, sports and now internet wagering. For most people it remains recreational. But for a vulnerable minority, gambling shifts from an activity into an addiction.

That conceptual shift is important. Gambling disorder was historically grouped with impulse-control disorders. DSM-5 moved it into the category of non-substance-related addictive disorders, reflecting evidence that its behavioural patterns, reward circuitry, craving, impaired control and relapse resemble substance addictions.

Holmes enters the first chamber and sees nine great levers controlling the disorder.

The gambler needs increasingly large wagers for excitement.

Attempts to cut down produce restlessness and irritability.

Repeated promises to stop fail.

Thoughts become consumed by gambling.

Dysphoria triggers further play.

Losses are chased.

Lies conceal the extent of involvement.

Relationships and occupations are jeopardised.

Money is sought from others to rescue the financial consequences.

Four or more of these features over a twelve-month period establish the diagnosis in the framework described by the source.

Yet Holmes quickly realises that one feature dominates the whole casino:

CHASING LOSSES.

A person loses £100 and returns to recover it.

Then £500.

Then £5,000.

The original goal was profit.

Now the goal becomes escape from loss.

But every attempt to escape creates a deeper loss.

The gambler begins moving money between credit cards, family accounts, loans, savings and borrowed funds. What was once financial planning becomes the machinery that sustains the chase.

The casino contains no clocks.

That is appropriate.

The pathological gambler increasingly lives in an eternal present.

Future consequences - debt, divorce, unemployment, prosecution - become psychologically distant compared with the immediate possibility of the next wager.

Holmes now understands the word repeatedly used in the chapter:

Action.

The gambler is not merely seeking money.

The wager itself generates arousal.

Anticipation.

Risk.

Possibility.

The moment before the outcome becomes intensely rewarding.

Winning allows continued gambling.

Losing creates pressure to recover.

Either outcome can feed the next bet.

This helps explain why severe gambling disorder can eventually continue even when gambling itself brings little genuine pleasure.

Holmes then enters the Cognitive Distortion Hall.

A player remembers spectacular wins while forgetting hundreds of losses.

Another believes five consecutive losses mean a win must now be due.

Another interprets a near miss as evidence that success is getting closer.

Another exaggerates personal skill in an activity dominated by chance.

Another sees patterns where none exist.

The casino exploits these cognitive vulnerabilities expertly.

Lights.

Sounds.

Near misses.

Free drinks.

Rewards for prolonged play.

“Comps.”

Constant availability.

Online access.

Every feature encourages another wager.

The next chamber contains the brain.

Reward and decision-making circuits illuminate across the prefrontal cortex, striatum and mesolimbic dopamine system.

Neuroimaging research suggests abnormalities in systems involved in reward processing, inhibition, judgement and decision-making. Gambling cues activate networks associated with craving. Real monetary risk recruits visual, cingulate, striatal and prefrontal regions.

Dopamine becomes an especially important clue.

Some people treated with dopamine agonists for Parkinson disease unexpectedly develop severe gambling behaviour despite no previous history of the disorder. In many, the gambling diminishes after the medication is withdrawn.

The observation powerfully demonstrates that gambling behaviour is not simply a failure of morality.

Biological vulnerability matters.

But biology is not destiny.

Two people can experience the same gambling environment and respond very differently.

Genetics.

Family exposure.

ADHD.

Mood disorder.

Substance use.

Personality.

Social environment.

Availability.

Reinforcement.

All influence vulnerability.

Holmes next enters the Hall of Comorbidity.

Depression.

Bipolar disorder.

Alcohol dependence.

Cocaine use.

Nicotine dependence.

ADHD.

Personality pathology.

These conditions commonly accompany gambling disorder.

Sometimes depression precedes the gambling.

Sometimes catastrophic gambling debt produces depression.

Sometimes each amplifies the other.

The result can become extremely dangerous.

Suicidal thinking is a major concern.

For some people, disclosure of enormous debt, deception or criminal behaviour creates a catastrophic moment of exposure.

Professional reputation collapses.

Relationships fracture.

The person sees no route out.

Holmes writes one instruction above every consultation room:

ASK ABOUT SUICIDE.

He then studies the differential diagnosis.

A gambling binge during mania is not automatically gambling disorder.

Substance intoxication can temporarily disinhibit gambling.

Psychosis can generate bizarre gambling behaviour.

Dopamine agonists can precipitate excessive wagering.

Antisocial behaviour may involve gambling for reasons quite different from addiction.

And recreational gamblers - even enthusiastic ones - retain something crucial:

Control.

They establish limits.

Losses remain acceptable.

Life continues.

The pathological gambler cannot reliably stop.

Treatment begins not with moral condemnation but with engagement.

This matters because denial is powerful.

Many patients do not seek treatment until something external forces the issue:

Divorce.

Debt.

Job loss.

Arrest.

Exposure.

Psychotherapy therefore often begins with motivational interviewing.

The question is not initially:

“Why haven’t you stopped?”

It is:

“What has gambling begun to cost you?”

CBT then targets triggers, distorted beliefs, craving, impulsive decision-making and the behavioural systems maintaining gambling.

Patients learn to recognise:

The gambler’s fallacy.

Selective memory for wins.

Illusions of control.

Overconfidence.

Near-miss thinking.

Chasing.

They also reconstruct life outside gambling.

Relationships.

Exercise.

Work.

Meaningful reward.

Financial structure.

Alternative sources of stimulation.

Groups such as Gamblers Anonymous provide social support from people who understand the logic of the chase from inside it.

Family and couple work may be essential because gambling disorder rarely damages only the gambler.

Finances may require external safeguards.

Access to cash may need restriction.

Debts may need structured repayment.

Casino or betting self-exclusion may help interrupt access.

Medication has a supporting role rather than a single established pharmacological solution. The source discusses antidepressants, mood stabilisers, opioid antagonists such as naltrexone, and N-acetylcysteine, though outcomes vary and treatment of comorbidity may account for part of the benefit.

Holmes finally reaches the deepest room.

There is no roulette wheel.

Only a staircase.

At every step, the gambler can choose:

Another wager

or

Stop the chase.

The disorder repeatedly whispers:

“One more bet will solve everything.”

Recovery begins when the patient recognises the opposite:

The next bet is not the solution to the previous loss.

It is the mechanism that keeps the loss alive.

Key Takeaways

1. Gambling Disorder Is an Addiction

One of the most important changes in modern psychiatric classification was moving pathological gambling away from the impulse-control disorders.

DSM-5 conceptualised it as a:

NON-SUBSTANCE-RELATED ADDICTIVE DISORDER

This reflects overlap with substance addictions in:

* craving

* impaired control

* tolerance-like escalation

* withdrawal-like distress

* reward circuitry

* persistence despite harm

* relapse.

2. Gambling Is Ancient - Gambling Disorder Is Not New

Humans have wagered for millennia.

Historical forms include:

* dice

* knucklebones

* animal contests

* cards

* lotteries

* racing

* gaming houses

* casinos.

Modern gambling adds:

* electronic gaming machines

* internet casinos

* online poker

* sports betting

* fantasy betting

* near-continuous mobile access.

The technology changes.

The behavioural reinforcement mechanisms remain recognisable.

3. Gambling Disorder Diagnostic Pattern

The chapter describes nine core DSM-style criteria.

A diagnosis requires four or more within 12 months.

These include:

Escalation

Increasing amounts of money are wagered to achieve the desired excitement.

Restlessness when reducing

Attempts to stop or reduce gambling produce irritability or restlessness.

Failed attempts to control

Repeated unsuccessful efforts are made to cut down.

Preoccupation

The person’s mental life increasingly revolves around gambling.

Gambling during dysphoria

Gambling occurs when distressed, depressed or anxious.

Chasing

The individual returns to recover previous losses.

Deception

The extent of gambling is concealed from others.

Jeopardising life roles

Relationships, education or employment suffer.

Financial rescue

The person increasingly relies upon others for money because of gambling losses.

4. Chasing Losses Is a Central Mechanism

Chasing occurs when the gambler responds to a loss by gambling more in an attempt to recover it.

The sequence becomes:

LOSS

↓

NEED TO RECOVER

↓

LARGER BET

↓

FURTHER LOSS

↓

GREATER URGENCY

↓

MORE GAMBLING

This can become one of the most destructive loops in the disorder.

5. The “Action” Can Become More Important Than Winning

The pathological gambler may initially gamble for:

money

but progressively become addicted to:

the process of wagering itself.

The wager produces:

* anticipation

* uncertainty

* arousal

* stimulation

* excitement.

Winning permits further gambling.

Losing creates pressure to chase.

Thus:

WIN → CONTINUE

and

LOSE → CONTINUE

Both outcomes can perpetuate play.

6. Tolerance-Like Escalation

Many patients progressively require:

larger bets

or

more intense forms of gambling

to generate the same excitement.

A person may move from:

lottery tickets

to sports betting

to casino gambling

to multiple simultaneous online wagers.

Increasing intensity is a clinically important warning sign.

7. The Gambling Spiral

A useful model from the chapter is:

GAMBLING

↓

LOSS

↓

CHASE

↓

BORROW

↓

MORE LOSS

↓

DECEPTION

↓

DEBT

↓

EXPOSURE

↓

BAILOUT

↓

PROMISE TO STOP

↓

RELAPSE

The bailout can paradoxically remove the immediate consequences without changing the addiction.

8. Financial Manipulation Becomes Part of the Disorder

The gambler increasingly becomes skilled at moving money.

Possible sources include:

* savings

* credit cards

* loans

* business funds

* family accounts

* friends

* loan sharks

* selling assets.

These financial manoeuvres can themselves become incorporated into the excitement and urgency of the chase.

9. Gambling Disorder Crosses Socioeconomic Boundaries

Although historical stereotypes emphasised middle-aged men, gambling disorder occurs across:

* socioeconomic groups

* ethnic groups

* occupations

* ages

* genders.

The chapter highlights several vulnerable populations.

10. Adolescents and Young Adults

Young people may be especially vulnerable because of:

* impulsivity

* sensation seeking

* peer influence

* internet access

* developing executive control

* ADHD.

Early exposure to gambling-like games may potentially increase later risk, although causation is complex.

11. Older Adults

Risk can increase after:

* retirement

* bereavement

* loneliness

* reduced social networks

* boredom

* physical illness.

Casinos and gaming venues can provide:

stimulation + companionship + escape

which may become particularly reinforcing.

12. Women

Historically, men greatly outnumbered women among identified pathological gamblers.

The gender gap has narrowed.

The chapter describes a possible:

TELESCOPING EFFECT

in which some women begin problematic gambling later but progress towards severe gambling disorder more rapidly.

Women may also show particularly important associations between gambling, emotional distress and suicidality.

13. Prison Populations

Gambling problems may be highly prevalent within correctional settings.

Gambling may emerge because of:

* boredom

* existing addiction

* competition

* social structures within prison.

Consequences can become severe when debts involve:

* coercion

* violence

* illicit economies.

14. Family History Matters

Family histories may contain elevated rates of:

* gambling disorder

* alcohol use disorder

* substance use

* depression

* bipolar disorder.

Both:

genetic vulnerability

and

environmental modelling

may contribute.

15. Gambling Disorder Is Not Merely a Moral Failure

Historically, pathological gambling was framed as:

* sin

* vice

* weakness

* lack of character.

Modern evidence supports a multifactorial model involving:

BIOLOGY + LEARNING + COGNITION + PERSONALITY + ENVIRONMENT + AVAILABILITY

Moral condemnation can increase shame and reduce help-seeking.

16. Reward and Decision-Making Circuits

Neuroimaging research implicates networks involving:

* prefrontal cortex

* ventral striatum

* cingulate cortex

* reward circuitry

* limbic structures.

Relevant functions include:

* judgement

* inhibitory control

* reward anticipation

* risk evaluation

* decision-making

* response to losses.

17. Gambling Cues Can Trigger Craving

Seeing:

* a casino

* betting odds

* gambling advertisements

* cards

* slot machines

* sports betting imagery

can activate gambling-related neural pathways and subjective craving.

This parallels cue-induced craving in substance addiction.

18. Dopamine Is Particularly Important

Dopaminergic pathways contribute to:

reward seeking

and

reinforcement.

A striking clinical observation is the development of pathological gambling in some people with Parkinson disease receiving dopamine agonists.

In affected patients, the behaviour may diminish after reducing or withdrawing the causative medication.

This provides strong evidence that gambling behaviour can be biologically modulated.

19. Not Everyone Exposed to Dopamine Agonists Develops Gambling

This matters.

Medication exposure alone does not explain the whole disorder.

Individual differences likely involve:

* genetics

* brain vulnerability

* personality

* environmental opportunity

* previous reward-seeking tendencies.

Gambling disorder therefore remains multifactorial.

20. Cognitive Distortions Are Central

Common gambling distortions include:

Gambler’s fallacy

“I have lost five times, so a win must now be due.”

Independent random events do not acquire memory because of previous losses.

Illusion of control

“My system can control an essentially random outcome.”

Selective recall

Wins are remembered vividly.

Losses fade.

Near-miss thinking

“I nearly won, so I am getting closer.”

A near miss is still a loss.

Skill inflation

The gambler exaggerates personal expertise while underestimating chance or opponents.

Chasing logic

“The only way out of debt is to win it back.”

This is often the thought that drives the deepest spiral.

21. Gambling Environments Intensify Reinforcement

Casinos and digital gambling environments can employ:

* lights

* music

* near misses

* continuous availability

* rapid repetition

* rewards

* complimentary services

* loyalty systems

* social reinforcement.

These features can increase persistence of play.

22. Gambling Disorder and ADHD

ADHD is significantly associated with gambling problems.

Possible shared mechanisms include:

* impulsivity

* boredom intolerance

* reward seeking

* impaired inhibitory control

* sensation seeking.

This comorbidity is especially important in younger populations.

23. Mood Disorders

Important comorbidities include:

* major depression

* bipolar disorder.

The temporal relationship can vary.

Mood episode → gambling escalation

or

gambling catastrophe → depression

or both processes may interact.

24. Substance Use Disorders

Common co-occurring addictions include:

* alcohol

* cocaine

* nicotine.

Substances can worsen gambling by:

* reducing inhibition

* impairing judgement

* increasing impulsive wagering.

Cross-addiction should therefore be actively assessed.

25. Suicide Risk

Suicide risk is clinically important in gambling disorder.

Potential precipitants include:

* overwhelming debt

* family disclosure

* humiliation

* job loss

* prosecution

* relationship breakdown

* depression.

Suicidality should be assessed directly, particularly during periods of exposure or closure.

26. Physical Health Can Also Deteriorate

Severe gambling may be associated with:

* poor diet

* sleep deprivation

* inactivity

* smoking

* alcohol misuse

* neglect of medical care.

The disorder can therefore produce indirect physical morbidity alongside psychological and financial harm.

27. Recreational Gambling versus Gambling Disorder

The central difference is not simply:

HOW OFTEN DOES THE PERSON GAMBLE?

Instead ask:

CAN THEY CONTROL IT?

Recreational gamblers generally:

* establish limits

* tolerate losses

* maintain other priorities

* stop when intended

* do not chase relentlessly

* do not jeopardise life roles.

28. Professional Gambling Is Not the Same as Gambling Disorder

Professional gamblers may wager frequently and for large amounts.

But they generally:

* use disciplined risk management

* accept losses

* maintain control

* make calculated rather than desperate decisions.

A professional gambler can still develop gambling disorder, but frequency alone does not establish the diagnosis.

29. Mania Must Be Distinguished

Excessive gambling during mania may arise from:

* grandiosity

* impulsivity

* increased reward seeking

* impaired judgement.

A diagnosis of gambling disorder should not be made when excessive wagering is better explained entirely by a manic episode.

30. Psychosis Can Occasionally Produce Gambling

A person may gamble because of:

* delusions

* hallucinations

* bizarre beliefs.

The gambling behaviour should then be understood within the primary psychotic disorder rather than automatically diagnosed as gambling disorder.

31. Substance-Induced Gambling

Alcohol or cocaine intoxication may temporarily increase:

* impulsivity

* risk-taking

* disinhibition.

A single intoxication-related gambling episode does not necessarily indicate a persistent gambling disorder.

32. OCD and Gambling Disorder Are Different

Gambling may look “compulsive”.

But the phenomenology differs.

OCD symptoms are commonly:

ego-dystonic

and experienced as intrusive or unwanted.

Gambling preoccupation is often:

ego-syntonic

especially during active wagering.

The patient usually wants to gamble even while recognising its consequences.

33. Assessment Requires Persistence

Patients may:

* minimise

* deny

* rationalise

* conceal.

Screening instruments mentioned in the source include:

South Oaks Gambling Screen - SOGS

and

NODS

Structured tools can help, but detailed clinical interview remains essential.

Collateral information may sometimes be crucial.

34. Treatment Engagement Is Difficult

Only a minority of people with serious gambling problems seek professional help.

Treatment often begins after:

* financial collapse

* marital ultimatum

* legal consequences

* occupational exposure

* suicidal crisis.

Early identification is therefore a major public-health goal.

35. Motivational Interviewing

Motivational interviewing has one of the stronger psychological evidence bases discussed in the chapter.

It aims to explore:

* ambivalence

* costs of gambling

* personal goals

* discrepancy between current behaviour and desired life.

The therapist avoids moralising.

That is essential.

36. Cognitive-Behavioural Therapy

CBT targets:

* gambling triggers

* urges

* distorted beliefs

* reinforcement

* impulsive decision-making

* alternative rewards.

Patients may monitor:

TIME GAMBLING

MONEY GAMBLING

TIME THINKING ABOUT GAMBLING

Seeing the true extent of involvement can itself be therapeutic.

37. CBT Challenges Gambling Fallacies

A central task is identifying and testing beliefs such as:

“I am due for a win.”

“I can win back the losses.”

“That near miss means my system is working.”

“I am better at this game than everyone else.”

“One big win will solve everything.”

Treatment replaces gambling mythology with probabilistic reality.

38. Abstinence versus Reduction

Some patients resist treatment if immediate total abstinence is demanded.

A harm-reduction approach may sometimes improve engagement early in treatment.

For others, complete abstinence is ultimately the safest goal.

Treatment should be individualised.

39. Family and Couple Therapy

Gambling disorder often produces:

* secrecy

* betrayal

* debt

* mistrust

* conflict

* emotional trauma.

Family involvement may therefore be essential.

Partners are not simply observers.

They often become casualties of the disorder.

40. Children Can Be Profoundly Affected

Children may experience:

* neglect

* financial insecurity

* parental conflict

* inconsistent caregiving

* abuse

* psychological distress.

They may also have elevated later vulnerability to gambling problems.

The disorder should therefore be viewed as affecting the family system, not merely the individual gambler.

41. Financial Recovery Is Part of Treatment

Psychological treatment without financial containment may fail.

Relevant strategies can include:

* restricting access to funds

* external management of finances

* cancellation of credit

* structured debt repayment

* self-exclusion from gambling venues

* limiting digital gambling access.

The aim is to make gambling harder while recovery becomes easier.

42. Gamblers Anonymous

Gamblers Anonymous follows a 12-step model.

Potential benefits include:

* peer support

* accountability

* sponsorship

* recognition by people with lived experience

* practical support around restitution.

Dropout can be substantial, particularly if GA is used as the only intervention.

Many patients benefit from combining peer support with professional treatment.

43. Pharmacological Treatment

No single medication functions as a universal treatment for gambling disorder.

Agents discussed in the chapter include:

* SSRIs

* bupropion

* lithium

* lamotrigine

* atypical antipsychotics

* opioid antagonists such as naltrexone

* N-acetylcysteine.

Evidence varies.

Improvement may sometimes result from treating an important comorbid disorder rather than directly reducing gambling behaviour.

44. Benzodiazepines Require Caution

Because substance-use disorders commonly coexist with gambling disorder, benzodiazepines should be avoided or carefully monitored where addiction risk is significant.

45. Emerging Interventions

Areas under investigation include:

* mindfulness-based treatment

* rTMS

* tDCS

* cognitive remediation.

Evidence remains developing.

46. Hospitalisation May Occasionally Be Necessary

Severe end-stage gambling can involve:

* suicidality

* overwhelming debt

* severe comorbidity

* inability to stop gambling

* acute psychosocial collapse.

Removing the person temporarily from the gambling environment may allow stabilisation and planning.

47. Gambling and Crime

The chapter notes that illegal behaviour is common in severe pathological gambling.

Most offences are financial rather than violent, including:

* fraud

* bad cheques

* embezzlement

* theft.

For many patients, these behaviours arise late in an otherwise non-antisocial life while desperately financing the chase.

This distinction matters clinically and legally.

48. Exposure, Bailout and Relapse

A particularly important cycle is:

EXPOSURE

↓

CRISIS

↓

BAILOUT

↓

RELIEF

↓

MEMORY OF CONSEQUENCES FADES

↓

RETURN TO GAMBLING

Financial rescue can be necessary.

But without addiction treatment, rescue alone may inadvertently reset the cycle.

49. Availability Matters

When gambling opportunities increase, gambling-related harm can increase.

The chapter describes associations between new gambling venues and subsequent rises in local gambling problems.

Digital gambling magnifies accessibility further:

24 HOURS

NO TRAVEL

NO CASH REQUIRED

RAPID REPEAT BETTING

Access itself becomes part of the clinical environment.

50. The Central Clinical Principle

Gambling disorder is best understood as a disorder of:

REWARD

IMPULSE CONTROL

DECISION-MAKING

COGNITIVE DISTORTION

REINFORCEMENT

CRAVING

and

RELAPSE

embedded within social and commercial environments designed to encourage continued wagering.

The treatment goal is not merely:

STOP BETTING

but:

RESTORE CONTROL, REPAIR CONSEQUENCES, REBUILD REWARD OUTSIDE GAMBLING, AND PREVENT THE NEXT CHASE.

Medlock Holmes leaves the Grand Dispensary of Anxiety and enters an entirely different institution: The Grand House of Repetition.

At first, everything appears orderly. Doors are locked. Hands are washed. Objects are aligned. Possessions are carefully preserved.

Then Holmes notices something unsettling.

The same actions are happening again.

And again.

And again.

A man checks a locked door for the twentieth time. A woman washes already-clean hands. Another person stands before a mirror searching endlessly for an imperfection nobody else can see. Rooms disappear beneath possessions that cannot be discarded. In adjoining chambers, hair is repeatedly pulled and skin repeatedly picked.

Above the entrance is written:

“When repetition stops serving us, we begin serving the repetition.”

This is the world of obsessive-compulsive and related disorders (OCRDs) - a diagnostic family that includes obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder, trichotillomania and excoriation disorder. Their grouping reflects important phenomenological and biological overlaps, while recognising that each disorder has its own characteristic focus.

At the centre stands OCD.

Holmes discovers its fundamental machinery: obsessions - recurrent, intrusive, unwanted thoughts, urges or images - and compulsions - repetitive behaviours or mental acts performed in response.

The compulsion may reduce distress.

But only temporarily.

That relief reinforces the behaviour, helping the cycle continue.

Yet OCD is more than excessive anxiety. Modern models increasingly describe disturbances in cognitive control, habit formation, error monitoring and cortico-striatal-thalamic-cortical circuitry. The orbitofrontal cortex, anterior cingulate and striatum become major clues.

Holmes also discovers that insight exists on a spectrum. Many patients recognise that their fears are unreasonable. Others are less certain. A small minority become completely convinced of their obsessive beliefs. Poor insight does not automatically transform OCD into psychosis.

The investigation then expands.

In body dysmorphic disorder, repetition revolves around perceived defects in appearance.

In hoarding disorder, difficulty discarding possessions gradually overwhelms living spaces.

In trichotillomania, recurrent hair pulling becomes difficult to resist.

In excoriation disorder, the repetitive behaviour is skin picking.

Different objects.

Different behaviours.

But repeatedly, Holmes finds variations on a deeper theme:

thought → urge → behaviour → temporary consequence → repetition.

Treatment therefore aims to break the loop.

For OCD, SSRIs and clomipramine provide important pharmacological tools, often at substantial therapeutic doses and for sufficiently long trials. But one of the most powerful interventions lies in deliberately confronting the very thing the disorder commands the patient to avoid.

Exposure and Response Prevention - ERP.

Exposure activates the feared uncertainty.

Response prevention blocks the ritual.

The patient learns that distress can be tolerated without obeying the compulsion and that catastrophic expectations need not determine behaviour.

For severe treatment-resistant OCD, Holmes eventually reaches more specialised chambers: antipsychotic augmentation, glutamatergic strategies, intensive behavioural programmes and, in exceptionally refractory illness, neuromodulation or neurosurgical approaches.

The lesson of the Grand House of Repetition is therefore hopeful.

These disorders can become chronic and profoundly disabling.

But the loop is not unbreakable.

Key Takeaways

1. A New Diagnostic Family

Obsessive-compulsive and related disorders became a distinct diagnostic grouping because these conditions share important features involving:

* intrusive or repetitive thoughts

* repetitive behaviours or mental acts

* difficulties controlling repetitive behaviour

* overlapping neurobiological mechanisms

* overlapping treatment approaches.

DSM-5-TR OCRDs include:

* Obsessive-compulsive disorder - OCD

* Body dysmorphic disorder - BDD

* Hoarding disorder - HD

* Trichotillomania - hair-pulling disorder

* Excoriation - skin-picking disorder

ICD-11 conceptualises the family somewhat more broadly and additionally incorporates conditions such as olfactory reference disorder and hypochondriasis within its OCRD framework.

2. Obsessive-Compulsive Disorder

OCD is defined by:

Obsessions, compulsions, or both.

Obsessions

Recurrent and persistent:

* thoughts

* urges

* images

that are experienced as:

* intrusive

* unwanted

* distressing.

The person commonly attempts to:

ignore → suppress → neutralise

them.

Compulsions

Repetitive:

* behaviours

or

* mental acts

that the individual feels driven to perform.

Examples include:

* washing

* checking

* ordering

* counting

* repeating

* praying

* mentally reviewing.

3. The Obsession–Compulsion Cycle

A useful conceptual model is:

INTRUSIVE THOUGHT

↓

THREAT / DOUBT / DISCOMFORT

↓

ANXIETY OR “NOT-JUST-RIGHT” FEELING

↓

COMPULSION

↓

TEMPORARY RELIEF

↓

REINFORCEMENT

↓

NEXT OBSESSION

The ritual solves the immediate distress while helping preserve the longer-term disorder.

4. OCD Is Not Simply “Being Particular”

Normal habits, preferences and routines are common.

For OCD, symptoms must become sufficiently:

* time-consuming

* distressing

* impairing.

The diagnostic threshold includes symptoms taking more than one hour per day or causing clinically significant distress or functional impairment.

5. Major OCD Symptom Dimensions

Symptoms commonly cluster around several dimensions.

Contamination / Cleaning

“What if I am contaminated?”

→ washing→ cleaning→ avoiding contact.

Forbidden Thoughts / Checking

Intrusive:

* aggressive

* sexual

* religious

* moral

thoughts may generate checking, reassurance or mental rituals.

Symmetry / Ordering

The person may experience:

“It isn’t right.”

Objects or actions are repeated or arranged until they feel complete.

Harm / Responsibility

“What if I caused something terrible?”

This may produce repeated:

* checking

* reviewing

* reassurance seeking.

Hoarding symptoms can also occur within OCD, although hoarding disorder is now diagnostically distinct.

6. OCD and Insight

Insight exists on a continuum.

Good or fair insight

The patient recognises that OCD beliefs are probably or definitely untrue.

Poor insight

The patient believes the obsessive concern is probably true.

Absent insight / delusional beliefs

The patient is completely convinced.

This distinction is clinically important.

Absent insight does not automatically mean schizophrenia or another primary psychotic disorder.

A small minority of people with OCD have absent insight.

7. Tic-Related OCD

OCD can receive a:

TIC-RELATED

specifier.

This means there is a current or previous tic disorder.

Tic-related OCD tends to:

* begin younger

* occur more commonly in males

* show more symmetry/ordering phenomena

* involve sensory or premonitory urges

* sometimes respond less strongly to SSRIs.

Complex tics and compulsions can sometimes be difficult to distinguish.

8. Epidemiology

OCD was historically thought to be rare.

It is not.

Its apparent rarity partly reflected:

SHAME → CONCEALMENT → UNDERDIAGNOSIS

The chapter reports a lifetime prevalence of approximately:

2.3%

in a major epidemiological survey.

Subclinical obsessive-compulsive symptoms are substantially more common.

9. Age of Onset

Median onset is approximately:

19 years

Around:

25%

of cases begin by age 10.

Early-onset OCD is more common in males and more frequently associated with tics.

Onset after age 30 is comparatively unusual.

Symptoms may also emerge or change during:

* adolescence

* pregnancy

* the puerperium.

10. OCD Can Be Highly Disabling

OCD can interfere profoundly with:

* education

* employment

* relationships

* family functioning

* social participation

* quality of life.

A person may lose hours each day to rituals.

Others restructure their entire lives around avoidance.

Family members can become drawn into rituals through family accommodation.

11. Suicide Risk Matters

Depression is a particularly important comorbidity.

Suicidal thoughts can also occur in OCD.

Therefore:

Do not assume that OCD is merely an anxiety-and-ritual disorder.

Routine clinical assessment should include:

* depression

* hopelessness

* suicidal ideation

* suicidal behaviour.

12. The Neurobiology of OCD

Modern models increasingly conceptualise OCD as a disorder involving abnormalities of:

COGNITIVE CONTROL

and

HABIT REGULATION

rather than simply excessive anxiety.

A central circuit is the:

Cortico-Striatal-Thalamic-Cortical Circuit

CORTEX

↓

STRIATUM

↓

THALAMUS

↓

CORTEX

Important regions include:

* orbitofrontal cortex

* anterior cingulate cortex

* striatum.

Alterations in these circuits may contribute to difficulty:

* inhibiting behaviour

* shifting cognitive sets

* monitoring errors

* stopping established habits.

13. Goal-Directed Behaviour versus Habit

A particularly useful model contrasts:

Goal-directed action

“I do this because it achieves something useful.”

with:

Habit-driven behaviour

“I continue doing this even though it no longer achieves anything useful.”

OCD appears to involve an excessive shift towards:

HABIT-DRIVEN BEHAVIOUR

This helps explain why patients can recognise that a ritual is unnecessary yet still feel compelled to perform it.

14. Fear Is Not the Whole Story

Anxiety disorders are strongly associated with abnormal fear processing.

OCD also involves other emotional processes, particularly:

DISGUST

Some contamination presentations may therefore involve exaggerated disgust processing rather than fear alone.

Other patients describe:

* incompleteness

* tension

* sensory discomfort

* “not-just-right” experiences

rather than conventional fear.

15. Neurochemistry

Several neurotransmitter systems appear relevant:

Serotonin

The efficacy of serotonin reuptake inhibitors helped generate the influential serotonin hypothesis of OCD.

However:

response to serotonergic treatment does not prove that OCD is simply caused by serotonin deficiency.

Dopamine

Dopaminergic mechanisms are also implicated.

This becomes clinically important because dopamine-blocking antipsychotics can augment SRIs in treatment-resistant OCD.

Glutamate

Growing evidence implicates glutamatergic systems.

Glutamatergic agents remain an important area of therapeutic investigation.

GABA

GABAergic mechanisms may also contribute to the broader circuitry.

16. Genetics

OCD has a significant genetic component.

Genetic influence appears particularly important in:

childhood-onset OCD.

However, OCD is not a single-gene disorder.

Current evidence supports:

many genetic variants + small individual effects + environmental influences

rather than one deterministic OCD gene.

17. Assessment

A good OCD assessment should determine:

* obsessions

* compulsions

* avoidance

* symptom dimensions

* time consumed

* distress

* functional impairment

* insight

* age of onset

* course

* precipitants

* comorbidity

* suicidality

* tic history

* family accommodation.

18. Y-BOCS

The:

Yale-Brown Obsessive-Compulsive Scale - Y-BOCS

is one of the most widely used clinician-rated measures of OCD severity.

It examines dimensions such as:

* time occupied

* interference

* distress

* resistance/control.

It is particularly useful for:

baseline severity → treatment monitoring → outcome measurement.

19. Differential Diagnosis

Repetitive thinking does not automatically mean OCD.

Important differentials include:

GAD

Worries tend to concern plausible real-life problems and are usually less intrusive and ego-dystonic.

Depression

Rumination tends to be mood-congruent.

Psychosis

Delusions are generally experienced as true rather than intrusive unwanted possibilities.

Autism spectrum disorder

Repetitive behaviours occur within a broader neurodevelopmental presentation.

Eating disorders

Repetitive thoughts and behaviours centre around eating, weight and shape.

Illness anxiety

Preoccupation centres around having or acquiring illness.

BDD

Preoccupation centres around perceived appearance defects.

Hoarding disorder

The central problem is difficulty discarding possessions.

20. OCD versus OCPD

These are not the same condition.

OCD

Characterised by:

obsessions + compulsions

Often experienced as intrusive and unwanted.

Obsessive-Compulsive Personality Disorder

Characterised by pervasive:

* perfectionism

* rigidity

* control

* orderliness.

The personality traits are often experienced as more consistent with the person’s preferred way of functioning.

21. Course

Without treatment, OCD can become:

CHRONIC

and may persist for decades.

But chronicity does not mean hopelessness.

Modern evidence-based treatments can produce substantial improvement.

The clinical message should therefore remain:

PERSIST WITH TREATMENT.

22. First-Line Treatment

Two major treatment pillars dominate OCD management:

SSRIs

and

CBT WITH EXPOSURE AND RESPONSE PREVENTION

These can be used:

* individually

* sequentially

* together.

23. Exposure and Response Prevention - ERP

ERP is one of the defining treatments for OCD.

EXPOSURE

Deliberately confront the:

* thought

* object

* situation

* uncertainty

that triggers the obsession.

RESPONSE PREVENTION

Do not perform the usual compulsion.

For example:

Touch door handle

↓

Feel contaminated

↓

Wash hands

↓

Remain with uncertainty

↓

Learn something new

The patient discovers:

“I can experience this feeling without performing the ritual.”

24. Why ERP Works

The older model emphasised:

habituation

- anxiety gradually falls with repeated exposure.

Contemporary models additionally emphasise:

inhibitory learning

The patient develops new learning:

“The feared consequence is not inevitable.”

“Uncertainty is tolerable.”

“I don’t need the ritual to remain safe.”

The goal is therefore not simply:

MAKE ANXIETY DISAPPEAR

but:

CHANGE THE PERSON’S RELATIONSHIP WITH UNCERTAINTY AND COMPULSION.

25. Pharmacotherapy

The first medication historically shown to be strongly effective was:

CLOMIPRAMINE

Modern first-line pharmacotherapy generally uses:

SSRIs

because they combine efficacy with better tolerability.

26. OCD Often Requires Different Antidepressant Strategy

Compared with depression, OCD may require:

* higher SSRI doses

* longer adequate trials

* greater patience before declaring non-response.

A medication should not be abandoned prematurely.

27. Treatment-Resistant OCD

Before declaring treatment resistance, check:

Correct diagnosis?

Adequate ERP?

Adequate SSRI dose?

Adequate duration?

Adherence?

Comorbidity?

Family accommodation?

Insight?

Tics?

Only then should more complex strategies be considered.

28. Antipsychotic Augmentation

For patients with inadequate response to an adequate SRI trial, augmentation with selected antipsychotics can be useful.

This reflects the involvement of dopaminergic as well as serotonergic mechanisms.

The strategy is:

SRI + carefully selected augmentation

rather than replacing the entire treatment framework.

29. Severe Refractory OCD

A small minority remain profoundly disabled despite multiple evidence-based treatments.

Specialist approaches can include:

* intensive ERP programmes

* pharmacological augmentation

* glutamatergic strategies

* neuromodulation

* deep brain stimulation

* selected neurosurgical procedures.

These belong at the far end of a carefully constructed treatment pathway.

30. Body Dysmorphic Disorder

BDD involves persistent preoccupation with:

one or more perceived defects or flaws in appearance

that are:

* not observable to others

or

* appear slight to others.

Patients commonly perform repetitive behaviours such as:

* mirror checking

* grooming

* comparing appearance

* reassurance seeking

* camouflaging.

The distress can be profound.

31. The Cosmetic Treatment Trap

Patients with BDD may seek:

* cosmetic surgery

* dermatological procedures

* dental procedures

* aesthetic interventions.

But changing the body does not necessarily treat the underlying disorder.

Repeated procedures may therefore occur without meaningful psychological improvement.

Recognition of BDD before cosmetic intervention is clinically important.

32. Hoarding Disorder

Hoarding disorder involves persistent difficulty:

discarding or parting with possessions

regardless of their actual value.

Accumulation eventually:

CONGESTS → CLUTTERS → COMPROMISES

living spaces.

The issue is not simply owning many things.

It is the pathological difficulty discarding them and the resulting impairment.

33. Trichotillomania

Trichotillomania involves:

recurrent hair pulling → hair loss

with repeated unsuccessful attempts to:

reduce or stop the behaviour.

Common sites include:

* scalp

* eyebrows

* eyelashes.

The behaviour may occur automatically or in response to emotional or sensory states.

34. Excoriation Disorder

Excoriation disorder involves:

recurrent skin picking → skin lesions

despite repeated attempts to stop.

Consequences can include:

* scarring

* infection

* shame

* concealment

* functional impairment.

Trichotillomania and excoriation disorder are often conceptualised together as:

BODY-FOCUSED REPETITIVE BEHAVIOURS.

35. The Unifying Clinical Idea

OCRDs are not identical diseases.

But many share a common architecture:

INTRUSIVE EXPERIENCE

↓

URGE / TENSION / DISCOMFORT

↓

REPETITIVE BEHAVIOUR

↓

SHORT-TERM CONSEQUENCE

↓

REINFORCEMENT

↓

REPETITION

Understanding the loop helps explain both:

why the disorders persist

and

how treatment can interrupt them.

Medlock Holmes enters an immense Neo-Victorian treatment complex called The Grand Pharmacological Dispensary of Anxiety.

Rows of treatment pathways stretch before him.

Some contain SSRIs and SNRIs.

Others hold benzodiazepines, pregabalin, buspirone, beta-blockers, older antidepressants, antipsychotics, neurostimulation devices, and emerging experimental therapies.

But Holmes immediately notices that the first room contains no medication at all.

It is labelled:

ASSESS BEFORE YOU PRESCRIBE.

Not every anxious person needs pharmacological treatment. Some symptoms are transient or subsyndromal. At the same time, clinically significant anxiety disorders remain frequently under-recognised and undertreated, particularly in primary care. Patients may describe insomnia, palpitations, gastrointestinal symptoms, pain or fatigue rather than saying, “I am anxious.” Screening tools such as the GAD-7 can improve recognition.

Treatment therefore begins with diagnostic precision.

What is the primary disorder?

How severe is it?

Are there medical causes?

Substance use?

Depression?

Other anxiety disorders?

Psychosocial stressors?

Previous treatment response?

Drug interactions?

Patient preference?

Cost and access?

The treatment-choice diagram on page 3 captures this broader logic: illness factors, patient factors and medication factors all contribute to the decision.

For many anxiety disorders, SSRIs and SNRIs are the first-line pharmacological treatments.

Holmes watches clinicians begin low and increase gradually.

Why?

Because anxious patients can experience an early transient increase in nervousness, agitation or insomnia.

The medications also require patience.

Some improvement may appear within two to four weeks, but an adequate therapeutic trial generally requires 8–12 weeks, and remission may take considerably longer.

The goal is not merely partial improvement.

It is remission, because residual symptoms continue to impair functioning and increase relapse risk.

Holmes then reaches the Benzodiazepine Chamber.

Here the effect is strikingly different.

The alarm quietens rapidly.

Benzodiazepines enhance GABAergic inhibition and can reduce anxiety quickly.

That makes them valuable in selected circumstances - short-term adjunctive treatment, occasional panic, performance-related anxiety, or severe disabling symptoms when alternatives have failed or are not tolerated.

But the chamber contains warning plaques:

Sedation.

Dependence.

Withdrawal.

Tolerance.

Interaction with alcohol.

Driving impairment.

Their speed is both their strength and their danger.

Next comes pregabalin.

It has evidence particularly in GAD and can be useful when insomnia or pain coexist.

Buspirone occupies another chamber, particularly for chronic generalized anxiety.

Beta-blockers sit in a small performance hall.

They do not treat generalized social anxiety.

Instead, they reduce peripheral manifestations such as tremor and tachycardia during specific performance situations.

Older agents remain available but sit farther down the treatment hierarchy.

TCAs can work but carry more anticholinergic effects, cardiotoxicity and overdose risk.

MAOIs can be highly effective, particularly phenelzine in panic and social anxiety, but dietary restrictions, drug interactions and safety concerns make them second-line options.

Holmes then passes through individual disorder galleries.

In GAD, SSRIs and SNRIs dominate first-line treatment, with alternatives such as pregabalin, buspirone and selected other agents.

In panic disorder, SSRIs and venlafaxine are preferred initial options, while benzodiazepines may provide rapid short-term relief.

In social anxiety disorder, SSRIs and SNRIs again feature prominently; pregabalin and clonazepam have evidence, while beta-blockers are mainly relevant to performance anxiety.

In specific phobia, however, the shelves are nearly empty.

The principal treatment is psychological - especially exposure therapy. Pharmacotherapy has little established role and benzodiazepines may even interfere with exposure learning.

This tells Holmes something important:

The presence of anxiety does not automatically imply that medication is the best treatment.

The next room is labelled:

TREATMENT RESISTANCE

Before adding another medication, Holmes checks the foundations.

Was the diagnosis correct?

Was the dose adequate?

Was the trial long enough?

Is there thyroid disease?

Substance use?

Comorbid depression?

Poor adherence?

Drug interaction?

Only then does he consider switching, augmentation, pregabalin, benzodiazepines, atypical antipsychotics or more experimental options.

Beyond this room lies the Future Therapies Laboratory.

rTMS.

tDCS.

Neurosteroids.

Ketamine.

Cannabinoids.

Complementary therapies.

Some show promise.

But Holmes sees a large sign:

PROMISING ≠ ESTABLISHED

The evidence remains preliminary for many of these approaches.

Finally, Holmes reaches the maintenance hall.

The mistake here is stopping too soon.

Anxiety disorders are frequently chronic or recurrent, and relapse after medication discontinuation is common.

For many patients with chronic illness, medication may need to continue for 1–2 years after response, followed by gradual tapering rather than abrupt cessation.

SSRIs and SNRIs can produce discontinuation symptoms, especially shorter-half-life agents such as paroxetine and venlafaxine.

Holmes closes the final treatment ledger.

The lesson is not that anxiety should simply be medicated.

It is that somatic treatment should be deliberate, collaborative, evidence-based and disorder-specific.

The right medication, for the right person, at the right dose, for the right duration, with careful monitoring - often alongside CBT - can transform disabling anxiety into something manageable.

Key Takeaways

Recognition before treatment

* Anxiety disorders carry substantial personal and societal burden.

* Not every anxious symptom requires somatic treatment.

* Transient and subsyndromal anxiety should not automatically be medicalised.

* Nevertheless, clinically significant anxiety disorders are commonly under-recognised and undertreated.

* Detection in primary care has historically been below 50%.

* Only a minority of recognised cases receive appropriate evidence-based treatment.

* Patients commonly present with physical rather than psychological symptoms.

* Reluctance to disclose emotional symptoms can contribute to missed diagnosis.

* Clinicians may fail to enquire directly about anxiety.

* Detection improves as severity increases and with repeated healthcare attendance.

* Structured screening tools such as the GAD-7 improve recognition.

* Anxiety can often be effectively managed in primary care when properly identified.

* Chronic physical illness and adverse social determinants increase vulnerability and should heighten clinical suspicion.

Principles of Pharmacological Management

The chapter’s treatment principles can be summarised as:

DIAGNOSE → ASSESS → EDUCATE → SELECT → MONITOR → OPTIMISE

Important elements include:

* establish the primary diagnosis

* identify psychiatric comorbidity

* identify medical comorbidity

* review current medications and substances

* assess psychosocial stressors

* document baseline severity and frequency

* perform appropriate physical examination and laboratory investigation

* discuss treatment options

* incorporate patient preference

* consider previous personal and family treatment response

* check drug interactions

* consider affordability and access

* monitor progress using validated scales.

The figure on page 3 groups treatment selection into three broad domains:

Illness Factors

* severity

* frequency

* chronicity

* comorbidity

* situational versus generalized symptoms.

Patient Factors

* preference

* adherence

* insight

* psychological-mindedness.

Medication Factors

* previous response

* family response

* drug interactions

* access

* cost.

Pharmacotherapy versus Psychotherapy

* Initial evidence-based options include pharmacotherapy, CBT, or both.

* Acute efficacy of medication and psychological therapy may be similar in many anxiety disorders.

* Long-term comparative evidence is less complete.

* Combination treatment is intuitively attractive but has not consistently been proven superior to either treatment alone.

* Sequential addition of CBT after partial medication response is often a pragmatic strategy.

* Patient preference should meaningfully influence treatment choice.

SSRIs and SNRIs

These are the principal first-line pharmacological treatments across anxiety disorders.

Common SSRIs include:

* fluoxetine

* sertraline

* paroxetine

* fluvoxamine

* citalopram

* escitalopram.

Common SNRIs include:

* venlafaxine

* desvenlafaxine

* duloxetine

* levomilnacipran.

Most guidelines favour an SSRI or venlafaxine as an initial antidepressant option.

Start low, go slow

Anxious patients can be particularly sensitive to early adverse effects.

Initial treatment may temporarily increase:

* nervousness

* agitation

* insomnia

* tremor

* gastrointestinal symptoms

* headache

* dizziness.

Treatment is therefore usually started at a low dose and titrated gradually.

Do not judge treatment too early

* Early improvement may occur within 2–4 weeks.

* A proper therapeutic trial generally requires 8–12 weeks at an adequate dose.

* Some patients require substantially longer before remission.

* The chapter notes that response or remission may sometimes take up to six months.

Remission is the goal

Partial response is not enough when substantial residual symptoms remain.

Residual symptoms are associated with:

* ongoing functional impairment

* poorer quality of life

* greater relapse risk.

Treatment should therefore aim for:

REMISSION + FUNCTIONAL RECOVERY

rather than mere reduction in symptom score.

SSRI/SNRI adverse effects

Common effects include:

* gastrointestinal disturbance

* insomnia

* nervousness

* agitation

* tremor

* headache

* dizziness

* sexual dysfunction.

Sexual dysfunction may involve:

* reduced desire

* impaired arousal

* erectile dysfunction

* delayed ejaculation

* orgasmic dysfunction.

The table on page 6 highlights meaningful differences between agents, with sexual adverse effects generally more frequent with several traditional SSRIs than with agents such as buspirone, mirtazapine or some newer antidepressants.

Less common but clinically important SSRI/SNRI risks

Potential serious complications include:

* serotonin syndrome

* seizures

* induction of mania

* hyponatraemia

* gastrointestinal bleeding, particularly with NSAIDs

* increased fracture risk in some older patients.

These events are uncommon but clinically important.

Venlafaxine

Venlafaxine is among the most widely used SNRIs.

Common adverse effects include:

* dry mouth

* sweating

* constipation

* insomnia

* headache

* sexual dysfunction.

At higher doses, noradrenergic effects become more prominent.

Dose-related hypertension occurs in a minority of patients, so blood pressure monitoring is appropriate at higher therapeutic doses.

Duloxetine

Duloxetine has broadly similar efficacy and tolerability to venlafaxine.

Important considerations include:

* discontinuation syndrome

* gastrointestinal effects

* avoidance or caution in significant hepatic dysfunction.

Antidepressant discontinuation syndrome

Abrupt cessation of SSRIs or SNRIs can produce:

* anxiety

* irritability

* tearfulness

* dizziness

* light-headedness

* malaise

* sleep disturbance

* concentration difficulty.

Symptoms commonly emerge within 2–4 days.

They are particularly associated with shorter-half-life medications such as:

paroxetine

and

venlafaxine.

Gradual tapering is preferred.

Fluoxetine’s long half-life can sometimes make it useful as a bridging strategy during difficult discontinuation.

Antidepressants and suicidality

* Regulatory warnings exist regarding treatment-emergent suicidal thoughts and behaviour in children and younger adults.

* In adults aged 24 and above, short-term analyses reviewed in the chapter did not demonstrate a clear increased suicidality signal.

* In younger patients, meta-analyses suggest an increase in suicidal thoughts and behaviours of roughly 1.5–2-fold, but not a corresponding increase in completed suicide.

* The absolute increase in risk is small.

* This must be balanced against the significant morbidity of untreated anxiety.

* Medication can therefore remain appropriate in younger patients when clinically indicated, with careful monitoring.

TCAs

Examples include:

* imipramine

* clomipramine

* amitriptyline

* nortriptyline

* desipramine

* doxepin.

TCAs inhibit monoamine reuptake but also affect:

* muscarinic receptors

* histamine receptors

* α1 adrenergic receptors.

This produces adverse effects such as:

* dry mouth

* constipation

* blurred vision

* sedation

* weight gain

* orthostatic hypotension.

More serious issues include:

* lowered seizure threshold

* cardiotoxicity

* toxicity in overdose.

They are therefore usually second-line despite efficacy in some anxiety disorders.

MAOIs

Common examples include:

phenelzine

and

tranylcypromine.

They can be highly effective, especially in:

* social anxiety disorder

* panic disorder.

But their use is limited by:

* dietary restrictions

* tyramine-related hypertensive crisis

* drug interactions

* washout requirements

* postural hypotension

* weight gain

* overdose concerns.

They are generally reserved for refractory illness.

RIMAs

Moclobemide is the principal example discussed.

Potential advantages over irreversible MAOIs include:

* fewer dietary restrictions

* generally better tolerability.

It has evidence particularly in social anxiety disorder.

Availability differs internationally.

Mirtazapine

Potential advantages:

* low propensity for sexual dysfunction

* sedative properties can help insomnia

* potential utility in panic and GAD.

Limitations include:

* increased appetite

* weight gain

* sedation

* dry mouth

* dizziness.

Bupropion

* Not generally a first-line treatment for primary anxiety disorders.

* There is clinical concern that it may initially increase agitation or anxiety.

* It is more often used to treat depression or as an adjunct to address antidepressant-associated sexual dysfunction.

Vortioxetine

* Multimodal serotonergic antidepressant.

* Anxiety evidence has focused mainly on GAD.

* Results remain preliminary or inconsistent.

* Its use for anxiety is not as well established as SSRIs or SNRIs.

Agomelatine

Acts via:

* MT1/MT2 melatonin agonism

* 5-HT2C antagonism.

Potential advantages include:

* low sexual dysfunction

* little weight gain

* minimal discontinuation syndrome.

Evidence suggests possible benefit in GAD.

Liver-function monitoring is recommended.

Vilazodone

Combines:

SSRI activity + partial 5-HT1A agonism

Some trials suggest benefit in GAD, but evidence remains insufficient to establish it alongside standard first-line treatments.

Benzodiazepines

Benzodiazepines enhance GABAergic inhibition.

They possess:

* anxiolytic

* sedative

* anticonvulsant

* muscle-relaxant properties.

Common examples include:

* clonazepam

* lorazepam

* alprazolam

* diazepam

* oxazepam

* temazepam.

Liver metabolism

Most benzodiazepines undergo hepatic oxidative metabolism.

Lorazepam, oxazepam and temazepam undergo conjugation and may therefore be preferable when hepatic function is impaired.

A useful memory aid is:

LOT

LorazepamOxazepamTemazepam

Benzodiazepine strengths

* rapid onset

* strong acute anxiolytic effect

* predictable symptom relief

* useful adjunct while antidepressants take effect

* can be effective even in longer-term carefully selected use.

Benzodiazepine limitations

Important concerns include:

* sedation

* psychomotor impairment

* driving risk

* interaction with alcohol

* dependence

* withdrawal

* misuse

* potential tolerance.

Avoid or use very cautiously in people with significant substance-use histories.

Short-term adjunctive use

Benzodiazepines may be prescribed for approximately 3–4 weeks when initiating an antidepressant to help manage:

* severe anxiety

* insomnia

* jitteriness

* delayed antidepressant onset.

PRN benzodiazepines

May be useful in selected situations such as:

* occasional panic attacks

* discrete performance anxiety.

Frequent panic attacks are generally better treated preventively rather than repeatedly attempting to abort attacks with PRN benzodiazepines.

Pregabalin

Pregabalin has meaningful evidence in anxiety disorders, particularly GAD.

Potential advantages include use where:

* pain is comorbid

* insomnia is prominent.

Adverse effects include:

* dizziness

* drowsiness

* weight gain.

Pregabalin is primarily renally cleared, so renal impairment is an important consideration.

Other anticonvulsants

Agents sometimes used include:

* gabapentin

* topiramate

* tiagabine

* lamotrigine

* levetiracetam.

Evidence is generally weaker or inconsistent compared with pregabalin.

Atypical antipsychotics

Agents include:

* quetiapine

* olanzapine

* risperidone

* aripiprazole

* ziprasidone

* lurasidone.

Evidence in primary anxiety disorders is limited.

Quetiapine has demonstrated efficacy in GAD, but adverse effects limit its use.

Key concerns include:

* weight gain

* metabolic syndrome

* diabetes risk

* lipid abnormalities.

They are therefore generally later-line or augmentation strategies.

Beta-blockers

Common options:

* propranolol

* atenolol.

They reduce peripheral adrenergic symptoms such as:

* tremor

* tachycardia.

Their principal role is performance anxiety.

They are not effective treatments for generalized social anxiety disorder.

Relevant contraindications include some:

* cardiac disease

* pulmonary disease

* diabetes

* angle-closure glaucoma.

Buspirone

Buspirone is an azapirone with serotonergic activity.

It is primarily useful for:

GAD

Important characteristics:

* not immediately acting

* usually taken in divided doses

* response develops over time

* does not provide benzodiazepine-like rapid relief.

Hydroxyzine

Hydroxyzine is an antihistamine with evidence for GAD.

Potential advantages:

* relatively rapid early symptom relief

* alternative to benzodiazepines in selected patients.

Common adverse effects:

* sedation

* dry mouth

* tremor.

Tolerance to anxiolytic effects may develop.

Treatment-resistant anxiety

Before labelling anxiety treatment-resistant:

RECHECK THE CASE

Specifically assess:

* diagnosis

* medical causes

* thyroid disease

* substance use

* comorbid psychiatric disorders

* adherence

* drug interactions

* adequate dose

* adequate duration

* access to effective CBT.

Augmentation strategies

Possible augmentation agents include:

* pregabalin

* benzodiazepines

* selected anticonvulsants

* atypical antipsychotics.

The evidence base is limited relative to first-line treatments.

Treatment-resistant GAD is sometimes treated by adding pregabalin or a benzodiazepine to an SSRI/SNRI.

For treatment-resistant panic disorder, clonazepam augmentation may be considered when CBT is unavailable or unsuitable.

Novel Treatments

rTMS

Evidence for pure anxiety disorders remains limited.

Some preliminary benefit has been reported for:

* GAD

* SAD

* panic disorder.

A small fMRI-guided GAD study reported promising results, but larger controlled trials are required.

tDCS

Transcranial direct-current stimulation is another non-invasive neuromodulation technique.

Early reports suggest possible benefit in GAD and panic disorder, but evidence remains preliminary.

Neurosteroids

Intranasal neurosteroidal compounds such as PH94B have shown promising results in social anxiety disorder.

These remain investigational.

Ketamine

Ketamine has demonstrated substantial efficacy in treatment-resistant depression.

Small studies suggest possible rapid anxiolytic effects in:

* social anxiety disorder

* GAD.

The evidence remains insufficient to establish ketamine as standard treatment for primary anxiety disorders.

Cannabinoids

Cannabinoids are increasingly used by patients seeking relief from anxiety.

Some evidence suggests possible anxiolytic effects in GAD and SAD.

However, the chapter emphasises major limitations:

* heterogeneous preparations

* inconsistent dosing

* limited long-term data

* methodological problems

* publication bias.

No firm therapeutic conclusions can therefore be drawn.

Complementary and Alternative Therapies

Patients commonly use:

* herbal preparations

* acupuncture

* yoga

* biofeedback

* supplements.

Clinicians should actively ask about these treatments because herbal agents can cause clinically important drug interactions.

Kava

Kava has some evidence for mild-to-moderate anxiety.

However:

* efficacy in specific anxiety disorders remains uncertain

* hepatotoxicity is a concern

* CYP-mediated drug interactions can occur.

Exercise

Aerobic exercise has evidence for reducing anxiety symptoms and provides substantial broader health benefits.

The chapter supports routinely recommending physical exercise when appropriate.

Yoga also has preliminary evidence, particularly in performance and other anxiety states.

Duration of Pharmacotherapy

An adequate acute trial generally requires:

8–12 weeks at a therapeutic dose

For chronic anxiety disorders, continuing medication after response is usually necessary.

Relapse studies report approximately:

20–50% relapse within several months of antidepressant discontinuation.

The chapter recommends maintenance therapy for many patients for approximately:

1–2 years

before considering discontinuation.

Tapering

Discontinuation should be slow.

The chapter describes dose reductions of roughly:

10–25% every 1–2 months

with monitoring for recurrence.

Tapering must be individualised.

Abrupt cessation should generally be avoided.

Expected Pharmacotherapy Response

Approximate response rates described in the chapter include:

Panic disorder: 60–70%

GAD: 50–60%

Social anxiety disorder: 50–60%

Panic disorder is therefore among the more pharmacologically responsive anxiety disorders.

Agoraphobia may reduce response rates when comorbid with panic disorder.

Evidence-Based Monotherapy Pattern

The table on pages 17–18 provides a useful broad hierarchy.

SSRIs

First-line: SAD, GAD, PD

SNRIs

First-line: SAD, GAD, PD

TCAs

* not recommended in SAD

* second-line in GAD

* second-line in PD

MAOIs

* second-line in SAD

* second-line in PD

* limited evidence in GAD

Benzodiazepines

Generally second-line

Pregabalin

* strong role in SAD

* second-line in GAD in the source’s summary table

* insufficient evidence in PD

Quetiapine

Second-line in GAD but limited by adverse effects.

Generalized Anxiety Disorder

Preferred pharmacological options include:

SSRIs

and

SNRIs

Alternatives include:

* pregabalin

* buspirone

* quetiapine

* mirtazapine

* selected newer antidepressants.

SSRIs are generally the preferred initial option.

Pregabalin is another important option.

Benzodiazepines are effective but usually restricted because of dependence and tolerance concerns.

Quetiapine works but is generally second-line because of metabolic adverse effects.

Propranolol has not demonstrated meaningful efficacy for GAD.

Panic Disorder

First-line pharmacological treatments include:

SSRIs

and

venlafaxine

Effective older treatments include:

* clomipramine

* imipramine

* phenelzine

* tranylcypromine.

Their adverse-effect burden places them later in the hierarchy.

Benzodiazepines such as:

* alprazolam

* lorazepam

* diazepam

* clonazepam

can provide rapid short-term relief.

Maintenance antidepressant treatment can prevent relapse for years in responsive patients.

Agoraphobia

Pharmacological evidence for pure agoraphobia is limited.

Most pharmacological improvement occurs through treatment of:

* panic disorder

* depression

* other comorbid anxiety disorders.

CBT, especially exposure therapy, has a stronger direct evidence base.

Social Anxiety Disorder

First-line treatments described include:

* SSRIs

* SNRIs

* pregabalin

* clonazepam.

Phenelzine is highly efficacious but generally second-line because of adverse effects and dietary restrictions.

Other options include:

* mirtazapine

* moclobemide

* selected benzodiazepines

* gabapentin.

Beta-blockers are useful for:

PERFORMANCE ANXIETY

but not generalized social anxiety disorder.

Specific Phobia

This is the major exception to the medication-focused approach.

Best-established treatment:

EXPOSURE-BASED PSYCHOTHERAPY

Medication evidence is very limited.

SSRIs may occasionally be considered when psychotherapy fails or cannot be used.

Benzodiazepines have not demonstrated clear benefit and may interfere with exposure-based learning.

Therefore:

SPECIFIC PHOBIA → THINK EXPOSURE FIRST

Separation Anxiety Disorder

Evidence is strongest in younger populations.

SSRIs show benefit in studies of mixed paediatric anxiety populations including:

* GAD

* SAD

* separation anxiety disorder.

TCAs and clonazepam have not shown convincing benefit.

Adult pharmacological data remain sparse.

Selective Mutism

Psychosocial treatment is generally preferred.

SSRIs such as:

* fluoxetine

* fluvoxamine

may be considered in more severe or treatment-resistant cases.

Evidence remains considerably smaller than for other anxiety disorders.

Children and Adolescents

Anxiety disorders are highly prevalent in young people.

SSRIs and SNRIs have evidence in paediatric:

* GAD

* social anxiety disorder

* separation anxiety disorder.

Psychological treatment is often preferred initially, particularly for milder cases.

Combination treatment may provide greater benefit in some paediatric anxiety disorders.

Antidepressant treatment requires appropriate monitoring for treatment-emergent suicidal thoughts or behaviours.

The chapter emphasises that the absolute risk is small and should be balanced against the morbidity of untreated anxiety.

Optimising Treatment

The chapter’s pharmacotherapy checklist can be condensed into:

Aim for remission.

Choose an evidence-based first-line drug.

Start low.

Increase gradually.

Educate about adverse effects.

Allow 8–12 weeks at an adequate dose.

Use benzodiazepines selectively and usually short-term.

Maintain successful treatment long enough to reduce relapse.

Taper gradually.

Add CBT when appropriate.

The Central Clinical Principle

Somatic treatment of anxiety is not:

“The patient is anxious → prescribe an anxiolytic.”

It is:

Diagnosis → Severity → Comorbidity → Preference → Evidence → Safety → Adequate Trial → Monitoring → Remission → Maintenance → Careful Discontinuation

Medication should therefore be understood not as a universal antidote to anxiety, but as one component of a broader treatment strategy.

Medlock Holmes enters an immense Victorian experimental laboratory called The Institute of Fear and Learning.

Around him, patients are trapped within apparently different mysteries.

One avoids dogs. Another fears crowded trains because a panic attack might occur. Another rehearses every sentence before speaking, terrified of humiliation. Another spends hours worrying about disasters that may never happen.

Yet Holmes notices the same mechanism running beneath them all.

Threat → Anxiety → Escape or Safety Behaviour → Relief → Stronger Future Fear.

Avoidance works remarkably well in the short term. That is precisely why it becomes such a problem.

Each escape produces relief. Relief negatively reinforces avoidance. And every avoided encounter prevents the person from discovering something potentially transformative:

Perhaps the predicted catastrophe would not have happened.

Cognitive-behavioural therapy breaks this cycle.

At its centre lies the concept of the fear structure: interconnected representations of stimuli, responses, and meanings. A dog becomes associated with danger. Palpitations become associated with heart attack. Social attention becomes associated with humiliation. Uncertainty becomes associated with intolerable catastrophe.

The fear itself is not necessarily pathological. The problem is that the structure inaccurately represents reality.

For therapeutic change to occur, two things are required. The fear structure must first be activated. Then the patient must encounter information incompatible with its pathological predictions. Modern formulations describe this in terms of prediction error: the brain predicts catastrophe, encounters a different outcome, and is given an opportunity to update its model.

This explains why exposure sits at the heart of CBT for anxiety disorders.

Exposure may be in vivo - entering the avoided lift, touching the feared animal, speaking in front of others.

It may be imaginal - deliberately approaching distressing memories, images, thoughts, or feared future scenarios.

Or it may be interoceptive - deliberately producing the bodily sensations that have themselves become feared, such as dizziness, breathlessness or a racing heart.

But exposure is not simply a test of endurance.

Its purpose is learning.

The patient predicts:

“If my heart races, something terrible will happen.”

The experiment produces a racing heart.

The catastrophe does not occur.

Or perhaps something uncomfortable does happen - embarrassment, anxiety, uncertainty - and the patient discovers that even this is tolerable.

The prediction begins to change.

Holmes therefore realises that falling anxiety during a single exposure is not the ultimate objective. Someone may feel better because they distracted themselves, escaped psychologically, performed a ritual, sought reassurance, or relied upon another safety behaviour.

The more important question is:

What did they learn?

That distinction also explains why safety behaviours matter. The patient who survives a feared situation while gripping a bottle of water, checking their pulse, rehearsing every sentence or staying beside a trusted companion may conclude:

“I survived because my protection worked.”

The old fear remains intact.

CBT therefore combines exposure with cognitive work: identifying catastrophic predictions, examining evidence, using Socratic questioning, uncovering deeper meanings, and designing behavioural experiments that allow beliefs to collide with reality.

Different anxiety disorders require different experiments.

In panic disorder, treatment targets the fear of fear itself. Interoceptive exposure deliberately produces feared sensations so that palpitations, dizziness or breathlessness can be experienced without catastrophe.

In specific phobia, the person progressively approaches the feared object or situation.

In social anxiety disorder, exposure targets feared scrutiny and rejection while attention is shifted outward and safety behaviours are dropped.

In generalized anxiety disorder, where there may be no single feared object, treatment focuses more heavily upon worry, intolerance of uncertainty, cognitive work, problem-solving and sometimes imaginal exposure to uncertain future outcomes.

Acceptance and mindfulness can also be incorporated - not as methods of making anxiety disappear, but as ways of reducing the struggle against internal experience.

By the end of the investigation, Holmes understands the paradox.

The anxious person has often spent years becoming exceptionally skilled at preventing feared outcomes.

CBT asks them to relinquish enough protection to discover whether that protection was ever necessary.

The therapeutic question therefore changes from:

“How can I make sure I never feel afraid?”

to:

“What happens when I approach what matters, allow anxiety to be present, and discover for myself what is actually dangerous?”

That is the central experiment of cognitive-behavioural therapy.

Key Takeaways

1. Anxiety disorders share a common CBT architecture

Despite different symptom presentations, anxiety disorders commonly involve three interacting elements:

Threat cognition → anxiety response → avoidance or defensive behaviour.

The feared outcome differs by disorder:

* Panic disorder: catastrophic consequences of anxiety or bodily sensations - the “fear of fear”.

* Social anxiety disorder: embarrassment, negative evaluation and rejection.

* Specific phobia: harm associated with a circumscribed object or situation.

* GAD: uncertainty regarding future negative outcomes.

* Similar CBT principles also extend to OCD and PTSD despite their classification outside the DSM-5 anxiety-disorders grouping.

2. The fear structure

Emotional processing theory conceptualises fear as an interconnected structure containing:

STIMULUS + RESPONSE + MEANING

For example:

Dog → tachycardia/urge to flee → “Dogs are dangerous and uncontrollable.”

The structure is adaptive when it accurately identifies danger and generates effective protective behaviour.

It becomes pathological when safe or relatively harmless stimuli, responses or situations acquire unrealistic meanings.

3. Emotional processing requires activation plus corrective information

Two conditions are central:

1. Activate the fear structure.

The patient must encounter or meaningfully represent what they fear.

2. Introduce incompatible information.

Experience must provide evidence inconsistent with the pathological associations.

Thus:

Prediction → Experience → Prediction Error → Updating

Exposure provides an especially powerful environment for this process.

4. Exposure is not simply about “getting used to anxiety”

Exposure deliberately confronts feared but objectively safe:

* objects

* situations

* activities

* thoughts

* memories

* images

* physiological sensations.

Its therapeutic purpose is to alter the meaning attached to these experiences.

The patient can learn:

“Anxiety is uncomfortable, but tolerable.”

“My prediction was exaggerated.”

“The catastrophe did not occur.”

“Even when something unpleasant happened, I could cope.”

5. Between-session learning matters more than simply feeling calmer during one exposure

Earlier models emphasised within-session habituation - anxiety progressively declining during an exposure.

The chapter cautions that this is neither necessary nor sufficient for successful treatment.

Anxiety may decline because the patient:

* distracts themselves

* performs a compulsion

* uses reassurance

* engages in a safety behaviour

* mentally disengages.

The more meaningful evidence of emotional processing is enduring change that transfers beyond the immediate exercise, particularly between-session reductions in fear and pathological cognitions.

6. Avoidance is maintained by negative reinforcement

The mechanism is simple:

Fear → Escape → Relief

Relief rewards escape.

Therefore:

Fear → Escape → Relief → More Escape Next Time

Avoidance also prevents exposure to corrective information.

The person concludes:

“Nothing bad happened because I avoided it.”

rather than discovering:

“Perhaps it was safe.”

This makes avoidance one of the central maintaining mechanisms of anxiety disorders.

7. Safety behaviours can preserve fear

Safety behaviours are actions intended to prevent catastrophe during feared situations.

Examples include:

* reassurance seeking

* checking

* carrying “protective” objects

* remaining near exits

* rehearsing speech

* monitoring bodily sensations

* relying excessively on another person.

The difficulty is misattribution.

Instead of learning:

“The feared situation was safe,”

the patient learns:

“I survived because I protected myself.”

CBT therefore frequently requires dropping subtle safety behaviours during exposure.

8. Benzodiazepines can interfere with exposure learning

The chapter describes research in fear of flying in which benzodiazepine use reduced anxiety during the initial exposure but impaired later learning when the medication was absent.

The broader principle is important:

Immediate reduction in distress is not synonymous with therapeutic learning.

If medication, distraction or another safety strategy becomes the explanation for survival, the underlying fear prediction may remain unchanged.

9. Distraction is more nuanced

Distraction does not invariably undermine exposure.

Its effects depend upon factors such as:

* intensity of distraction

* divided versus complete attention

* interpersonal involvement

* severity of anxiety

* number and duration of exposures.

When emotion is overwhelming, some distraction may make engagement possible.

The clinically important question remains whether sufficient processing and corrective learning occur.

Three complementary models of exposure

Emotional Processing Theory

Pathological fear structures must be activated and modified through incompatible corrective information.

Belief Disconfirmation

Maladaptive beliefs generate emotional and behavioural responses.

Treatment tests those beliefs against evidence.

Inhibitory Learning

Exposure creates inhibitory learning that competes with the original fear association rather than necessarily deleting it.

This explains why fear can return.

Modern exposure therefore attempts to maximise:

expectancy violation, prediction error, removal of safety signals, variability of exposure and learning across contexts.

These models use different terminology but substantially overlap in clinical practice.

The four major procedural families of CBT

The chapter describes four broad components:

* Exposure

* Anxiety/stress-management strategies

* Cognitive therapy

* Specific skills training

Treatment usually begins with:

Assessment → Psychoeducation → Individual formulation → Treatment targets → Collaborative plan → Homework and monitoring

CBT is therefore structured without being mechanically standardised.

The Three Forms of Exposure

1. In Vivo Exposure

Direct confrontation with feared real-world situations.

Examples:

Spider phobia: photograph → spider behind glass → approaching spider → touching spider.

Social anxiety: initiating conversations, speaking publicly, allowing visible anxiety.

Panic/agoraphobia: queues, lifts, public transport, crowded environments.

Exposure can be graduated, but contemporary approaches do not require rigid progression from the easiest item to the hardest.

2. Imaginal Exposure

The patient vividly approaches feared:

* thoughts

* images

* memories

* scenarios

* consequences.

It is particularly useful when the feared event cannot safely or practically be reproduced.

Imaginal exposure can also help distinguish:

Remembering danger ≠ being in danger now.

It may also reveal that an imagined catastrophe is less probable, less severe or more manageable than assumed.

3. Interoceptive Exposure

The feared stimulus is generated inside the body.

Exercises deliberately reproduce sensations such as:

* dizziness

* tachycardia

* breathlessness

* tingling

* nausea

* derealisation-like sensations.

Examples include spinning, aerobic exercise or controlled hyperventilation.

The purpose is not simply symptom provocation.

It is learning:

Sensation ≠ catastrophe.

This is particularly important in panic disorder.

Imagery Rescripting

Imagery rescripting extends imaginal approaches.

A distressing memory is revisited while new perspectives or responses are incorporated into the representation of the event.

The person may imagine their current self entering the old memory and providing protection, understanding or unmet needs.

The purpose is not to pretend the historical event changed.

It is to alter its current emotional meaning.

Cognitive Therapy

Cognitive therapy begins from the proposition that emotional reactions depend substantially upon how events are interpreted.

Important distortions include:

* probability overestimation

* catastrophising

* all-or-nothing thinking

* overgeneralisation

* selective attention to confirming evidence.

Three traditional techniques highlighted are:

Socratic dialogue

Questions help the patient examine assumptions rather than simply being told that they are wrong.

Downward arrow

Repeated questioning uncovers the deeper meaning beneath an automatic thought.

Thought records

The patient records beliefs, evidence for and against them, cognitive distortions and more realistic alternatives.

Behavioural Experiments: where cognition meets exposure

Behavioural experiments integrate cognitive and behavioural approaches.

The patient makes a specific prediction:

“If I become very dizzy, I will lose control.”

The experiment intentionally creates dizziness.

The actual outcome is observed.

The discrepancy becomes evidence.

This can be conceptualised as:

Prediction → Test → Observation → Reappraisal

The goal is not therapist reassurance.

It is patient-generated evidence.

Acceptance and Mindfulness

Acceptance-based approaches challenge another form of avoidance:

avoidance of internal experience itself.

Trying desperately to suppress anxiety can paradoxically strengthen the struggle with it.

Acceptance involves acknowledging anxiety and observing it without automatically attempting to eliminate it.

The principle fits naturally with exposure:

“I can experience this feeling without escaping from it.”

ACT, mindfulness-based approaches and related methods can therefore be integrated with conventional CBT.

Anxiety Management and Stress Inoculation

Anxiety can be understood through interacting:

Cognitive

Physiological

and

Behavioural

channels.

Management strategies may include:

* coping self-statements

* diaphragmatic breathing

* progressive muscle relaxation

* behavioural rehearsal

* role-play

* problem-solving.

These approaches can improve perceived competence, although strategies intended purely to suppress anxiety should not become safety behaviours that undermine exposure learning.

Interpersonal Skills

Some people with social anxiety have genuine interpersonal skill deficits in addition to fear.

Treatment may therefore include:

* assertiveness

* initiating conversations

* maintaining conversations

* ending conversations

* interpersonal practice.

Importantly, social interaction should not become another performance test.

A more adaptive goal may be:

connection rather than perfect performance.

CBT for Specific Phobias

Exposure is the core intervention and is strongly supported.

Historically, treatment evolved from:

Systematic desensitisation

towards more direct:

In vivo exposure

and guided mastery/participant modelling.

In vivo exposure is generally more effective than imaginal exposure when safe direct exposure is feasible.

Virtual-reality exposure also has evidence of effectiveness.

CBT for Panic Disorder

The core vicious cycle is:

Bodily sensation → Catastrophic interpretation → Anxiety → More bodily sensation → Panic

Treatment commonly includes:

* psychoeducation

* cognitive restructuring

* interoceptive exposure

* in vivo exposure where avoidance/agoraphobia exists.

Interoceptive exposure is particularly important because panic disorder involves fear of the anxiety response itself.

The chapter reports substantial evidence supporting CBT, including durable outcomes after treatment cessation.

Relaxation and breathing retraining were historically prominent but are not necessary components and may sometimes interfere when used defensively.

CBT for Social Anxiety Disorder

The central fear involves:

scrutiny → perceived poor performance → humiliation/rejection

Effective contemporary treatment emphasises:

* exposure to social situations

* cognitive restructuring

* specific predictions before exposure

* dropping safety behaviours

* shifting attention away from excessive self-monitoring

* external attention

* feedback after exposure

* video feedback where useful.

Individual CBT has particularly strong evidence.

Internet-based CBT has also produced promising outcomes.

CBT for Generalized Anxiety Disorder

GAD differs because the feared stimulus is diffuse.

The central problem is:

excessive and difficult-to-control worry about uncertain future outcomes.

Treatment has traditionally included:

* cognitive therapy

* relaxation

* worry-focused exposure

* problem-solving.

More recent formulations increasingly target:

intolerance of uncertainty

and:

meta-worry - worrying about worry itself.

A useful distinction is between:

Current solvable problem → Problem-solving

versus

Unknown future possibility → Learning to tolerate uncertainty

Imaginal exposure can be used for feared uncertain outcomes.

CBT is effective for GAD, although treatment effects have historically been less robust than for some more circumscribed anxiety disorders.

Treatment Delivery Matters

Knowing the name of a technique is not equivalent to delivering it competently.

Effective CBT requires the therapist to identify:

* the patient’s actual core fear

* overt avoidance

* covert avoidance

* safety behaviours

* the appropriate exposure target

* the prediction being tested

* the corrective information available.

Therapeutic warmth, empathy and alliance remain important because they facilitate engagement and adherence.

But nonspecific therapeutic qualities alone do not substitute for technical competence.

Internet-Based CBT

Therapist-supported internet interventions have increasingly demonstrated efficacy across disorders including:

* panic disorder

* social anxiety disorder

* GAD.

This is particularly important because one of CBT’s limitations is access to clinicians with adequate specialist expertise.

Digital delivery may therefore substantially expand treatment availability.

CBT and Medication

Combining medication with CBT does not automatically produce superior outcomes.

The chapter’s overall interpretation is that adding medication to effective CBT generally produces either a small additional advantage or none, whereas adding CBT to medication can improve medication outcomes.

Sequential augmentation may sometimes be more informative than beginning both simultaneously.

Treatment should therefore be strategically combined rather than assuming:

more treatment = better treatment.

The enduring lesson

The aim of CBT is not to convince the patient intellectually that nothing bad will ever happen.

Nor is it to guarantee permanent calm.

The deeper objective is to change the relationship between:

Prediction

Fear

Avoidance

Experience

and

Learning.

The therapist does not simply tell the patient:

“You are safe.”

Instead, treatment creates conditions in which the patient can discover:

“I predicted catastrophe. I approached rather than escaped. I relinquished the behaviours I believed were protecting me. I experienced what actually happened. And now I have new evidence.”

That is the engine of cognitive-behavioural therapy for anxiety disorders.

Medlock Holmes enters the Grand Neuroanatomical Theatre of Fear.

At the centre hangs an enormous transparent brain.

The amygdala glows brightly.

But Holmes does not stop there.

Around it are the hippocampus.

The medial and orbital prefrontal cortex.

The anterior cingulate cortex.

The insula.

The thalamus.

The hypothalamus.

The bed nucleus of the stria terminalis.

The periaqueductal grey.

The locus coeruleus.

Sensory association cortices.

White-matter pathways.

Every structure is connected.

The chapter begins with an important methodological principle.

To understand the circuitry of anxiety, investigators move step by step:

First, identify the clinical phenomenon.

Then identify the brain systems that normally perform that function.

Then determine whether those systems behave differently in people with anxiety disorders.

Finally, ask whether those abnormalities relate to symptoms, course, or treatment response.

The functional problems are familiar:

Persistent learning about threat.

Exaggerated fear.

Poor extinction.

Difficulty suppressing attention to danger.

Overgeneralisation from one threat to similar safe stimuli.

Heightened perception of threat.

Increased sensitivity to bodily sensations.

Neuroimaging attempts to map these phenomena onto circuits.

Holmes enters the Fear Learning Laboratory.

A neutral cue appears.

Then an aversive event.

Again.

And again.

Eventually the cue alone produces fear.

The cue has become the CS+.

Another cue that was never paired with danger becomes the CS−.

The amygdala learns the association.

But then the experiment changes.

The CS+ is repeatedly presented without the aversive event.

Fear gradually decreases.

This is extinction.

Holmes notices something crucial.

Extinction does not erase the original fear memory.

It creates a new competing safety memory.

That means extinguished fear can return.

After time.

In another context.

After an unexpected aversive event.

The fear memory was not destroyed.

It was inhibited.

The chapter distinguishes this from memory reconsolidation.

When a fear memory is retrieved, it temporarily becomes unstable.

During a reconsolidation window, new information may modify the original memory itself.

This raises the possibility that future interventions might not simply suppress old fear, but update it.

The clinical relevance is immediate.

Exposure therapy works through these same learning principles.

The therapeutic challenge is therefore not merely helping the patient endure fear.

It is helping the brain encode and retain safety.

Holmes now enters the Amygdala Chamber.

Sensory information arrives through two major routes.

The first is fast.

The thalamus sends relatively crude information directly towards the lateral amygdala.

Danger can be detected before the cortex has fully analysed what is happening.

The second is slower.

Sensory cortex processes the stimulus in greater detail before communicating with the amygdala.

The lateral amygdala receives converging information about the conditioned and unconditioned stimuli.

The basal and accessory basal nuclei help shape learning and memory.

The central nucleus becomes the major output station.

From there, signals descend towards the hypothalamus, brainstem, and motor systems.

Heart rate rises.

Blood pressure changes.

Breathing accelerates.

The body freezes or prepares to flee.

Stress hormones are released.

Facial expression changes.

The figure on page 6 maps this architecture beautifully: external threat enters through sensory and thalamic pathways, converges upon the amygdala, and then recruits systems controlling endocrine, autonomic, behavioural, and motor responses.

But Holmes notices another structure beside the amygdala:

The Bed Nucleus of the Stria Terminalis.

The distinction becomes fundamental.

The amygdala is strongly involved in acute fear.

The BNST is particularly important for sustained anxiety.

An obvious danger appears.

The amygdala responds.

An uncertain threat may appear sometime soon.

The BNST keeps the organism vigilant.

This distinction becomes especially important in generalized anxiety disorder.

Holmes then reaches the Prefrontal Control Room.

The medial prefrontal cortex and anterior cingulate are not passive observers.

They regulate fear.

Interpret context.

Predict consequences.

Modify behaviour.

Help determine whether the amygdala should continue sounding the alarm.

The prelimbic and infralimbic regions in animal models provide an important conceptual framework.

Prelimbic circuitry can support fear expression.

Infralimbic circuitry contributes to extinction.

In humans, the ventromedial prefrontal cortex performs an analogous regulatory role.

The source’s figure on page 9 places fear expression and fear extinction beside one another.

During fear expression, amygdala output activates downstream physiological responses.

During extinction, hippocampal contextual information and infralimbic/vmPFC pathways recruit inhibitory interneurons within the amygdala, suppressing central-amygdala output.

The same fear cue can therefore produce a very different response depending on which circuit dominates.

Holmes sees anxiety as a problem of balance.

Threat detection must be fast enough to protect.

But cortical regulation must be strong enough to stop fear when the danger is no longer relevant.

The next chamber belongs to the hippocampus.

The amygdala asks:

“Is this dangerous?”

The hippocampus adds:

“Where are we?”

Context matters.

A person bitten by a dog may learn fear.

But whether that fear is expressed later depends partly on whether the current environment resembles the original context.

The hippocampus helps distinguish:

This place was dangerous.

This place is safe.

This cue used to predict harm.

Here, it no longer does.

Without contextual discrimination, fear generalises.

The same signal spreads across places and situations that were never dangerous.

The hippocampus therefore helps determine whether the original fear memory or the newer extinction memory should dominate.

Holmes then encounters the Orbitofrontal Chamber.

The orbitofrontal cortex tracks changing reinforcement.

What used to predict danger may no longer do so.

What used to be safe may now carry risk.

Behaviour must change accordingly.

Damage to orbitofrontal systems produces perseveration.

The person continues using an old strategy despite changed circumstances.

In anxiety, dysfunctional orbitofrontal regulation may contribute to continued fearful thoughts and behaviours even when reinforcement no longer supports them.

The next room belongs to the insula.

Here, Holmes hears the body.

Heartbeat.

Breathing.

Nausea.

Chest tightness.

Internal temperature.

Visceral sensations.

The insula plays a central role in interoception.

This is particularly relevant to panic disorder.

The person does not merely experience bodily sensations.

They monitor them.

Interpret them.

Amplify them.

A harmless change in heart rate becomes evidence of catastrophe.

The brain’s representation of internal bodily state becomes part of the threat itself.

Holmes enters the Imaging Observatory.

Different instruments examine different dimensions of brain structure and function.

Structural MRI measures regional size and shape.

Voxel-based morphometry compares grey-matter architecture.

Diffusion tensor imaging estimates white-matter organisation through measures such as fractional anisotropy.

PET examines blood flow or metabolism.

fMRI measures BOLD signal.

EEG records electrical activity.

MEG measures magnetic fields generated by neuronal activity.

But Holmes quickly learns that brain imaging is always state dependent.

A resting brain.

A brain viewing fearful faces.

A brain recalling panic.

A brain anticipating shock.

A brain undergoing treatment.

These are not equivalent experiments.

Neuroimaging therefore depends as much on the task as on the scanner.

The next chamber examines healthy fear learning.

Human studies repeatedly show increased amygdala activity to a CS+ compared with a CS−.

During extinction, vmPFC activation becomes important.

Stronger vmPFC activation predicts better retention of extinction.

The hippocampus becomes particularly active when context determines whether fear or safety should be expressed.

Together, the amygdala, vmPFC, and hippocampus form a central circuit for human fear acquisition and extinction.

Holmes then enters the Emotional Face Gallery.

Hundreds of faces look towards him.

Fearful.

Angry.

Happy.

Neutral.

Surprised.

The amygdala responds to many emotionally salient expressions, but fearful and ambiguous faces can produce particularly strong responses.

Why?

A fearful face says:

“Something dangerous is nearby.”

But it does not reveal what the danger is.

Uncertainty itself becomes salient.

Even when fearful faces are presented too briefly for conscious recognition, the amygdala can still respond.

Threat processing can therefore occur before explicit awareness.

The anterior cingulate detects conflict.

The lateral prefrontal cortex helps redirect attention.

The insula monitors bodily state.

The amygdala enhances memory for emotionally salient events.

Holmes sees why anxiety can become so persistent.

The brain not only detects threat.

It can preferentially remember it.

The investigation now turns to individual disorders.

The first chamber is Panic Disorder.

Holmes must explain something unusual.

Why does panic sometimes appear to occur without any trigger?

One theory suggests a false alarm.

Normal fear circuitry activates inappropriately because of abnormalities in internal homeostatic systems.

Another theory suggests failed regulation.

A small anxiety response begins but cortical systems fail to contain it.

A third possibility is that the trigger exists, but is processed outside conscious awareness.

The patient experiences the attack as spontaneous.

The brain may have detected something the conscious mind did not.

Neuroimaging in panic disorder shows abnormalities across hippocampal and parahippocampal regions, temporal cortex, amygdala, insula, ACC, orbitofrontal cortex, and prefrontal systems.

Resting-state abnormalities are found even when no panic attack is occurring.

During panic-related provocation, the insula, frontal cortex, cingulate cortex, hippocampus, and striatum may become unusually active.

Emotional-face studies often show increased amygdala and insula activation alongside reduced vmPFC and ACC recruitment.

The overall pattern suggests excessive bottom-up alarm combined with insufficient top-down regulation.

Treatment begins to alter this architecture.

Following CBT, activity in frontal regions can decrease while functional connectivity with the amygdala, hippocampus, and prefrontal systems improves.

Stronger baseline negative ACC–amygdala connectivity has even been associated with better later response to pharmacotherapy or CBT.

Holmes writes:

Treatment does not merely reduce symptoms. It can reorganise the circuitry supporting those symptoms.

The next chamber contains Specific Phobias.

Here the neurobiology becomes more stimulus-specific.

Show a spider to someone with spider phobia.

The amygdala activates.

The insula activates.

The anterior cingulate activates.

Present an unrelated emotional stimulus.

The same exaggerated response may disappear.

The hypersensitivity is closely tied to the feared category.

The source describes an elegant distinction.

During brief, predictable exposure to a phobic stimulus, the amygdala is particularly active.

During prolonged, uncertain threat, the BNST and ACC become more involved.

The finding mirrors the larger distinction between immediate fear and sustained anxiety.

The source also shows that successful exposure therapy changes brain function.

Before treatment:

High amygdala.

High insula.

High ACC activity.

Shortly after treatment:

Amygdala activation falls.

Prefrontal engagement rises.

Months later:

Amygdala reactivity remains lower, even though the prefrontal system no longer needs to work as hard.

The brain has not simply learned to suppress fear consciously.

The threat representation itself has become less reactive.

Holmes moves next to Social Anxiety Disorder.

The feared stimulus is no longer a spider.

It is another human being.

A face.

A judgement.

A stare.

A critical comment.

An audience.

Social-anxiety imaging repeatedly shows heightened amygdala responses to socially relevant stimuli.

The threshold for perceiving social threat appears lower.

The insula also becomes hyperresponsive.

Frontolimbic connectivity may be weaker.

Most strikingly, the abnormality is selective.

A socially anxious patient may show heightened amygdala activity to a human face but not to an aversive smell.

Self-referential criticism produces particularly strong amygdala and medial prefrontal responses.

The brain is not overreacting equally to everything unpleasant.

It is selectively tuned to social evaluation.

CBT again changes the circuitry.

After treatment, patients show greater dorsolateral and dorsomedial prefrontal engagement during cognitive reappraisal and stronger negative coupling between dmPFC and amygdala.

The cortex becomes more effective at regulating limbic response.

Pretreatment imaging can even improve prediction of who responds to CBT beyond clinical measures alone.

The possibility of personalised psychiatry begins to emerge.

The next chamber belongs to Generalized Anxiety Disorder.

Here the threat has no single object.

The problem is sustained uncertainty.

Worry.

Overgeneralisation.

Failure to distinguish danger from safety.

The amygdala findings are therefore less straightforward.

Some studies show hyperactivity.

Some do not.

Some show responses even to neutral stimuli.

But the BNST becomes especially important.

The source’s figure on page 30 shows delayed but sustained BNST activation during threat anticipation in GAD.

The amygdala responds more rapidly.

The BNST response emerges later and persists.

The brain has moved from:

“Danger now.”

to

“Danger may be coming.”

The distinction maps closely onto the clinical difference between fear and anxiety.

GAD also shows persistent activity in the dACC and dmPFC after worry induction.

Healthy individuals activate these regions during worry, then return towards baseline.

People with GAD continue activating them even after the provoking task ends.

The worry circuit does not disengage.

Fear-generalisation experiments reveal another clue.

When a harmless stimulus resembles the original threat cue, people with GAD are more likely to generalise fear towards it.

At the same time, vmPFC recruitment is reduced.

The brain becomes less effective at saying:

“This looks similar, but it is not the danger.”

Connectivity between ACC and amygdala is also impaired.

The uncinate fasciculus - a major white-matter pathway connecting frontal and temporal regions - shows reduced integrity in some studies.

The disorder therefore appears to involve not simply an overactive fear centre, but impaired communication between regulation and threat systems.

Holmes now steps back and compares the disorders.

The amygdala appears across all of them.

But not in the same way.

In panic disorder, hyperreactivity may extend across both specific and general threat cues.

In specific phobia, the response is particularly tied to the phobic stimulus.

In social anxiety, it is especially strong for socially relevant threat.

In GAD, the pattern is less consistently amygdala-dominated, with the BNST becoming especially important for sustained anticipatory anxiety.

The anterior insula appears across several disorders.

The hippocampus seems particularly important in panic disorder.

The prefrontal cortex and ACC contribute varying degrees of deficient control.

There is therefore both shared circuitry and disorder-specific circuitry.

The final major chamber is labelled:

DEVELOPMENT

Holmes sees the same brain changing across childhood, adolescence, and adulthood.

The amygdala develops relatively early.

The hippocampus also matures earlier.

But prefrontal regulatory systems develop slowly.

They do not achieve mature organisation until early adulthood.

That creates an important developmental imbalance.

The alarm system becomes powerful before the regulatory system has fully matured.

Adolescence may therefore represent a particularly vulnerable period for fear regulation.

The capacity to extinguish conditioned fear appears reduced during adolescence compared with childhood and adulthood.

At the same time, social stimuli become increasingly important.

This may help explain why many anxiety disorders peak during adolescence.

The source’s figure on page 35 demonstrates something even more important.

Amygdala–vmPFC connectivity differs not only by anxiety diagnosis, but by age.

Adults and young people with anxiety do not necessarily show the same neural pattern.

The biology of anxiety changes across development.

That means we cannot simply take a circuit identified in anxious adults and assume it operates identically in children.

The developmental context changes everything.

Social anxiety provides a striking example.

During adolescence, peer evaluation becomes biologically salient.

Adolescents with social anxiety show increased amygdala activation when anticipating evaluation from peers they do not want to interact with.

They may show reduced nucleus accumbens activation when anticipating feedback from desirable peers.

Threat becomes stronger.

Reward becomes weaker.

The social world becomes organised around potential rejection.

In paediatric GAD, amygdala and prefrontal abnormalities are also evident.

Some studies suggest increased amygdala reactivity alongside altered vlPFC–amygdala connectivity.

The ventrolateral prefrontal cortex may serve a compensatory role.

Higher activation can be associated with lower symptom severity.

Even treatment response may depend on these developmental circuits.

Holmes reaches the final gallery.

A child with behavioural inhibition stands before an unfamiliar face.

The amygdala responds strongly.

Years later, the same pattern may be found in an adult with an anxiety disorder.

But Holmes refuses to assume that the abnormality is caused by the illness.

Perhaps it existed before the illness.

Perhaps it was a risk marker.

Perhaps another brain compensates successfully and the disorder never develops.

This is one of neuroimaging’s greatest challenges.

A difference between patients and controls may represent:

Cause.

Consequence.

Risk.

Compensation.

Treatment effect.

Development.

Or an unrelated epiphenomenon.

Only longitudinal research can disentangle them.

Holmes closes the imaging atlas.

The chapter leaves him with a more sophisticated understanding of anxiety.

The amygdala matters.

But anxiety cannot be reduced to the amygdala.

The hippocampus tells the brain where fear belongs.

The BNST sustains uncertainty.

The insula listens to the body.

The prefrontal cortex regulates interpretation and response.

The anterior cingulate monitors conflict.

The orbitofrontal cortex updates reinforcement.

White-matter pathways determine whether these regions can communicate efficiently.

And development determines how the entire system is organised at a particular age.

The mystery therefore lies not in finding the one place where anxiety lives.

It lies in understanding how the network decides what is dangerous, what is safe, and whether the difference can still be learned.

Key Takeaways

* Neuroimaging has greatly expanded understanding of the circuitry underlying normal and pathological fear and anxiety.

* Anxiety neurocircuitry is best understood through interactions among cortical, limbic, sensory, autonomic, and neuroendocrine systems.

* Major structures include the amygdala, hippocampus, medial and orbital PFC, ACC, thalamus, hypothalamus, BNST, PAG, insula, locus coeruleus, and sensory association cortices.

* Research commonly bridges phenomenology to circuitry in a stepwise fashion.

* Investigators first identify the clinical functional domain that appears abnormal.

* They then identify the normal neural circuitry supporting that function.

* They test whether abnormalities exist in those circuits in anxiety disorders.

* Finally, they examine whether those abnormalities relate to symptoms or treatment response.

* Important functional domains include persistent threat learning, exaggerated fear, impaired extinction, impaired extinction retention, threat overgeneralisation, attentional bias, emotional interference, perceptual hypersensitivity, and anxiety sensitivity.

* Classical fear conditioning remains a major experimental model.

* A neutral conditioned stimulus becomes a CS+ when repeatedly paired with an aversive unconditioned stimulus.

* A stimulus not paired with the aversive event functions as the CS−.

* Fear responses to the CS+ can include startle, freezing, autonomic activation, and preparation for danger.

* Fear extinction occurs when the CS+ is repeatedly presented without the aversive outcome.

* Extinction does not erase the original fear memory.

* Instead, extinction creates a competing safety memory.

* Because the original fear memory remains, extinguished fear can return.

* Spontaneous recovery refers to return of fear after passage of time.

* Reinstatement refers to return of fear after exposure to an unsignalled aversive event.

* Context can determine whether the original fear memory or extinction memory dominates.

* Extinction learning is often strongest in the context where extinction occurred.

* Return to the original conditioning context can restore fear.

* Context dependence has important implications for exposure therapy.

* Exposure learning should ideally generalise across multiple situations and environments.

* Memory reconsolidation differs conceptually from classical extinction.

* Retrieved memories temporarily enter a labile state.

* New information presented during the reconsolidation window may modify the original memory.

* Reconsolidation research may eventually provide alternative ways to update maladaptive fear.

* Exposure-based therapy relies heavily on principles derived from fear extinction.

* Effective treatment may therefore depend upon extinction acquisition, retention, and generalisation.

* Emotional processing can be divided into evaluation, expression, experience, and modulation.

* Emotional evaluation involves assessing valence, significance, prior experience, and context.

* Emotional expression includes behavioural, autonomic, and endocrine responses.

* Emotional experience refers to subjective feelings.

* Emotional modulation prevents responses from becoming persistent, excessive, or maladaptive.

* Fear circuitry allows both rapid responses to simple threats and slower responses to complex contextual information.

* The amygdala plays a central role in fear learning and organisation of fear responses.

* The amygdala comprises multiple nuclei with distinct functions.

* The lateral amygdala acts as a major sensory interface.

* It receives information from the thalamus and sensory cortex.

* Conditioned and unconditioned information converge within the lateral amygdala.

* Direct thalamus-to-amygdala pathways permit rapid processing of simple potential threats.

* Cortical sensory pathways provide slower but more detailed stimulus analysis.

* Rapid threat processing can occur before conscious recognition.

* The basal and accessory basal nuclei contribute to fear-memory learning.

* The central nucleus of the amygdala is a major output structure.

* The central amygdala coordinates behavioural, autonomic, endocrine, and motor manifestations of fear.

* The source’s circuitry diagram on page 6 shows sensory and thalamic input converging upon the amygdala and projecting onwards to systems controlling fear expression.

* Central-amygdala projections influence the hypothalamus, PAG, facial motor systems, autonomic nuclei, and neuroendocrine pathways.

* Amygdala output contributes to cardiovascular responses, hyperventilation, freezing, startle, facial expression, and endocrine activation.

* Amygdala plasticity contributes to rapid learned-fear responses.

* Cortical plasticity contributes particularly to higher-order and declarative components of emotional learning.

* The amygdala can strengthen long-term memory of emotionally significant events.

* Noradrenergic signalling in the basolateral amygdala contributes to emotional-memory consolidation.

* Glucocorticoids interact with noradrenergic systems during emotional learning.

* The BNST is particularly important in sustained anxiety.

* Central-amygdala systems are especially involved in acute fear responses to explicit threat.

* BNST activity is particularly associated with longer-lasting responses to uncertain or poorly defined threat.

* This distinction supports the conceptual separation between acute fear and sustained anxiety.

* The medial and orbital PFC regulate emotional responses.

* Prefrontal systems interpret higher-order significance and consequences of emotional stimuli.

* The PFC and amygdala communicate through extensive reciprocal projections.

* The mPFC can regulate amygdala output through basal-amygdala and intercalated-cell pathways.

* Prelimbic circuitry in animals contributes to fear expression.

* Infralimbic circuitry contributes importantly to fear extinction.

* The infralimbic cortex is often considered analogous to parts of the human vmPFC.

* The prelimbic cortex has functional parallels with dorsal ACC regions.

* Damage to extinction-related prefrontal circuitry impairs later recall that the threat is safe.

* The figure on page 9 contrasts circuitry of fear expression with circuitry of extinction.

* During extinction, contextual information from the hippocampus and vmPFC-like systems recruits inhibitory mechanisms within the amygdala.

* GABAergic intercalated cells can suppress central-amygdala output.

* Pregenual ACC activity increases during experimentally induced anxiety.

* Electrical stimulation of related ACC regions can produce fear, panic, or foreboding.

* Subgenual ACC abnormalities have been described in GAD and other affective and stress-related disorders.

* mPFC lesions can disrupt autonomic responses and the ability to use probabilistic information about rewarding and aversive outcomes.

* Rostral mPFC activity may help attenuate cardiovascular and behavioural responses to threat.

* The hippocampus is particularly important for contextual fear.

* Hippocampal projections allow the organism to identify where danger was encountered.

* Contextual information helps determine whether a fear memory or extinction memory should be expressed.

* Hippocampal impairment can weaken contextual discrimination.

* Poor contextual discrimination may contribute to inappropriate generalisation of fear.

* Hippocampal-vmPFC interactions contribute to context-dependent extinction.

* The hippocampus may contribute directly to consolidation and maintenance of contextual fear memory rather than simply supplying contextual information to the amygdala.

* The perirhinal cortex contributes to processing complex sensory stimuli associated with fear.

* The anterior insula and vlPFC contribute to contextual and emotional processing.

* The temporopolar cortex contributes to evaluation of emotionally salient visual stimuli and autonomic modulation.

* The orbitofrontal cortex helps update behaviour when reinforcement contingencies change.

* OFC dysfunction can produce perseveration and failure to stop previously reinforced behaviours.

* Abnormal OFC function may therefore contribute to persistent maladaptive emotional or behavioural responses in anxiety.

* Posterior cingulate and retrosplenial regions participate in affective salience and contextual memory.

* The medial cerebellum shows activation across several normal and pathological anxiety states.

* Cerebellar circuits may contribute to autonomic regulation as well as broader cortical processing.

* The amygdala is involved in more than fear.

* It responds to biologically salient positive and negative information.

* It contributes to uncertainty, novelty, violations of expectation, emotional memory, social information, and arousal.

* Amygdala lesions impair recognition of fear in faces and fear or anger in voices.

* Amygdala responses to emotional faces can occur without conscious awareness.

* Emotional arousal strengthens amygdala-mediated memory encoding.

* The hypothalamus and autonomic nervous system convert neural threat signals into peripheral physiological responses.

* Lateral hypothalamic activation contributes to sympathetic responses.

* These include increased heart rate, blood pressure, sweating, piloerection, and pupillary dilation.

* The PVN contributes to HPA-axis activation.

* CRH stimulates ACTH.

* ACTH promotes adrenal cortisol secretion.

* Limbic circuitry also influences parasympathetic pathways producing visceral symptoms.

* The vagus and splanchnic nerves contribute to visceral manifestations of anxiety.

* Prefrontal regions also modulate heart rate, blood pressure, and glucocorticoid secretion.

* Structural MRI provides measures of brain size, shape, and tissue characteristics.

* Voxel-based morphometry can identify regional structural differences.

* Cortical-thickness analysis provides another measure of structural variation.

* Diffusion tensor imaging assesses organisation of white-matter tracts.

* Fractional anisotropy is commonly used as an index of white-matter organisation.

* PET can measure regional blood flow or glucose metabolism.

* fMRI measures changes in blood oxygenation through the BOLD signal.

* EEG measures electrical activity.

* MEG measures magnetic fields generated by neuronal activity.

* Imaging results depend on the individual’s cognitive and emotional state during acquisition.

* Resting-state paradigms assess brain function without specific symptom provocation.

* Symptom-provocation paradigms deliberately induce disorder-relevant states.

* Cognitive or behavioural activation paradigms probe defined neural processes.

* Longitudinal imaging can assess development or treatment-related change.

* Pretreatment imaging may help identify predictors of treatment response.

* Human fear-conditioning studies show increased amygdala activation to CS+ compared with CS−.

* Greater amygdala activation during acquisition often corresponds with stronger conditioned responses.

* vmPFC activation is particularly important during extinction and extinction recall.

* vmPFC activity can predict how well extinction learning is retained.

* Greater medial OFC thickness has been associated with better extinction recall in some studies.

* Hippocampal activation occurs during contextual conditioning and context-dependent extinction.

* Humans with hippocampal lesions show impairment in contextually mediated reinstatement.

* Amygdala, vmPFC, and hippocampus therefore form a core human circuit for fear conditioning and extinction.

* Emotional-face paradigms reliably recruit the amygdala.

* Fearful faces tend to produce particularly strong amygdala activation.

* Fearful faces may be especially salient because they communicate threat without specifying its source.

* Surprised faces also strongly recruit the amygdala because they are ambiguous.

* Backward-masked faces can activate the amygdala without explicit awareness.

* Repeated emotional-face presentations can be used to examine habituation.

* Anxiety disorders are associated with attentional bias towards threat.

* The dorsal ACC is strongly involved in cognitive conflict.

* The ventral ACC contributes particularly to emotional conflict.

* The lateral PFC contributes to cognitive control and redirection of attention.

* The amygdala and hippocampus participate in enhanced memory for emotionally arousing information.

* The insula is strongly implicated in interoception.

* Interoceptive processes include perception and interpretation of heartbeat, visceral sensations, and internal bodily states.

* Altered interoceptive processing is particularly relevant to panic disorder.

* A broad model of anxiety disorders involves excessive amygdala reactivity and/or deficient cortical regulation.

* Abnormal amygdala-mPFC and amygdala-hippocampal connectivity appears across multiple anxiety disorders.

* Panic disorder must account for both spontaneous panic attacks and learned avoidance following attacks.

* One theory conceptualises panic as aberrant recruitment of normal fear circuitry because of homeostatic disturbance.

* The false suffocation alarm model is one example.

* Another model proposes deficient regulation that allows minor anxiety to escalate into panic.

* A third model proposes that apparently spontaneous panic may be triggered by stimuli processed without conscious awareness.

* Amygdala hyperresponsivity to implicit cues could therefore generate attacks perceived as spontaneous.

* Hippocampal or parahippocampal dysfunction may impair conscious contextual recognition.

* Panic disorder has been associated with abnormalities in brainstem systems, monoaminergic function, lactate metabolism, hippocampus, parahippocampus, amygdala, insula, ACC, and PFC.

* Resting-state imaging shows abnormalities even between panic attacks.

* Altered hippocampal, parahippocampal, and superior temporal activity has been described.

* Increased ACC–precuneus connectivity has also been reported.

* Whether resting abnormalities cause chronic anticipatory anxiety or result from it remains unclear.

* Panic-provocation imaging studies have produced heterogeneous findings.

* Reported changes include frontal reductions and increased putamen or ACC activity.

* Insula findings during panic are inconsistent.

* Spontaneous-panic imaging studies are rare and based on very small samples.

* Panic-related cognitive and visual stimuli can produce exaggerated frontal, cingulate, OFC, hippocampal, insular, and striatal responses.

* Emotional-face studies often show increased amygdala and insula activation with reduced vmPFC and ACC recruitment.

* Unpredictable aversive stimuli may produce particularly strong insula activation in panic disorder.

* CBT-related remission in panic disorder has been associated with altered frontal activity and stronger frontolimbic connectivity.

* Baseline ACC-amygdala connectivity may predict response to both pharmacotherapy and CBT.

* Structural imaging in panic disorder has reported smaller OFC, putamen, and temporal-lobe volumes in some studies.

* Increased insula and brainstem volumes have also been reported.

* Reduced parahippocampal grey-matter density has been described.

* Amygddala-volume findings in panic disorder remain inconsistent.

* Overall, temporal and hippocampal abnormalities may contribute to deficient top-down regulation after an initial panic attack.

* Specific phobias involve neural hypersensitivity to specific feared stimuli.

* Meta-analyses consistently show increased insula and amygdala activation during phobic-stimulus exposure.

* ACC, OFC, thalamic, and cerebellar activation may also increase.

* Acute predictable phobic threat is especially associated with amygdala activation.

* Sustained unpredictable phobic threat is more strongly associated with BNST and ACC activation.

* BNST-amygdala connectivity may be increased in specific phobia.

* Amygdala hyperreactivity is generally specific to the phobic stimulus rather than to all emotional stimuli.

* Reduced vmPFC activity may contribute to impaired automatic regulation of phobic fear.

* Reduced dACC/dmPFC recruitment may impair effortful regulation.

* Different phobia subtypes may have partly distinct neural signatures.

* Spider phobia may involve stronger dACC and insula abnormalities.

* Blood-injection-injury phobia may involve greater PFC, thalamic, and occipito-temporo-parietal alterations.

* Sensory association cortices involved in a particular sensory modality may become selectively sensitised.

* Exposure therapy changes the neural representation of phobic stimuli.

* Successful exposure reduces limbic and frontal activation.

* Immediately after exposure therapy, reduced amygdala activity may be accompanied by increased prefrontal control.

* Months later, reduced amygdala response can persist without continued excessive prefrontal recruitment.

* This suggests lasting reorganisation rather than permanent effortful suppression.

* Lower visual-cortex activation after exposure has predicted better later outcome in spider phobia.

* Structural abnormalities reported in specific phobias include altered cortical thickness and regional grey-matter volume.

* Findings differ among animal, dental, blood-injection-injury, and spider phobias.

* Social anxiety disorder involves heightened neural sensitivity to socially relevant threat.

* Potential mechanisms include excessive threat sensitivity, sensitivity to scrutiny, and reduced reward value of positive social stimuli.

* Public-speaking and contemptuous-face paradigms consistently produce heightened amygdala activity in SAD.

* Amygdala activation correlates with social-anxiety severity in some studies.

* The amygdala may activate at a lower threshold of social threat in SAD.

* Increased insula activation is also common.

* Reduced striatal responses during implicit learning have been reported.

* Alterations in OFC, ACC, mPFC, and parahippocampal function may also occur.

* Weaker frontolimbic connectivity may contribute to heightened social-threat reactivity.

* Neural abnormalities in SAD can be selective for social rather than nonsocial threat.

* Human faces may provoke amygdala hyperreactivity whereas aversive odours do not.

* Self-referential criticism particularly activates the amygdala and mPFC.

* The neural response therefore appears tuned to personal social judgement.

* CBT can increase dlPFC and dmPFC engagement during cognitive reappraisal.

* CBT may strengthen negative dmPFC-amygdala coupling.

* Earlier recruitment of regulatory prefrontal systems may accompany successful treatment.

* Pretreatment PFC and amygdala activity can help predict CBT response.

* Amygdala-ACC connectivity may also predict outcome.

* Neural measures can improve treatment-response prediction beyond clinical variables in some studies.

* Structural imaging in SAD has found reduced uncinate-fasciculus FA.

* This supports impaired structural connectivity between frontal and limbic regions.

* Increased cortical thickness has been reported in ACC, insula, dlPFC, and parietal cortex.

* Lower grey-matter volume has been described in lateral OFC, parahippocampus, and cerebellum.

* Generalized anxiety disorder requires a model that explains excessive worry and fear overgeneralisation.

* Amygdala findings in GAD are less consistent than in several other anxiety disorders.

* Some studies show normal or reduced amygdala activation to fearful faces.

* Others suggest nonspecific hyperreactivity to both negative and neutral stimuli.

* The BNST appears particularly important in sustained anxiety in GAD.

* GAD can involve brief phasic amygdala responses followed by delayed sustained BNST activation.

* The figure on page 30 demonstrates elevated sustained BNST activity during threat anticipation in GAD.

* The BNST response in the study shown was delayed by approximately 6–7 seconds.

* This temporal distinction supports a model of amygdala-mediated acute fear followed by BNST-mediated sustained anxiety.

* GAD is also associated with persistent dACC and dmPFC activation during and after worry induction.

* Healthy individuals may return towards baseline after worry, whereas individuals with GAD maintain activity.

* dACC/dmPFC activation correlates with subjective worry.

* GAD patients show greater fear generalisation to stimuli resembling a conditioned threat.

* Reduced vmPFC recruitment accompanies poor threat-versus-safety discrimination.

* vmPFC dysfunction may therefore contribute to overgeneralisation.

* GAD is associated with impaired cortical-limbic connectivity.

* Healthy subjects show negative pgACC-amygdala coupling during emotional regulation.

* Patients with GAD may fail to recruit the pgACC or develop this inhibitory connectivity.

* Abnormal resting amygdala connectivity has also been described.

* Pretreatment ACC and amygdala activity may predict response to venlafaxine.

* Citalopram treatment can reduce prefrontal and limbic responses to worry-related stimuli.

* CBT can reduce amygdala and sgACC activation to threatening faces.

* CBT can increase responsiveness to positive stimuli.

* Reduced FA in the bilateral uncinate fasciculus has been reported in GAD.

* Lower uncinate FA is associated with weaker negative cingulate-amygdala connectivity.

* Structural and functional connectivity abnormalities may jointly contribute to poor threat-safety discrimination.

* Across anxiety disorders, the amygdala is one of the most consistently implicated structures.

* However, the nature of amygdala dysfunction differs by diagnosis.

* Panic disorder may show responses to both disorder-specific and general threat.

* Specific phobia shows particularly stimulus-specific amygdala reactivity.

* SAD shows particularly socially specific amygdala reactivity.

* GAD shows less consistent amygdala abnormality and stronger evidence for sustained BNST dysfunction.

* Increased anterior-insula activity occurs across multiple anxiety disorders.

* Hippocampal abnormalities appear particularly relevant to panic disorder.

* Prefrontal and ACC dysfunction varies across disorders.

* Shared and disorder-specific circuitry supports both the grouping and separation of anxiety diagnoses.

* Far less neuroimaging research exists for separation anxiety disorder and selective mutism.

* Development is essential to understanding anxiety circuitry.

* Anxiety disorders are extremely common in childhood and adolescence.

* The amygdala develops relatively early.

* The hippocampus also matures earlier than the PFC.

* The PFC undergoes prolonged development extending into early adulthood.

* Amygdala connections with PFC and hippocampus continue developing through childhood and adolescence.

* Earlier maturation of threat-reactivity systems than regulatory prefrontal systems may create a developmental imbalance.

* Adolescence may therefore be a period of altered fear regulation.

* Basic discrimination between threat and safety improves with age.

* Fear expression and extinction show nonlinear developmental trajectories.

* Adolescence may be associated with reduced cued-fear extinction compared with childhood and adulthood.

* Youth with anxiety disorders generally show stronger fear responses than nonanxious youth even where overall acquisition and extinction patterns appear similar.

* Age modifies the relationship between anxiety and amygdala-vmPFC connectivity.

* The figure on page 35 shows that anxious adults and anxious youths can exhibit different or even opposite amygdala-vmPFC connectivity patterns.

* Developmental neuroimaging therefore warns against assuming that adult anxiety circuitry applies unchanged to children.

* Sensitive developmental periods represent both vulnerability and opportunity.

* Environmental influences may have greater impact during periods of heightened neuroplasticity.

* Stress during sensitive periods can alter neurodevelopmental trajectories.

* The same plasticity may also make early intervention particularly powerful.

* Behavioural inhibition is a childhood temperament associated with increased later anxiety risk.

* Behavioural inhibition is associated with heightened amygdala response to novelty.

* Similar amygdala patterns are found in adult anxiety disorders.

* Cross-sectional studies therefore cannot determine whether an imaging abnormality represents disease or pre-existing risk.

* Risk markers must ideally be studied in people who carry the vulnerability but have not developed the disorder.

* Age, sex, medication, menstrual phase, and diurnal variation can influence brain-based measures.

* Developmental neuroimaging in children primarily uses fMRI to avoid radiation exposure associated with PET.

* Child fear-conditioning paradigms use developmentally appropriate aversive stimuli such as noises, air puffs, or images.

* High comorbidity means many paediatric studies examine mixed anxiety groups rather than isolated diagnoses.

* Greater frontal activation has been associated with better treatment response in anxious youth.

* Social anxiety in adolescence must be understood within increasing developmental salience of peer evaluation.

* Adolescents with SAD show increased amygdala activity when anticipating evaluation by undesirable peers.

* Greater positive vmPFC-amygdala connectivity in this context correlates with symptom severity.

* Socially anxious adolescents may show reduced nucleus-accumbens activity when anticipating feedback from desirable peers.

* This suggests a combination of enhanced social-threat processing and reduced positive social-reward processing.

* Unexpected positive feedback can produce abnormal striatal and frontostriatal responses in adolescents with SAD.

* Some neural markers of social processing may precede later social-anxiety symptoms.

* Paediatric GAD also involves altered amygdala and prefrontal function.

* Youth with GAD may show increased amygdala responses when attending to their own fear.

* Heightened amygdala activity to masked angry faces has also been demonstrated.

* Greater amygdala reactivity correlates with higher anxiety severity in some studies.

* Youth with GAD show weaker vlPFC-amygdala connectivity.

* Increased vlPFC activity may play a compensatory role.

* Greater vlPFC activation is associated with lower symptom severity in some studies.

* Paediatric GAD may involve larger amygdala volume and increased cortical thickness in several regions.

* Higher pretreatment amygdala activity may predict greater improvement with CBT or pharmacotherapy in some young people.

* Treatment may increase vlPFC recruitment.

* Neuroimaging abnormalities cannot automatically be interpreted as causes of anxiety.

* They may represent vulnerability, illness effects, compensation, developmental variation, treatment effects, or epiphenomena.

* Longitudinal studies are essential for distinguishing these possibilities.

* Future research should integrate neuroimaging with genetics and neurochemistry.

* Psychiatric diagnoses remain neurobiologically heterogeneous.

* Integrated approaches may identify more biologically meaningful anxiety phenotypes.

* Neuroimaging may eventually contribute to personalised treatment selection.

* The most useful overarching model is not one of an isolated fear centre but of dynamic communication among threat-detection, contextual-memory, interoceptive, regulatory, autonomic, and extinction systems.

* Anxiety disorders arise when these systems become poorly calibrated to one another.

* The central neuroanatomical problem is therefore not simply excessive fear, but impaired ability to discriminate danger from safety and update the brain when circumstances change.

Medlock Holmes enters the Neurobiological Citadel of Fear.

At its centre stands an enormous transparent brain.

It is not silent.

Signals move constantly between the amygdala, hippocampus, prefrontal cortex, thalamus, hypothalamus, locus coeruleus, and brainstem.

Some pathways detect threat.

Others generate autonomic responses.

Others encode memories.

Others decide whether a stimulus is dangerous.

Others determine whether the alarm can finally be switched off.

Holmes immediately sees the problem.

Anxiety is not produced by a single fear centre.

It is produced by a network.

The central diagram on page 4 captures this clearly. The thalamus contributes to autonomic and endocrine regulation. The hippocampus and amygdala participate in salience detection and associative learning. The locus coeruleus projects widely to cortex and helps regulate attention, arousal, and pain evaluation. The prefrontal cortex helps coordinate higher-order regulation of these responses.

The first chamber belongs to norepinephrine.

The locus coeruleus sits in the pons like an emergency broadcasting tower.

When danger appears, norepinephrine surges.

Heart rate increases.

Pupils dilate.

Breathing accelerates.

Attention narrows.

Vigilance rises.

The organism becomes ready to fight or flee.

In the short term, this is adaptive.

But when the noradrenergic system becomes excessively active, the same protective response can become pathological.

The person remains hyperaroused when danger has passed.

Startle becomes excessive.

Attention remains locked onto threat.

Autonomic symptoms themselves become frightening.

This is particularly relevant to panic disorder and phobic states.

Holmes sees the paradox.

Drugs that increase norepinephrine acutely may provoke anxiety.

Yet SNRIs and tricyclic antidepressants can treat anxiety disorders over time.

The explanation lies in adaptation.

Their therapeutic effects emerge not from the immediate increase in monoamine signalling, but from longer-term receptor and network changes.

The next chamber is the HPA Axis Observatory.

Stress activates the hypothalamus.

CRH rises.

ACTH follows.

The adrenal glands release cortisol.

Again, the system is protective.

Cortisol mobilises energy.

Sharpens vigilance.

Modifies memory.

Suppresses nonessential processes.

Helps the organism survive an acute threat.

But Holmes watches what happens when the system stays active for too long.

Persistently elevated glucocorticoids affect the hippocampus.

Cell survival changes.

Morphology changes.

Memory becomes impaired.

Metabolic and cardiovascular effects accumulate.

The source describes hypertension, osteoporosis, immunosuppression, insulin resistance, dyslipidaemia, coagulation abnormalities, and cardiovascular disease among the possible consequences of prolonged glucocorticoid exposure.

Yet when Holmes compares patients with different anxiety disorders, he does not find one uniform HPA abnormality.

Panic disorder shows mixed findings.

GAD may show increased, decreased, or dysregulated cortisol activity.

Some studies of long-term hair cortisol in GAD even suggest lower concentrations, raising the possibility that chronic anxiety can eventually downregulate the stress axis.

Social anxiety also shows inconsistent findings influenced by age and sex.

Specific phobias, however, can produce clear cortisol increases during exposure to the feared stimulus.

The lesson is important:

The stress system is dysregulated in anxiety, but not in one identical direction across all disorders.

Holmes then enters the chamber of corticotropin-releasing hormone.

CRH does more than activate cortisol.

It operates throughout the brain.

Amygdala.

Prefrontal cortex.

Cingulate cortex.

Bed nucleus of the stria terminalis.

Nucleus accumbens.

Periaqueductal grey.

Locus coeruleus.

Raphe nuclei.

CRH therefore coordinates behavioural as well as endocrine responses to stress.

Early-life stress may alter CRH signalling for years.

High CRH exposure can contribute to allostatic load.

CRH-1 and CRH-2 receptors appear to have partly opposing functions.

CRH-1 activation tends to increase anxiety-like behaviour in animal models.

CRH-2 may contribute to more adaptive or anxiolytic responses.

It appears biologically compelling.

But clinical translation has been disappointing.

CRH-1 antagonists have not yet produced reliable therapeutic success in anxiety disorders.

Holmes writes another principle in his notebook:

Biological plausibility does not guarantee clinical efficacy.

The next chamber belongs to dopamine.

Dopamine is usually associated with reward and motivation.

But during stress it also changes.

The medial prefrontal cortex is particularly sensitive.

Moderate stress increases prefrontal dopamine.

This can improve adaptive responding.

Too much dopamine impairs cognition.

Too little may delay extinction of conditioned fear.

Holmes sees an inverted-U-shaped control system.

Optimal dopamine allows flexible learning.

Excessive dopamine destabilises cognition.

Insufficient dopamine makes the brain slow to update when danger is no longer present.

This becomes especially important in fear extinction.

The person may know intellectually that the situation is now safe, but the defensive system fails to learn it.

The next chamber is serotonin.

Here the biology becomes even more complex.

Serotonin can both promote and reduce anxiety depending on where in the brain it acts.

In the prefrontal cortex and amygdala, serotonin can enhance awareness of threat.

In the dorsal periaqueductal grey, it can suppress fight-or-flight behaviour.

This dual role helps explain why serotonin can participate in panic, anticipatory anxiety, and generalized worry.

The 5-HT1A and 5-HT2 receptor families are particularly important.

Imaging studies show reduced 5-HT1A receptor binding in several regions in panic disorder and social anxiety.

Early-life changes in serotonergic systems may have persistent effects on anxious behaviour.

SSRIs eventually alter these circuits and remain among the most effective treatments for panic disorder, social anxiety disorder, and GAD.

But again, the effect is delayed.

The immediate neurochemical change is not the same as the final therapeutic change.

Holmes then enters the GABA Chamber.

Here everything becomes quieter.

GABA is the major inhibitory neurotransmitter in the brain.

It reduces neuronal excitability.

It restrains the alarm.

The GABA-A receptor sits at the centre of the chamber.

Benzodiazepines bind allosterically to this receptor complex and amplify inhibition.

Anxiety falls quickly.

The person relaxes.

Panic diminishes.

But the chamber contains a warning.

Tolerance.

Dependence.

Sedation.

Memory effects.

Abuse potential.

This explains why benzodiazepines, despite their clear anxiolytic efficacy, are no longer considered first-line treatment for panic disorder, social anxiety disorder, or GAD.

Holmes also notices something interesting.

Flumazenil - a benzodiazepine antagonist - can provoke panic in people with panic disorder but not reliably in healthy controls.

This suggests that the GABA system is not merely a target for treatment.

It may already be altered within the disorder itself.

The next chamber belongs to glutamate.

The excitatory counterpart to GABA.

Holmes watches the balance shift:

GABA inhibition ↓

Glutamate excitation ↑

The alarm system becomes easier to trigger.

Glutamate also interacts with norepinephrine and serotonin.

NMDA receptors become particularly important because they are involved in both fear acquisition and fear extinction.

Block NMDA receptors and fear learning can be impaired.

But extinction can also be impaired.

That produces a therapeutic puzzle.

How do we reduce pathological fear without preventing the brain from learning safety?

One answer emerged through D-cycloserine.

Rather than acting as a traditional anxiolytic, it partially stimulates the glycine site of the NMDA receptor.

The hope was that it could enhance the learning that occurs during exposure therapy.

Early trials were promising.

Acrophobia.

Social anxiety.

Panic disorder.

But larger studies produced inconsistent findings.

Again, Holmes sees the translational challenge:

A molecule may enhance learning.

But the quality and timing of the learning experience still matter.

If exposure goes badly, enhancing learning could theoretically reinforce the wrong memory.

Ketamine enters the story from another direction.

Small preliminary studies suggest rapid reductions in refractory social anxiety and generalized anxiety symptoms.

But this evidence remains limited.

Other glutamatergic drugs have produced similarly mixed or preliminary results.

The source repeatedly reminds Holmes not to confuse promising mechanism with established treatment.

The next room is filled with hormones derived from cholesterol.

These are neurosteroids.

Allopregnanolone.

Pregnanolone.

Other progesterone metabolites.

They modulate GABA-A receptors and may provide endogenous anxiolytic effects.

The biology becomes particularly striking during pregnancy and the postpartum period.

Progesterone and allopregnanolone rise during pregnancy.

Some women with panic disorder experience improvement.

Hormone concentrations fall rapidly after delivery.

Anxiety may rebound.

The source explores this as one example of how endogenous neurosteroid systems may influence fear and anxiety.

Holmes moves onward.

The next chambers contain an expanding collection of neuropeptides.

Vasopressin.

Oxytocin.

Neuropeptide Y.

Galanin.

Cholecystokinin.

Each modifies the stress system differently.

Oxytocin is particularly associated with social behaviour, social cognition, and attenuation of stress responses.

Intranasal oxytocin has reduced amygdala responses to fearful faces and altered social-anxiety circuitry in experimental studies.

It may facilitate extinction of social fear.

But clinical implementation remains uncertain.

Neuropeptide Y appears to play a different role.

Resilience.

Stress buffering.

Fear-memory modulation.

Higher NPY activity can reduce anxiety-like behaviour in animal models.

Early human work suggests potential anxiolytic effects, but clinical evidence remains preliminary.

Galanin interacts closely with the noradrenergic system of the locus coeruleus and may become especially important under high stress.

Again, human treatment studies are sparse.

Cholecystokinin presents the opposite picture.

CCK-4 can provoke panic.

In both healthy people and those with panic disorder, administration can generate intense panic-like responses.

This made CCK an attractive drug target.

But CCK antagonists repeatedly failed to become effective anxiolytic treatments.

Another compelling biological mechanism had failed the clinical test.

Holmes reaches the Endocannabinoid Chamber.

CB1 receptors are distributed through the prefrontal cortex, amygdala, hippocampus, and periaqueductal grey.

Endocannabinoid activity increases during threat and may counteract fear responses.

But dose matters.

Low CB1 activation may reduce anxiety.

High activation may worsen it.

THC can therefore be anxiolytic at low doses and panicogenic at higher doses.

CBD has shown anxiolytic effects in experimental public-speaking paradigms and in some studies of social anxiety.

But the chapter treats this as an evolving research area rather than established standard treatment.

The final biological chamber is labelled:

INFLAMMATION

Stress activates the sympathetic nervous system and HPA axis.

Catecholamines influence immune cells.

Cytokines may change.

But unlike in some models of depression, the evidence in anxiety disorders is inconsistent.

Some panic studies show higher inflammatory markers.

Others show lower concentrations.

Some GAD studies show elevated CRP.

Social anxiety may show lower CRP in some groups.

Age.

Sex.

BMI.

Medication.

Stress.

All can confound the findings.

Holmes refuses to create certainty where the evidence does not support it.

The final chamber contains no neurotransmitter.

It contains learning.

A harmless stimulus was once associated with danger.

Fear developed.

Then the fear spread.

A sound.

A place.

A bodily sensation.

A facial expression.

Eventually the alarm generalised far beyond the original threat.

Anxiety disorders may therefore involve not only excessive fear acquisition, but also fear generalisation and impaired fear extinction.

This insight connects neuroscience directly to psychotherapy.

Exposure therapy is not merely making someone tolerate discomfort.

It is a biological learning process.

The patient discovers:

“The feared outcome did not occur.”

“The bodily sensation is survivable.”

“The context is safe.”

“I can remain here without escaping.”

New learning competes with old fear memory.

The chapter’s future direction therefore becomes clear.

The goal is not simply to discover another sedative.

It is to understand the precise circuits responsible for fear acquisition, generalisation, extinction, resilience, and recovery.

Optogenetics.

Chemogenetics.

Genomics.

Neuroimaging.

Circuit-specific interventions.

Drugs designed to enhance psychotherapy.

The future lies in identifying the biological mechanism operating in the particular patient.

Holmes returns to the enormous brain at the centre of the citadel.

He finally understands the deeper principle.

Anxiety is not an alarm that should never sound.

The alarm evolved for survival.

The disorder emerges when threat detection becomes exaggerated, fear spreads beyond the original danger, inhibition weakens, stress systems remain activated, or the brain fails to learn that the world has become safe again.

Key Takeaways

* Anxiety disorders arise from interacting neurochemical, neuroendocrine, neural-circuit, genetic, developmental, and environmental processes.

* No single neurotransmitter or brain region explains all anxiety disorders.

* Animal studies provide important information about defensive responses but cannot fully model the subjective human experience of fear and anxiety.

* Translational work requires close collaboration between basic and clinical neuroscience.

* Neuroimaging has improved understanding of human fear and anxiety circuitry.

* Genetic research increasingly examines vulnerability to anxiety disorders and treatment response.

* Overgeneralisation of learned fear to harmless stimuli is an important model of pathological anxiety.

* Severe or prolonged stress can produce chronic alterations across multiple biological systems.

* Early-life stress or trauma may increase later anxiety vulnerability through neuroendocrine, neural, epigenetic, or neurotoxic mechanisms.

* Individual differences in susceptibility and resilience remain central areas of investigation.

* The major fear-and-anxiety circuitry illustrated on page 4 involves the prefrontal cortex, thalamus, hypothalamus, amygdala, hippocampus, and locus coeruleus.

* The thalamus contributes to autonomic and endocrine regulation.

* The hippocampus and amygdala contribute to salience detection and associative learning.

* The hippocampus also contributes to learning, memory, and plasticity.

* Locus-coeruleus projections to cortex contribute to attention, arousal, and pain evaluation.

* Norepinephrine is released centrally primarily from the locus coeruleus.

* Acute threat activates the noradrenergic system as part of the fight-or-flight response.

* Norepinephrine increases vigilance, arousal, autonomic activation, and readiness to respond.

* Acute noradrenergic activation is adaptive when danger is real.

* Excessive or sustained noradrenergic output may contribute to pathological anxiety.

* The locus coeruleus projects extensively to cortical and limbic structures.

* Norepinephrine modulates dopamine, serotonin, glutamate, and GABA systems.

* Sympathetic norepinephrine also contributes to peripheral physiological responses.

* α1 adrenergic receptors are principally postsynaptic.

* α2 adrenergic receptors are principally presynaptic and contribute to negative feedback regulation.

* α2 agonists such as clonidine and guanfacine reduce noradrenergic activity.

* α2 antagonists such as yohimbine and idazoxan increase norepinephrine release.

* Yohimbine can provoke panic in patients with panic disorder.

* Idazoxan can also provoke panic responses.

* Panic disorder shows evidence of altered noradrenergic responsivity.

* Phobic individuals may show elevated catecholamine release in response to feared stimuli.

* GAD has been associated with increased plasma norepinephrine and MHPG in some studies.

* Beta-blockers reduce peripheral autonomic symptoms such as tremor and tachycardia.

* Propranolol can therefore be helpful in performance anxiety.

* Beta-blockers do not directly remove anticipatory social anxiety.

* Alcohol, opioids, and benzodiazepines reduce noradrenergic activation and may be used maladaptively as self-medication.

* Drugs such as SNRIs and tricyclic antidepressants initially increase norepinephrine but treat anxiety through delayed adaptive receptor and circuit changes.

* The HPA axis is a central stress-response system.

* CRH stimulates ACTH.

* ACTH stimulates adrenal cortisol release.

* Cortisol increases arousal, vigilance, attention, memory formation, and energy mobilisation during acute stress.

* Cortisol also inhibits growth, reproductive, and immune processes during stress.

* Cortisol regulates hippocampal, amygdala, and prefrontal function.

* Glucocorticoids can enhance emotional-memory encoding.

* Noradrenergic activation within the amygdala interacts with cortisol in memory formation.

* Cortisol has biphasic effects on cognition and memory.

* Moderate cortisol activity can be adaptive.

* Persistent excessive glucocorticoid exposure can be harmful.

* Chronic glucocorticoid exposure is associated with hypertension, osteoporosis, immunosuppression, insulin resistance, dyslipidaemia, coagulation abnormalities, and cardiovascular disease.

* The hippocampus contains high concentrations of glucocorticoid and mineralocorticoid receptors.

* The hippocampus plays an important role in negative feedback regulation of the HPA axis.

* High glucocorticoid levels can impair hippocampal cell survival and alter cell morphology.

* Stress-related hippocampal damage may contribute to cognitive and memory problems.

* HPA findings in panic disorder are inconsistent.

* Some studies show elevated cortisol or ACTH, while others show normal values.

* Naturally occurring panic attacks may produce modest cortisol increases.

* Pharmacologically provoked panic does not always activate the HPA axis in the same way.

* Yohimbine-induced panic is more consistently associated with cortisol elevation than lactate-induced panic.

* HPA activation may depend partly on environmental novelty and context.

* GAD also shows HPA-axis abnormalities, but findings are heterogeneous.

* Some studies show increased cortisol, others reduced cortisol, and others normal levels.

* Reduced HPA negative-feedback sensitivity has been reported in GAD.

* Long-term hair cortisol studies have found concentrations approximately 50–60% lower in some GAD samples than controls.

* This may indicate downregulation of the HPA axis during chronic anxiety.

* Successful GAD treatment has been associated with reduced cortisol alongside reduced anxiety symptoms.

* Social anxiety disorder does not show one consistent basal cortisol abnormality.

* Age and sex may influence HPA findings in social anxiety.

* Specific-phobia exposure can increase cortisol.

* Successful psychotherapy for specific phobia has been associated with reduced cortisol responses to the feared stimulus.

* Glucocorticoids may interfere with retrieval of fear memories.

* Experimental cortisol administration has reduced social fear and specific-phobia responses in some studies.

* Cortisol has also been studied as an adjunct to exposure therapy.

* CRH coordinates behavioural and physiological responses to stress.

* CRH acts both through the HPA axis and through widespread extrahypothalamic pathways.

* CRH neurons are found in the prefrontal cortex, cingulate cortex, amygdala, BNST, nucleus accumbens, PAG, locus coeruleus, and raphe nuclei.

* Amygdala CRH activation can produce fear-related behaviour.

* Cortical CRH activity may reduce reward expectation.

* Early-life stress may produce lasting changes in CRH concentrations.

* Persistent CRH activation contributes to allostatic load.

* CRH-1 and CRH-2 receptors appear to have different functions.

* CRH-1 activation tends to promote anxiety-like behaviour in animal models.

* CRH-2 signalling may contribute to anxiolytic or adaptive stress responses.

* CRH-1 knockout animals show less anxiety-like behaviour.

* CRH-2 knockout animals show greater anxiety-like behaviour.

* Genetic variation in CRH systems has been associated with behavioural inhibition and panic disorder.

* Despite promising preclinical rationale, CRH-1 antagonists have not demonstrated convincing clinical efficacy in anxiety disorders.

* Pexacerfont failed to outperform placebo in GAD.

* This illustrates the difficulty of translating compelling animal mechanisms into effective psychiatric treatments.

* Dopamine contributes to reward, motivation, goal-directed behaviour, and stress responses.

* Stress increases dopamine release in the medial prefrontal cortex.

* The mPFC dopaminergic system is especially sensitive to relatively low-intensity stress.

* Greater-intensity stress recruits mesolimbic and striatal dopamine systems.

* Amygdala activity influences stress-induced prefrontal dopamine release.

* Prefrontal dopamine contributes to fear extinction.

* Too little prefrontal dopamine may delay extinction.

* Excessive stress-related prefrontal dopamine can impair cognition.

* Optimal dopamine activity therefore appears to follow an inverted-U relationship.

* Extreme mesocortical dopamine activity may inhibit subcortical reward processes and contribute to helpless responses.

* Reduced dopamine-transporter and D2-receptor density has been reported in social anxiety disorder.

* Dopamine-agonist withdrawal can produce anxiety.

* Dopamine abnormalities in panic disorder remain inconsistent.

* Serotonin is released primarily from the dorsal raphe system and participates extensively in stress and anxiety.

* Serotonin has a dual role in defensive behaviour.

* Serotonergic activity in the prefrontal cortex and amygdala can increase threat awareness.

* Serotonergic activity in the dorsal periaqueductal grey can inhibit fight-or-flight responses.

* This model may help explain both anticipatory anxiety and panic.

* 5-HT1A and 5-HT2A receptors are particularly relevant to anxiety.

* 5-HT1A receptors are distributed in cortex, hippocampus, amygdala, PAG, and raphe nuclei.

* Reduced 5-HT1A binding has been reported in panic disorder.

* Reduced 5-HT1A receptor binding has also been reported in social anxiety disorder.

* Early-life serotonergic disruption may produce long-lasting anxious phenotypes.

* Early stress may reduce 5-HT1A receptor expression through CRH and cortisol mechanisms.

* SSRIs may affect different serotonergic circuits depending on the anxiety disorder.

* In panic disorder, SSRIs may eventually enhance serotonergic modulation of the dorsal PAG.

* In GAD, SSRIs may act partly through 5-HT2C desensitisation and 5-HT1A stimulation.

* Peripheral serotonin findings in anxiety disorders are inconsistent.

* Tryptophan-depletion studies have produced mixed results.

* Reduced serotonin can increase sensitivity to panic provocation in some patients.

* Serotonergic medications remain among the most effective pharmacological treatments for panic disorder, social anxiety disorder, and GAD.

* SSRIs and SNRIs have the strongest established roles among these agents.

* Buspirone acts partly through 5-HT1A mechanisms.

* Newer 5-HT1A agents have shown inconsistent results.

* GABA is the principal inhibitory neurotransmitter in the brain.

* GABA-A receptors are fast ligand-gated ion channels.

* GABA-B receptors operate more slowly.

* Benzodiazepines, barbiturates, alcohol, anaesthetics, neurosteroids, and some anticonvulsants enhance GABA-A function.

* Benzodiazepines bind to an allosteric site associated with the GABA-A receptor complex.

* Benzodiazepines produce rapid anxiolytic effects.

* GABA inverse agonists can produce anxiety.

* Flumazenil can provoke panic in patients with panic disorder.

* Imaging studies have reported reduced GABA-A or benzodiazepine-receptor binding in panic disorder.

* Reduced GABA has been reported in anterior cingulate and basal-ganglia regions in panic disorder.

* Benzodiazepines remain effective anxiolytic drugs.

* They are no longer considered first-line treatment for panic disorder, social anxiety disorder, or GAD.

* Concerns include tolerance, dependence, misuse, sedation, and possible cognitive and memory effects.

* Appropriate prescribing can nevertheless provide safe and effective symptom relief in selected patients.

* Newer GABA-A subtype-selective compounds aim to retain anxiolysis while reducing sedation and dependence.

* Neurosteroids are also being investigated as GABA-A modulators.

* Gabapentin and pregabalin are structurally related to GABA but act primarily through voltage-sensitive calcium channels rather than GABA receptors.

* Glutamate is the principal excitatory neurotransmitter in the CNS.

* Panic may partly reflect imbalance between glutamatergic excitation and GABAergic inhibition.

* Glutamate also regulates serotonergic and noradrenergic systems.

* Major ionotropic glutamate receptors include NMDA, AMPA, and kainate receptors.

* NMDA receptors participate in fear conditioning.

* NMDA-receptor blockade can impair acquisition of fear.

* NMDA receptors are also important for fear extinction.

* Fear extinction therefore requires intact excitatory plasticity rather than simple suppression of all glutamate.

* D-cycloserine is a partial agonist at the glycine modulatory site of the NMDA receptor.

* D-cycloserine was investigated as a pharmacological enhancer of exposure-based learning.

* Early studies suggested benefit when augmenting exposure therapy in acrophobia, social anxiety, and panic disorder.

* Later trials were inconsistent.

* Larger studies have not consistently replicated initial D-cycloserine findings.

* The efficacy of learning-enhancing drugs may depend critically on the quality of the exposure session.

* Glycine-transporter inhibition has also been investigated as an exposure-augmentation strategy without convincing clinical benefit.

* Metabotropic glutamate receptor modulators show anxiolytic effects in animal models.

* Translation into human treatment has been limited.

* Some compounds demonstrated safety concerns or failed to outperform placebo.

* Ketamine has shown preliminary rapid anxiolytic effects in small studies of treatment-refractory social anxiety and GAD.

* These findings remain early and are not equivalent to an established first-line treatment.

* Pregabalin has demonstrated efficacy in multiple GAD trials.

* Pregabalin is recommended as a first-line option for GAD when comorbid epilepsy is present in the source.

* Riluzole has shown preliminary benefit in GAD.

* Its analogue troriluzole failed to distinguish itself from placebo in a large Phase III GAD trial.

* Neurosteroids are steroids synthesised within the CNS that regulate neuronal excitability.

* Allopregnanolone and pregnanolone positively modulate GABA-A receptors.

* Neurosteroids may have endogenous anxiolytic properties.

* Progesterone can increase allopregnanolone.

* Animal studies suggest increased progesterone during pregnancy may contribute to reduced anxiety-like behaviour.

* Some women with panic disorder show improvement during pregnancy and worsening postpartum.

* Rapid postpartum reductions in progesterone and allopregnanolone provide one possible biological explanation.

* Altered neurosteroid concentrations have been reported in panic disorder.

* Neurosteroid findings in GAD and social anxiety remain inconsistent.

* Arginine vasopressin contributes to stress regulation through V1a and V1b receptors.

* Vasopressin interacts with CRH in ACTH release.

* Animal work suggests increased vasopressin signalling can promote anxiety-like behaviour.

* Genetic variation in vasopressin receptors has been associated with panic disorder.

* Clinical trials of vasopressin antagonists in GAD have not demonstrated clear efficacy.

* Oxytocin is produced in hypothalamic nuclei and released centrally and through the posterior pituitary.

* Oxytocin modulates social-emotional processing, reward, and stress responses.

* It can attenuate HPA-axis activity.

* Lower CSF oxytocin has been associated with greater anxiety in some studies.

* Oxytocin-receptor polymorphisms may interact with early-life stress.

* Intranasal oxytocin can reduce amygdala responses to fearful faces.

* Oxytocin may improve aspects of emotion recognition and social cognition.

* Intranasal oxytocin has reduced anxiety during experimental social-stress tasks.

* Preliminary studies suggest possible benefit in GAD and social anxiety.

* Oxytocin may facilitate extinction of social fear.

* Oxytocin has altered amygdala-frontal and amygdala-insula connectivity in social anxiety studies.

* Sex differences may influence oxytocin effects.

* Evidence is not yet sufficient for routine clinical use in anxiety disorders.

* Neuropeptide Y is widely distributed in the locus coeruleus, hypothalamus, septum, PAG, hippocampus, amygdala, and brainstem.

* NPY has strong anxiolytic effects in animal models.

* NPY appears involved in stress resilience.

* NPY may impair retention of traumatic memories.

* NPY can reduce anxiety during stressful tasks.

* Reduced NPY expression is associated with increased anxiety-like behaviour in some animal models.

* Intranasal NPY has shown preliminary anxiolytic effects in small human studies outside the currently defined anxiety disorders.

* Further clinical trials are needed.

* Galanin is coexpressed with norepinephrine neurons in the locus coeruleus.

* Galanin projects to amygdala, hippocampus, and prefrontal cortex.

* It can reduce locus-coeruleus firing.

* Galanin may have anxiolytic effects particularly during states of high noradrenergic activation.

* Human evidence remains very limited.

* Cholecystokinin, particularly CCK-4, can provoke panic.

* CCK receptors are densely distributed in cortex, hypothalamus, substantia nigra, PAG, amygdala, and hippocampus.

* CCK-4 and pentagastrin can produce panic attacks experimentally.

* Panic disorder may involve heightened sensitivity to CCK challenge.

* Despite strong panicogenic effects, CCK-2 antagonists have repeatedly failed to demonstrate clear clinical anxiolytic efficacy.

* This again illustrates the gap between mechanistic models and successful treatment.

* The endocannabinoid system contributes to sleep, appetite, pain, emotional memory, fear, and anxiety.

* Major endogenous ligands include anandamide and 2-AG.

* CB1 receptors are widely distributed throughout prefrontal, limbic, and subcortical fear circuitry.

* Endocannabinoid activity increases during threat and may counteract fear responses.

* CB1 activation has dose-dependent effects.

* Low levels of cannabinoid activation may be anxiolytic.

* Higher levels can be anxiogenic and panicogenic.

* THC can therefore reduce anxiety at low doses and worsen anxiety at higher doses.

* CBD has reduced anxiety during simulated public-speaking paradigms.

* Small studies suggest possible benefit for social anxiety.

* FAAH inhibition may enhance endogenous anandamide signalling and facilitate fear extinction.

* Reduced FAAH expression has been associated with stronger fronto-amygdala connectivity and improved extinction learning.

* Cannabinoid modulation of fear-memory consolidation and reconsolidation is complex.

* Endocannabinoid treatments remain experimental for anxiety disorders.

* Inflammation may contribute to anxiety biology, but evidence remains inconsistent.

* Stress activates HPA and sympathetic systems that can influence immune signalling.

* Some panic studies show elevated cytokines, while others show reduced concentrations.

* CRP may be elevated in some GAD samples.

* CRP may be lower in some social-anxiety groups.

* Age, sex, BMI, medication, and other confounders complicate interpretation.

* There is not yet sufficient evidence to define anxiety disorders broadly as inflammatory illnesses.

* Fear conditioning remains one of the most important experimental models in anxiety neuroscience.

* Fear acquisition, fear generalisation, and fear extinction represent distinct but interacting processes.

* Pathological anxiety may involve excessive generalisation of fear to safe stimuli.

* It may also involve impaired extinction of previously learned fear.

* Exposure therapy can be understood as a form of new inhibitory or safety learning.

* Successful exposure does not necessarily erase the original fear memory.

* It teaches a competing prediction that the feared outcome does not occur.

* Pharmacological augmentation of psychotherapy aims to strengthen this corrective learning.

* Optogenetics and chemogenetics increasingly allow researchers to study highly specific anxiety circuits in animal models.

* Work in the central amygdala has identified somatostatin-expressing neurons and dynorphin-related mechanisms as possible contributors to anxiety.

* Future research may identify increasingly precise circuit-based targets.

* Biomarker development remains a major goal.

* Future work is likely to combine neural circuitry, genomics, intermediate phenotypes, and treatment-response data.

* The eventual goal is more individually tailored treatment.

* Anxiety disorders are therefore best understood not as the product of one abnormal chemical, but as disorders of threat detection, stress regulation, inhibitory control, learning, generalisation, and extinction across interacting biological systems.

Medlock Holmes enters the Global Atlas of Anxiety.

At the centre floats an enormous illuminated globe.

Every continent is marked.

Every age group is represented.

And across the map, the same message appears:

Anxiety disorders are everywhere.

Epidemiology asks more than how many people are affected.

It asks:

Who develops anxiety?

When does it begin?

Which disorders persist?

What travels with them?

Which people receive treatment - and which remain invisible?

Holmes begins with a warning.

Clinical populations show only the tip of the iceberg.

People reaching specialist services are often more severely ill, more impaired, and more likely to have multiple disorders than people with anxiety in the wider community.

To understand the true magnitude of anxiety disorders, Holmes must leave the clinic and investigate entire populations.

The first chamber contains the world’s largest epidemiological surveys.

The WHO World Mental Health initiative spans more than 25 countries and over 130,000 participants.

Across studies, anxiety disorders repeatedly emerge as the most prevalent class of mental disorders.

But rates vary considerably between countries.

The international table on page 5 illustrates this clearly.

Panic disorder, agoraphobia, social anxiety disorder, specific phobia, and GAD all show substantial cross-national variation. For example, 12-month social anxiety estimates range from around 0.2% in Nigeria to 7.1% in one United States survey, while lifetime specific-phobia estimates range from approximately 1.5% in Italy to 10.8% in New Zealand.

Holmes is careful not to assume that every difference is biological.

Language.

Translation.

Diagnostic thresholds.

Cultural interpretation.

Interview technique.

Sampling.

All can change measured prevalence.

Epidemiology therefore measures not only illness.

It also measures the instruments used to detect it.

The next gallery belongs to children and adolescents.

Here the finding is even more striking.

A meta-analysis across 27 countries estimated a pooled 12-month prevalence of any anxiety disorder at approximately 6.5% in young people.

The US National Comorbidity Adolescent Supplement found lifetime anxiety rates of 31.9% in adolescents, compared with 28.8% in adults.

The comparison table on page 7 shows that adolescents actually had higher aggregate 12-month anxiety prevalence than adults: 24.9% versus 18.1%.

Holmes realises why.

Anxiety disorders begin early.

The median age of onset across the major anxiety disorders is approximately 12 years in adult retrospective surveys, while adolescent data suggest an even earlier median around 6 years.

But each anxiety disorder has its own developmental clock.

Separation anxiety and specific phobias often emerge in middle childhood.

Social anxiety becomes prominent in adolescence.

Agoraphobia and panic disorder peak from late adolescence into young adulthood.

GAD tends to emerge later, often in young adulthood.

The disorders therefore unfold like different constellations appearing at different points in development.

The investigation next turns to sex differences.

Women have approximately twice the lifetime rates of panic disorder, GAD, agoraphobia, and specific phobia compared with men in many community studies.

Girls also show higher rates of most anxiety disorders.

The difference persists across the lifespan, becoming particularly pronounced in early and middle adulthood.

But epidemiology cannot yet fully explain why.

Biology.

Hormonal influences.

Temperament.

Stress exposure.

Social roles.

Behavioural conditioning.

Cultural expectations.

All may contribute.

Holmes then enters the Risk Observatory.

One instrument is labelled:

Behavioural Inhibition

Some children react strongly to novelty.

They withdraw.

Freeze.

Watch carefully.

Show increased physiological arousal.

Behavioural inhibition can represent an early vulnerability to later anxiety.

Another instrument measures:

Anxiety Sensitivity

This is not simply anxiety.

It is fear of the sensations of anxiety themselves.

A racing heart becomes:

“I am having a heart attack.”

Dizziness becomes:

“I will faint.”

Visible trembling becomes:

“Everyone will see that I cannot cope.”

Anxiety sensitivity predicts later anxiety symptoms and disorders more specifically than depression.

The chapter then turns to families and genes.

Anxiety disorders aggregate within families.

Twin and family studies show meaningful genetic contributions.

But heritability is moderate rather than absolute.

Environment matters greatly.

Genes may influence autonomic reactivity.

Behavioural inhibition.

Startle.

Respiratory sensitivity.

Social fear.

But what ultimately emerges depends upon development and experience.

Holmes sees anxiety as neither inherited destiny nor learned behaviour alone.

It is an interaction.

The next chamber is labelled:

COMORBIDITY

The room is crowded.

Anxiety disorders cluster with one another.

They also overlap with:

Mood disorders.

Substance-use disorders.

Eating disorders.

Disruptive behaviours.

Physical illnesses.

The relationship with depression is particularly important.

Anxiety frequently appears first.

Depression follows later.

Family and twin studies suggest that panic disorder, GAD, and depression may share part of their familial and genetic liability.

Anxiety may therefore sometimes represent an early developmental expression of a vulnerability that later appears as depression.

Holmes then enters the Medical Wing.

Diabetes.

Cardiovascular disease.

Respiratory illness.

Epilepsy.

Migraine.

Multiple sclerosis.

Parkinson disease.

Medical comorbidity is especially strong for panic disorder and GAD.

But causality is complicated.

Anxiety may share biological vulnerability with the medical disorder.

It may develop in response to disability.

It may arise from treatment.

Or the presence of both illnesses may simply increase the likelihood that a patient reaches medical care.

The epidemiologist must distinguish association from explanation.

The next chamber concerns life experience.

Trauma and stressful events can precipitate anxiety.

But the relationship is not simple.

Some phobias appear after frightening experiences.

Others arise without any obvious precipitating event, possibly reflecting evolutionary preparedness.

Humans may be biologically easier to condition towards certain ancient threats.

Snakes.

Spiders.

Heights.

Dangerous environments.

Yet another person can encounter the same threat and recover completely.

The ability to extinguish fear may therefore be just as important as the ability to acquire it.

Stressful events can also interact with inherited vulnerability.

The event is not always the cause.

Sometimes it is the trigger.

Holmes now reaches the Course Observatory.

Not all anxiety disorders behave alike.

Phobic disorders, particularly social anxiety, tend to show greater stability.

GAD and panic symptoms fluctuate more over time.

Persistence is more likely when anxiety is severe, longstanding, poorly responsive to treatment, and accompanied by particular psychological vulnerabilities.

Longitudinal studies reveal another uncomfortable truth:

Anxiety beginning in childhood can shape adult life.

The 15-year Smoky Mountains follow-up found that childhood anxiety predicted later difficulties in health, finances, and relationships.

The pattern differed by diagnosis.

Young people with GAD showed broad impairment.

Those with social phobia showed particularly strong interpersonal difficulty.

Those with separation anxiety showed more later health problems.

Anxiety is therefore not simply a childhood phase when it becomes clinically significant.

It can alter the trajectory of development.

The final chamber contains an enormous brass balance labelled:

GLOBAL BURDEN

One side carries:

Years Lived with Disability

The other:

Years of Life Lost

The source reports approximately 370 years lived with disability per 100,000 population attributable to anxiety disorders.

Total disability-adjusted life-year estimates are approximately 459 for females and 282 for males, with peak disability concentrated between ages 10 and 24 years.

Anxiety is described as the eighth leading cause of years lived with disability in the global burden estimates discussed in the chapter.

Holmes looks beyond the numbers.

Missed school.

Reduced educational achievement.

Absence from work.

Restricted relationships.

Substance use.

Physical illness.

Lost opportunities.

And, for a minority, suicide.

The burden is amplified because anxiety begins so early and can persist for so long.

Yet the final mystery is the most frustrating.

Effective treatments exist.

CBT works.

Pharmacological treatments work.

But enormous numbers of people never receive them.

The treatment gap remains global.

Holmes closes the atlas.

Epidemiology has revealed that anxiety disorders are not peripheral illnesses.

They are among the central public-health problems of psychiatry.

The most important discovery may therefore be not how common anxiety is.

It is how early it begins, how long its consequences can persist, and how many people remain untreated despite living for years within reach of effective care.

Key Takeaways

* Epidemiology examines the distribution and determinants of disease within populations.

* Descriptive epidemiology studies disease according to person, place, and time.

* Analytic epidemiology examines determinants and potential causal factors.

* Case-control studies compare people with and without a disorder to identify associated exposures or risk factors.

* Cohort studies follow exposed and unexposed groups over time to compare disease incidence.

* Community samples are essential because clinical samples often represent only the tip of the iceberg.

* People seen in specialist settings generally have more severe illness, more comorbidity, and greater impairment than untreated community cases.

* Epidemiology has contributed structured and semistructured diagnostic interviews to psychiatry.

* Population studies have clarified prevalence, correlates, natural history, risk factors, and treatment gaps.

* Community studies repeatedly demonstrate substantial subthreshold anxiety that causes impairment despite failing to meet full categorical diagnostic criteria.

* High rates of comorbidity challenge the assumption that psychiatric diagnoses have completely distinct boundaries.

* Anxiety disorders are the most prevalent class of mental disorders in population studies.

* The WHO World Mental Health initiative includes nationally or regionally representative surveys from more than 25 countries and over 130,000 individuals.

* DSM-5 removed PTSD and OCD from the anxiety-disorder category.

* DSM-5 added separation anxiety disorder and selective mutism to the anxiety-disorders section.

* Panic disorder and agoraphobia are diagnosed separately in DSM-5.

* DSM-5 no longer requires adults to recognise explicitly that their anxiety is excessive or unreasonable.

* International prevalence estimates vary substantially across regions.

* Most studies report 12-month panic-disorder prevalence between approximately 0.2% and 1.1%.

* The source reports a higher 12-month panic-disorder prevalence of 3.1% in the US NESARC-III study.

* Lifetime panic-disorder prevalence ranges approximately 0.2–4.7% across the studies reviewed.

* GAD prevalence varies substantially between countries.

* US studies described 12-month GAD prevalence of approximately 4.0–5.3%.

* International 12-month GAD estimates ranged from approximately 0% in Nigeria to 4.3% in Murcia, Spain.

* Lifetime GAD estimates ranged from approximately 0.1% in Nigeria to 8.0% in Australia.

* Agoraphobia prevalence is generally relatively low across international community studies.

* Lifetime agoraphobia estimates ranged from approximately 0.2% in China to 2.9% in Brazil, with a median around 0.9%.

* Social-anxiety prevalence varies widely across countries.

* Twelve-month social-anxiety estimates ranged from approximately 0.2% in Nigeria to 7.1% in one US survey.

* Lifetime social-anxiety estimates ranged from approximately 1.2% in East Mediterranean countries to 12.1% in the United States.

* Specific-phobia prevalence also varies substantially across surveys.

* Twelve-month prevalence estimates ranged from approximately 1.9% in China to 9.1% in the United States.

* Lifetime specific-phobia estimates ranged from approximately 1.5% in Italy to 10.8% in New Zealand, with a median near 6%.

* The international prevalence table on page 5 demonstrates marked cross-national variation across panic disorder, agoraphobia, social anxiety, specific phobia, GAD, and aggregate anxiety.

* Apparent cross-national differences may reflect genuine cultural variation, methodological differences, translation, sampling, diagnostic thresholds, or combinations of these factors.

* DSM-5 separation anxiety disorder no longer contains an age-of-onset restriction.

* Mean 12-month separation-anxiety prevalence across 20 countries was approximately 1.0%.

* Mean lifetime separation-anxiety prevalence was approximately 3.1%.

* Separation-anxiety rates varied substantially between countries.

* Childhood anxiety prevalence estimates vary more than adult estimates because of developmental and methodological differences.

* Important methodological influences include age, sex, informant source, assessment method, disorder definitions, and which diagnoses are included.

* A meta-analysis of 41 studies across 27 countries estimated pooled 12-month prevalence of any childhood or adolescent anxiety disorder at approximately 6.5%.

* The NCS-A estimated lifetime prevalence of any anxiety disorder in adolescents at 31.9%.

* The corresponding NCS-R lifetime estimate in adults was 28.8%.

* Twelve-month aggregate anxiety prevalence was 24.9% in adolescents versus 18.1% in adults.

* The adult-versus-adolescent comparison table on page 7 illustrates these differences across major anxiety subtypes.

* Severe impairment is substantially less common than the presence of lifetime diagnostic criteria alone.

* The similarity of lifetime rates between adolescents and adults supports the conclusion that many anxiety disorders begin early in life.

* Adult lifetime prevalence is nevertheless greater for GAD, panic disorder, and social anxiety in the NCS-R/NCS-A comparison.

* Longitudinal studies reveal much higher cumulative incidence than is evident from one-time cross-sectional assessments.

* The Zurich Cohort Study found cumulative lifetime anxiety prevalence of approximately 30%.

* In the Zurich cohort, specific phobia was most common at 26.9%, followed by GAD at 20.8%, social anxiety at 12.6%, agoraphobia at 6.8%, and panic disorder at 6.1%.

* Inclusion of subthreshold anxiety further increases the population burden.

* The EDSP longitudinal study reported cumulative incidence of approximately 31.3% for all anxiety disorders by young adulthood.

* Projected prevalence by age 33 was almost twice that observed at initial assessment.

* Late adolescence and early adulthood represent major periods of emergence for several anxiety disorders.

* The Great Smoky Mountains Study found cumulative anxiety incidence of approximately 22.7% between childhood and young adulthood.

* Longitudinal birth-cohort research suggests that parental mood and anxiety disorders and childhood sleep problems are associated with persistence of anxiety into adulthood.

* Women have greater rates of almost all major anxiety disorders.

* Women have approximately twice the lifetime rates of panic disorder, GAD, agoraphobia, and specific phobia compared with men in many studies.

* Girls also show higher rates of most anxiety disorders.

* Female predominance persists across adult life and is particularly pronounced in early and middle adulthood.

* Anxiety disorders generally begin earlier than mood and substance-use disorders.

* The NCS-R estimated median onset of anxiety disorders at approximately 12 years.

* The NCS-A estimated an even earlier median onset of approximately 6 years.

* Separation anxiety disorder and specific phobias commonly begin in middle childhood.

* Social anxiety commonly begins in middle adolescence.

* Agoraphobia and panic disorder commonly begin between late adolescence and young adulthood.

* GAD commonly begins in young adulthood.

* Social anxiety and specific phobias tend to demonstrate greater stability across development.

* GAD and panic symptoms show greater fluctuation and overlap with depressive episodes.

* Lower socioeconomic status and lower educational attainment are associated with anxiety in some but not all studies.

* Associations between anxiety and socioeconomic status are complex and inconsistent across surveys.

* Anxiety disorders have been reported more commonly among unemployed people, those with disability, homemakers, and certain student groups in some studies.

* Research examining anxiety prevalence across race and ethnicity has produced inconsistent findings.

* Methodological factors, socioeconomic interactions, education, and differential exposure to stress may contribute to apparent ethnic differences.

* Anxiety disorders frequently co-occur with one another.

* Comorbidity between anxiety and other mental disorders is already evident in childhood and adolescence.

* Anxiety disorders are associated with mood disorders, disruptive-behaviour disorders, eating disorders, and substance-use disorders.

* Anxiety may precede depression developmentally in some individuals.

* Family and twin studies suggest shared familial and genetic liability between panic disorder, GAD, and depression.

* Anxiety and depressive symptoms may partly arise from a common genetic diathesis.

* Anxiety and substance-use disorders show more evidence of independent underlying etiologies despite frequent comorbidity.

* Familial aggregation has been demonstrated for all major anxiety subtypes.

* Genetic factors contribute substantially to familial transmission but do not fully account for it.

* Moderate heritability highlights the importance of environmental factors.

* Inherited components may include physiological responses such as pulse, respiration, autonomic reactivity, and galvanic skin response.

* Offspring of parents with anxiety disorders show increased rates of anxiety symptoms and disorders.

* Childhood vulnerability may manifest through behavioural inhibition, autonomic reactivity, somatic symptoms, social fear, enhanced startle, and respiratory sensitivity.

* Anxiety and fear are biologically heterogeneous rather than single uniform traits.

* Behavioural inhibition is an early vulnerability marker characterised by physiological reactivity and withdrawal in novel or challenging situations.

* Behavioural inhibition may represent a biologically influenced predisposition towards later anxiety.

* Anxiety sensitivity refers to believing that anxiety sensations themselves have dangerous physiological, psychological, or social consequences.

* Anxiety sensitivity may precede anxiety disorders.

* Anxiety sensitivity appears to predict anxiety more specifically than depression.

* Anxiety disorders frequently coexist with medical illnesses.

* Medical associations include diabetes, cardiovascular disease, respiratory illness, epilepsy, migraine, multiple sclerosis, and Parkinson disease.

* Medical comorbidity is particularly strong for GAD and panic disorder compared with phobic disorders.

* Medical-anxiety associations may reflect shared vulnerability, disability-related anxiety, medication effects, or treatment-seeking bias.

* Comprehensive medical assessment is important in people presenting with anxiety.

* Life events and environmental exposures can contribute to anxiety development.

* Some phobias develop after direct frightening experiences.

* Other phobias may emerge without obvious exposure, suggesting evolutionary preparedness.

* Humans may possess biologically prepared fear tendencies towards historically dangerous stimuli.

* Successful extinction of acquired fears may protect against clinically significant phobia.

* Stressful events such as parental divorce or unemployment may precipitate both anxiety and depressive symptoms.

* Life events should be considered separately across anxiety subtypes rather than assumed to operate identically.

* Stress can interact with familial vulnerability to precipitate panic or other anxiety symptoms.

* Anxiety disorders vary considerably in longitudinal course.

* GAD and panic attacks fluctuate more over time.

* Phobic disorders, particularly social anxiety, tend to be more persistent.

* Persistence is associated with poorer treatment response, greater symptom severity, and longer illness duration.

* Psychological characteristics also influence persistence.

* Anxiety disorders may be associated with increased mortality, potentially involving cardiovascular and respiratory comorbidity.

* Global disease-burden studies increasingly recognise anxiety as a major source of disability.

* Disability-adjusted life years combine disability and premature mortality.

* Years lived with disability are a particularly important component of anxiety burden.

* The source reports approximately 370 YLDs per 100,000 population attributable to anxiety disorders.

* Total DALY estimates are approximately 459 for females and 282 for males in the global figures described.

* Disability related to anxiety peaks between approximately 10 and 24 years of age.

* Anxiety is described as the eighth leading cause of YLDs in the global burden estimate reviewed.

* The early onset of anxiety magnifies its lifetime consequences.

* Childhood anxiety predicts later impairment in health, finances, and interpersonal functioning.

* Long-term outcomes differ by anxiety subtype.

* Childhood GAD was associated with broad impairment across multiple adult domains in the Smoky Mountains follow-up.

* Social phobia was especially associated with later interpersonal impairment.

* Separation anxiety was associated with increased later health problems.

* Anxiety disorders increase risk of later mood, behavioural, and substance-use disorders.

* Suicide contributes to the burden in a smaller proportion of affected individuals.

* Anxiety disorders reduce educational and occupational attainment.

* They contribute to missed school and work days.

* They impair relationships and social functioning.

* Effective behavioural and pharmacological treatments exist.

* Despite this, the gap between prevalence and treatment remains substantial worldwide.

* Low treatment rates remain a major public-health challenge.

* Integrating psychiatry more closely with paediatrics and general medicine may improve detection and treatment.

* Future epidemiology will increasingly draw upon biobanks, treatment registries, insurance databases, pharmacological datasets, genetics, and neuroscience.

* These new datasets require careful evaluation because they may not represent the untreated general population.

* Future classification may increasingly move beyond simple diagnostic codes towards underlying dimensions and biological processes.

* Epidemiology shows that anxiety disorders should be viewed through a life-course perspective, because their onset commonly precedes adulthood and their consequences can persist for decades.

* The major public-health challenge is therefore not only that anxiety disorders are common, but that they are early, persistent, impairing, highly comorbid, and still frequently untreated.

Medlock Holmes enters the Grand Gallery of Anxious Minds.

At the entrance, every patient appears to have the same complaint:

“I am anxious.”

But Holmes knows that this is only the beginning of the investigation.

Anxiety is found across psychiatry.

The diagnosis depends not simply on the presence of fear, but on what is feared, when it occurs, what the person predicts will happen, and what they do to prevent it.

The gallery therefore separates into several chambers.

The first is the Panic Chamber.

A patient is sitting quietly when a warning bell suddenly erupts.

Heart pounding.

Sweating.

Trembling.

Breathlessness.

Chest discomfort.

Dizziness.

Paresthesias.

Derealisation.

Fear of losing control.

Fear of dying.

A panic attack is an abrupt surge of intense fear or discomfort that peaks within minutes and includes at least four characteristic physical or cognitive symptoms.

But Holmes writes an important distinction:

Panic attack ≠ Panic disorder.

Panic attacks occur in many psychiatric and medical conditions.

Panic disorder requires recurrent unexpected attacks accompanied by persistent concern about future attacks or maladaptive behavioural change lasting at least a month.

Patients may stop exercising because a rapid heartbeat reminds them of panic.

Avoid unfamiliar places.

Repeatedly attend emergency departments.

Request medical investigations.

The first attack lasts minutes.

The fear of the next attack can reorganise an entire life.

Holmes then enters the Agoraphobia Chamber.

Here the anxiety is not necessarily about panic itself.

It is about being somewhere from which escape may be difficult or help unavailable if something distressing occurs.

Public transport.

Open spaces.

Enclosed places.

Crowds.

Queues.

Being outside the home alone.

The person begins calculating exits.

Routes.

Distances.

Availability of help.

DSM-5 separated agoraphobia from panic disorder because many people with agoraphobia have no history of recurrent panic attacks.

The diagnostic clue is therefore not merely avoidance.

It is the reason for the avoidance.

A bridge may be avoided because of heights - specific phobia.

Because escape feels difficult - agoraphobia.

Because other people might notice anxiety - social anxiety disorder.

Because it reminds someone of trauma - PTSD.

Holmes repeatedly asks:

“What do you think will happen if you stay?”

The answer often reveals the diagnosis.

The next chamber is the Social Theatre.

A patient stands beneath the gaze of an audience.

They fear humiliation.

Embarrassment.

Negative evaluation.

Appearing foolish.

Or visibly anxious.

Social anxiety disorder persists for more than six months and causes significant impairment.

Sometimes the fear centres on public speaking.

But it can extend to ordinary acts:

Writing a signature while watched.

Eating in front of others.

Meeting unfamiliar people.

Entering a room.

Speaking to authority figures.

The person may fear not only performing badly, but being seen to be anxious.

Avoidance then becomes self-reinforcing.

The person never discovers that the feared judgement may not occur.

Social anxiety often begins early, with peak incidence in adolescence, and may become chronic if untreated. The source reports approximately 8% 12-month prevalence and 13% lifetime prevalence in the United States.

Holmes moves into a smaller chamber.

A spider sits beneath glass.

Another patient stands beside an aeroplane.

Another beside a needle.

Another at the edge of a height.

This is specific phobia.

The fear is tightly linked to a particular object or situation, occurs almost every time the stimulus is encountered, is out of proportion to actual danger, and leads to avoidance or intense distress.

The source distinguishes animal, natural-environment, blood-injection-injury, situational, and other phobias.

Most provoke sympathetic arousal.

But blood-injection-injury phobia is unusual.

Instead of the typical tachycardia and hypertension, some patients develop bradycardia and hypotension, creating the possibility of fainting.

The treatment principle is equally distinctive:

approach rather than avoidance.

Exposure-based behavioural treatment is the treatment of choice, with virtual-reality exposure emerging as another method in selected situations.

The next chamber contains no single feared object.

Instead, every wall is covered with future possibilities.

Money.

Work.

Health.

Family.

Time.

Mistakes.

Appointments.

Ordinary responsibilities.

This is generalized anxiety disorder.

The defining feature is excessive, difficult-to-control worry occurring more days than not for at least six months across multiple areas of life.

The worry is accompanied by symptoms such as:

Restlessness.

Fatigue.

Poor concentration.

Irritability.

Muscle tension.

Sleep disturbance.

Holmes notices that the content of the worries is often ordinary.

The abnormality lies in their breadth, persistence, catastrophic interpretation, and uncontrollability.

The person treats every possible problem as though it deserves immediate priority.

Minor uncertainty competes with genuine emergencies.

The mind becomes unable to rank threats.

GAD is often persistent, frequently presents in primary care through physical symptoms, and commonly coexists with depression and other anxiety disorders. The source estimates lifetime prevalence at approximately 5%.

Holmes then enters the Silent Classroom.

A child talks freely at home.

At school, they cannot speak.

This is selective mutism.

The silence is not deliberate defiance.

It occurs in particular social contexts despite intact capacity for speech elsewhere and causes educational or social impairment.

The disorder often presents around age five and frequently overlaps with social anxiety.

Behavioural and CBT approaches - especially those involving parents and schools - can produce substantial improvement, with long-term studies reporting full remission in more than half of treated children in some cohorts.

The final major chamber is the Attachment Hall.

A child refuses school because something might happen to their parent.

An adult cannot travel because they fear harm may come to their partner while they are away.

Another cannot sleep alone.

Nightmares revolve around separation.

This is separation anxiety disorder.

DSM-5 removed the assumption that it belongs only to childhood.

The source reports a lifetime prevalence of approximately 4.8%, with 43% of affected individuals experiencing onset after age 18.

The fear resembles agoraphobia, panic, or GAD.

Again, Holmes asks what the anxiety is about.

In agoraphobia:

“What if I cannot escape or obtain help?”

In separation anxiety:

“What if something happens to the person I need while we are apart?”

The investigation then reaches a corridor marked:

NOT EVERY ANXIETY DISORDER IS PRIMARY.

Stimulants.

Caffeine.

Cannabis.

Alcohol withdrawal.

Medications.

Hyperthyroidism.

Cardiopulmonary illness.

Neurological disease.

Endocrine disorders.

All can produce anxiety or panic.

Temporal relationship is therefore crucial.

Did symptoms begin after a substance was started?

During intoxication?

During withdrawal?

With a new medical illness?

If anxiety persists long after the physiological cause has resolved, Holmes reconsiders whether a primary anxiety disorder has emerged.

At the end of the gallery, Holmes notices that every chamber is connected by hidden passageways.

Panic appears in phobias.

Agoraphobia overlaps with panic.

Social anxiety overlaps with avoidant patterns.

GAD coexists with depression.

Separation anxiety accompanies other anxiety disorders.

Comorbidity is the rule rather than the exception.

The diagnostic categories remain useful.

But the borders are porous.

Holmes closes the final case file.

The essential clinical task is not simply to identify anxiety.

It is to identify its architecture:

What is feared?

How close is the threat?

How predictable is it?

What catastrophe is anticipated?

What is avoided?

And what does that avoidance prevent the person from learning?

Key Takeaways

* DSM-5 reorganised the former anxiety spectrum into anxiety disorders, trauma- and stressor-related disorders, and obsessive-compulsive and related disorders.

* The DSM-5 anxiety-disorders section includes separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, GAD, substance/medication-induced anxiety disorder, anxiety disorder due to another medical condition, other specified anxiety disorder, and unspecified anxiety disorder.

* PTSD is now classified among trauma- and stressor-related disorders.

* OCD is classified among obsessive-compulsive and related disorders.

* Despite separate diagnostic categories, anxiety symptoms occur across much of psychiatry.

* Differential diagnosis depends strongly on the content, context, and function of fear and avoidance.

* Panic attacks are abrupt surges of intense fear or discomfort that peak within minutes.

* A panic attack includes at least four characteristic physical or cognitive symptoms.

* Panic symptoms may include palpitations, sweating, trembling, dyspnoea, choking, chest discomfort, nausea, dizziness, temperature sensations, paresthesias, derealisation, depersonalisation, fear of losing control, and fear of dying.

* Culture-specific panic symptoms may occur but do not replace the required core DSM symptoms.

* A single panic attack does not establish panic disorder.

* Panic attacks can occur in numerous psychiatric and medical conditions.

* DSM-5 therefore permits a panic attack specifier to be applied to other disorders.

* Panic disorder requires recurrent unexpected panic attacks.

* At least one attack must be followed by at least one month of persistent concern about further attacks or maladaptive behavioural change.

* Avoidance of exercise, unfamiliar environments, or other situations associated with feared panic sensations can occur.

* Repeated emergency presentations and reassurance-seeking medical investigations may form part of panic-related behaviour.

* Some attacks in panic disorder may be triggered, but at least some must occur unexpectedly or “out of the blue.”

* Predictable panic occurring only in response to a specific feared stimulus does not establish panic disorder.

* Panic disorder has a lifetime prevalence of approximately 1 in 25 people.

* Panic attacks themselves are far more common, occurring in at least 1 in 7, with some estimates approaching one-third of the population.

* Panic disorder commonly begins in the late teenage years or early twenties.

* Women are affected approximately twice as often as men.

* Panic disorder is highly comorbid with mood, substance-use, trauma-related, and other anxiety disorders.

* Panic-like symptoms can be caused by temporal-lobe epilepsy, brain tumours, hyperthyroidism, pheochromocytoma, myocardial infarction, arrhythmia, asthma, and pulmonary embolism.

* Corticosteroids, stimulants, some hormones, asthma medications, caffeine, marijuana, illicit stimulants, and hallucinogens can produce panic symptoms.

* Estimated heritability of panic disorder is approximately 35–40%.

* Stressful life events may trigger panic disorder in genetically vulnerable individuals.

* Childhood trauma and anxious temperament are associated with greater risk.

* Panic disorder often follows a chronic but fluctuating course.

* Relapse may occur after apparently successful treatment.

* Naturalistic studies cited in the source show relapse rates greater than 50% within 12 months after discontinuing an effective antidepressant.

* Serotonergic antidepressants are a pharmacological mainstay of panic-disorder treatment.

* Benzodiazepines are effective but carry risks that require careful consideration.

* CBT has substantial evidence in panic disorder.

* Agoraphobia is now diagnostically independent of panic disorder.

* Agoraphobia involves fear, anxiety, or avoidance of situations where escape may be difficult or help unavailable if distressing symptoms occur.

* Agoraphobic symptoms must persist for approximately six months or longer.

* Agoraphobia may occur without full panic attacks.

* More than half of some community samples with agoraphobia may have no clear history of panic attacks.

* Agoraphobia can occur in children and adolescents.

* Agoraphobia can produce profound functional restriction, including becoming largely or completely housebound.

* Women are more commonly affected than men.

* Onset commonly peaks in the late teens and early twenties.

* Anxiety-disorder comorbidity in agoraphobia often exceeds 50%.

* Depressive disorders occur in approximately 33–52% of cases in the source.

* Differential diagnosis depends on why public situations are avoided.

* Specific phobia involves fear of a circumscribed stimulus.

* Agoraphobia requires a broader pattern involving at least two types of public situations.

* Social anxiety disorder involves fear of judgement or humiliation.

* Separation anxiety involves fear related to attachment figures.

* PTSD avoidance centres on trauma reminders.

* OCD avoidance may relate to obsessional concerns such as contamination.

* Behavioural treatments have demonstrated efficacy for agoraphobia independent of panic disorder.

* Social anxiety disorder involves persistent fear of negative evaluation in social or performance situations.

* The fear or avoidance must produce clinically significant impairment.

* Symptoms generally persist for at least six months.

* Patients may fear embarrassment, humiliation, appearing incompetent, or visibly showing anxiety.

* Social anxiety can involve ordinary activities such as writing, eating, meeting strangers, or speaking while observed.

* The patient may develop anxiety about appearing anxious, amplifying self-consciousness.

* DSM-5 removed the old “specific” versus “generalized” distinction.

* Performance only is the principal DSM-5 specifier.

* Avoidant personality disorder and social anxiety disorder overlap substantially but remain distinct diagnoses.

* The source reports approximately 8% 12-month prevalence and 13% lifetime prevalence of social anxiety disorder in the United States.

* Social anxiety commonly begins in early adolescence.

* Women are affected more commonly than men.

* Mood disorders and substance use commonly coexist with social anxiety disorder.

* Alcohol, cannabis, sedatives, and nonprescribed anxiolytics may be used as self-medication.

* Social anxiety is associated with autism-spectrum disorder at above-baseline rates.

* Social anxiety also occurs more frequently among people with schizophrenia.

* Risk factors include female sex, family history, and behavioural inhibition in childhood.

* Parenting style may contribute alongside familial and genetic influences.

* The Mini-SPIN can be used as an adult screening instrument.

* A crowded party may be avoided in social anxiety because of fear of judgement, in agoraphobia because escape feels difficult, or in PTSD because hypervigilance is overwhelmed by multiple stimuli.

* Suicide-attempt risk is elevated in social anxiety disorder.

* CBT and IPT have demonstrated efficacy, with stronger evidence for CBT.

* Serotonergic agents are first-line pharmacological treatments.

* Beta-blockers can be useful for selected performance-only presentations.

* Social anxiety is often chronic and may recur after treatment discontinuation.

* Specific phobia involves marked fear of a particular object or situation.

* The feared object or situation almost always produces immediate fear or anxiety.

* The stimulus is actively avoided or endured with intense distress.

* The fear is disproportionate to actual danger and sociocultural context.

* Symptoms generally persist for six months or longer.

* Specific phobia must cause clinically significant distress or impairment.

* Main categories include animal, natural environment, blood-injection-injury, situational, and other phobias.

* Multiple specific phobias commonly coexist.

* Lifetime prevalence in older US data is approximately 9%.

* Prevalence peaks in adolescence.

* Female sex and younger age are associated with increased risk.

* Specific phobia must be distinguished from PTSD, panic disorder, agoraphobia, social anxiety, OCD, and separation anxiety.

* Panic occurring only during exposure to a particular phobic stimulus does not establish panic disorder.

* Animal phobias may reflect evolutionary preparedness more strongly than traumatic learning.

* Blood-injection-injury phobia has distinctive physiology.

* Rather than the usual tachycardia and hypertension, blood-injection-injury phobia may produce bradycardia and hypotension.

* This physiological response helps explain fainting in some patients.

* Family and twin studies demonstrate familial risk for phobic disorders generally but not necessarily for the exact phobic subtype.

* Conditioning, trauma, cognition, and environmental learning contribute to specific phobias.

* Exposure-based behavioural therapy and systematic desensitisation are treatments of choice.

* Virtual-reality exposure has demonstrated efficacy in selected phobias.

* Pharmacological evidence for specific phobia is comparatively limited.

* Generalized anxiety disorder involves excessive and difficult-to-control worry about multiple domains.

* Worry occurs more days than not for at least six months.

* Adults require at least three associated symptoms; children require only one.

* Associated symptoms include restlessness, fatigue, poor concentration, irritability, muscle tension, and sleep disturbance.

* GAD worries often involve ordinary life domains such as finances, health, punctuality, school, or work.

* The pathology lies in excessive probability estimation, catastrophic expectation, persistence, and difficulty controlling the worry.

* Patients with GAD may have difficulty prioritising genuine immediate problems over less important hypothetical concerns.

* GAD has an estimated lifetime prevalence of approximately 5%.

* Incidence is elevated in both early adulthood and older adulthood.

* Women are affected more frequently than men.

* GAD commonly coexists with depression, other anxiety disorders, and substance-use disorders.

* GAD often presents in primary care through physical symptoms.

* Distinguishing GAD from anxiety occurring solely during major depression may require longitudinal observation during euthymic periods.

* GAD can be persistent rather than episodic, although severity fluctuates.

* Genetic associations have been described but do not currently guide treatment.

* Childhood maltreatment and abuse increase risk.

* New-onset or markedly changing GAD-like symptoms should prompt consideration of medical, neurological, medication, and substance causes.

* Atypical age of onset, marked functional deterioration, or treatment resistance may warrant broader medical evaluation.

* TCAs, SSRIs, and SNRIs have demonstrated efficacy in GAD.

* Benzodiazepines and buspirone have historical evidence but should be understood in the context of changing diagnostic criteria and safety considerations.

* GAD frequently relapses.

* Greater baseline severity, prolonged avoidance, and high behavioural inhibition predict persistence.

* Short follow-up after treatment can overestimate long-term remission.

* Stepped-care and collaborative-care approaches can improve outcomes.

* The GAD-7 is useful for screening and treatment monitoring.

* GAD is associated with increased risk of suicide attempts.

* CBT, relaxation, imagery exposure, and meditation-based strategies have evidence in GAD.

* Long-term follow-up supports sustained benefit from CBT.

* Selective mutism primarily affects children who can speak normally in some settings but cannot speak in particular social contexts.

* The absence of speech commonly becomes apparent at school.

* Symptoms must impair educational or social functioning for more than one month.

* Mutism related solely to adjustment to a new school or unfamiliar language does not establish the diagnosis.

* The historical term elective mutism was replaced by selective mutism to remove the implication that the child was deliberately refusing to speak.

* DSM-5 placed selective mutism within anxiety disorders because anxiety, particularly social anxiety, commonly accompanies it.

* Selective mutism usually presents around age five.

* Prevalence is approximately 1% in many child studies.

* Social anxiety disorder is probably its most common comorbidity.

* Communication disorders, autism spectrum disorder, and developmental delay should be considered in the differential.

* Genetic, temperamental, environmental, and neurodevelopmental factors may contribute.

* CBT and behavioural interventions can be effective.

* Parent and school involvement may strengthen treatment.

* Some long-term CBT studies report full remission in more than 50% of children.

* People with childhood selective mutism remain at increased later risk for phobic disorders.

* SSRIs may provide partial benefit, but the evidence base is small.

* Separation anxiety disorder involves excessive distress related to actual or anticipated separation from significant attachment figures.

* Patients may fear that harm will occur to themselves or loved ones during separation.

* Avoidance of school, work, travel, or independent activity may follow.

* Patients may fear sleeping alone or experience nightmares involving separation.

* Somatic anxiety symptoms can accompany separation fears.

* Childhood symptoms need persist for only four weeks.

* Adult symptoms generally need to persist for six months.

* DSM-5 removed the previous requirement that separation anxiety begin before age 18.

* Separation anxiety disorder can begin in adulthood.

* The source reports a lifetime prevalence of approximately 4.8%.

* Approximately 43% of affected individuals in the cited worldwide study experienced onset after age 18.

* Childhood-onset separation anxiety is more common in girls.

* Adult-onset cases have a more balanced female-to-male ratio.

* More than half of affected people show remission within the first decade after onset.

* Separation anxiety is associated with later or concurrent major depression, bipolar disorder, panic disorder, OCD, social anxiety, and specific phobia.

* Comorbid separation anxiety may reduce CBT response in panic disorder, GAD, and social anxiety.

* Treatment may therefore need to address separation fears directly rather than assuming they will resolve automatically.

* Separation anxiety differs from agoraphobia because the feared catastrophe concerns the attachment figure rather than inability to escape or receive help.

* Separation-related panic is usually context-linked rather than unexpected.

* GAD involves broader worry themes than separation anxiety.

* Some adult-onset separation anxiety may overlap phenomenologically with complicated grief or trauma-related disorders.

* Separation anxiety aggregates in families, although genetic and environmental contributions remain uncertain.

* Oxytocin, serotonin, dopamine, and other biological systems are being investigated.

* Both adult separation anxiety disorder and panic disorder show associations with carbon-dioxide sensitivity.

* Traumatic experience is associated with increased separation-anxiety prevalence.

* CBT is commonly used for both childhood and adult presentations, although adult treatment evidence remains limited.

* Childhood CBT may incorporate parental education and social-skills work.

* SSRIs are sometimes used in children who do not respond adequately to CBT, but pharmacological evidence is mixed.

* Substance/medication-induced anxiety disorder can present with generalized anxiety or panic.

* Diagnosis requires a plausible temporal relationship between anxiety and intoxication, withdrawal, or medication exposure.

* Relevant substances include alcohol, caffeine, cannabis, PCP, hallucinogens, inhalants, opioids, sedatives, stimulants, cocaine, and other agents.

* Anxiety should generally resolve following removal of the offending substance or resolution of withdrawal.

* Persistent anxiety months later should prompt consideration of an independent primary anxiety disorder.

* Evidence for extremely prolonged toxic or withdrawal effects extending well beyond physiological exposure is limited in the source.

* Anxiety disorder due to another medical condition requires a recognised medical condition capable of causing anxiety or panic.

* Possible causes include endocrine, metabolic, neurological, cardiopulmonary, infectious, and oncological disorders.

* Temporal relationship between medical illness and anxiety symptoms is an important diagnostic clue.

* Modern anxiety nosology remains based primarily on clinical phenomenology rather than biomarkers.

* Genetics, neuroimaging, epigenetics, pharmacogenetics, and other neuroscience tools have not yet been incorporated directly into routine DSM classification.

* High comorbidity suggests that anxiety-disorder categories do not represent completely isolated biological entities.

* Transdiagnostic CBT protocols can be effective across different anxiety disorders.

* The boundaries between anxiety disorders remain clinically useful while also being biologically porous.

* The most important diagnostic question is often not “Does this person have anxiety?” but “What exactly is the person afraid will happen, and what behaviour has developed to prevent it?”